Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2018

Prescription Drug Monitoring Programs and Opioid Poisoning:
Evaluating the Impact of Prescriber Use Mandates on Prescription
Opioid Poisoning Emergency Department Visits
Sarah Almanie

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Pharmacoeconomics and Pharmaceutical Economics Commons, and the Public Health
Commons
© Almanie A. Sarah

Downloaded from
https://scholarscompass.vcu.edu/etd/5545

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Almanie A. Sarah
All Rights Reserved

2018

Prescription Drug Monitoring Programs and Opioid Poisoning: Evaluating the Impact of
Prescriber Use Mandates on Prescription Opioid Poisoning Emergency Department Visits

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Science at Virginia Commonwealth University.

by

Sarah A. Almanie
B.S. 2006, Kuwait University
M.S., 2015 Virginia Commonwealth University

Director: David A. Holdford, R.Ph., M.S., Ph.D., FAPhA
Professor
Department of Pharmacotherapy and Outcomes Science

Virginia Commonwealth University
Richmond, Virginia
May, 2018

ii

Dedication

This dissertation is dedicated to my precious family: My mom “Dalal”, my husband
“Mohammad”, and my three little angels “Ghala”, “Dai”, and “Abdulmohsen”. You were with
me in the ups and downs, you shared with me my happiness and sadness. May “Allah” bless you
in your life. My Dad “Ali” I wish you was here, may “Allah” have mercy on you.

iii

Table of Contents

List of Tables .................................................................................................................................. v
List of Figures ................................................................................................................................. v
List of Abbreviations ...................................................................................................................... v
Abstract ......................................................................................................................................... vii
Chapter 1 ......................................................................................................................................... 1
Section 1.1: Introduction ............................................................................................................. 1
Section 1.2: Conceptual Framework ......................................................................................... 14
Section 1.3: Rationale ............................................................................................................... 16
Section 1.4: Objectives .............................................................................................................. 17
Chapter 2 ....................................................................................................................................... 18
Literature Review on Prescription Drug Monitoring Programs (PDMPs) ................................... 18
Part 1: Literature review on prescriber utilization of PDMPs ................................................... 22
Part II: Literature review on PDMP effectiveness .................................................................... 33
Part III: literature review on prescriber use mandates............................................................... 54
Overview of the literature ......................................................................................................... 58

iv

Chapter 3 ....................................................................................................................................... 59
Section 3.1-Methods.................................................................................................................. 59
Section 3.2-Results .................................................................................................................... 63
Chapter 4 ....................................................................................................................................... 65
Section 4.1-Methods.................................................................................................................. 65
Section 4.2-Results .................................................................................................................... 74
Chapter 5 ....................................................................................................................................... 88
Section 5.1-Methods.................................................................................................................. 88
Section 5.2-Results .................................................................................................................... 95
Chapter 6 ..................................................................................................................................... 110
Section 6.1 Methods ................................................................................................................ 110
Chapter 7 ..................................................................................................................................... 131
Section 7.1: Discussion ........................................................................................................... 131
Section 7.2: Conclusion........................................................................................................... 141
References ................................................................................................................................... 143
Appendix A ................................................................................................................................. 153
Appendix B ................................................................................................................................. 155

v

List of Tables

Table 1. 1: Terms and definitions of opioid related behaviors ....................................................... 2
Table 1. 2: Evidence based practices to increase prescriber utilization of PDMPs31 ................. 111

List of Figures

Figure 1. 1: PDMP use process ....................................................................................................... 8
Figure 1. 2: The Donabedian model ............................................................................................. 15

List of Abbreviations

vi

ACPM: American College of Preventive Medicine
AFS: Ambulance Fee Schedule
AHRQ: Agency for Healthcare Research and Quality
APICC: Hospital-specific all payer inpatient cost to charge ratio
ARCOS: Automation of Reports and Consolidated Orders System
ARR: adjusted Risk Ratio
BJA: Bureau of Justice Assistance
BNE-NYSDOH: Bureau of Narcotics Enforcement- New York State Department of Health
CCR: Cost to Charge Ratio
CCS: Clinical Classifications Software
CDC: Centers for Disease Control and Prevention
CI: Confidence Interval
CINHAL: Cumulative Index to Nursing and Allied Health Literature
CMS: Centers for Medicare and Medicaid Services
COE: Center of Excellence
CPT: Current Procedural Terminology
CS: Controlled Substance
DAWN: Drug Abuse Warning Network

iii

DEA: Drug Enforcement Agency
DHMH: Department of Health and Mental Hygiene
DID: Difference in Difference
E-codes: External Cause of Injury codes
ED: Emergency Department
EPs: Emergency Providers
FDA: Food and Drug Administration
GAPICC: Group average all-payer inpatient cost to charge ratio
HB1: House Bill 1
HCPCS: Healthcare Common Procedure Coding System
HCUP: Healthcare Cost and Utilization Project
ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification
IRB: Institutional Review Board
I-STOP: Internet System for Tracking Over-Prescribing
KASPER: Kentucky All Schedule Prescription Electronic Reporting
MEC: Medical Examiners Commission
MeSH: Medical Subject Headings
MME: Morphine Milligram Equivalents
MPE: Multiple Provider Episode
MPFS: Medicare Physician Fee Schedule
MT: Medical Toxicologists
NAMCS: National Ambulatory Medical Care Survey
NAMSDL: National Alliance for Model State Drug Laws

iv

NEDS: Nationwide Emergency Department Sample
NMPO: Non-Medical Use of Prescription Opioids
NPDS: National Poison Data System
NSDUH: National Survey on Drug Use and Health
OR: Odds Ratio
PDAPS: Prescription Drug Abuse Policy System
PSR: Prevention Status Report
RADARS: Researched Abuse, Diversion and Addiction-Related Surveillance
SAMSHA: Substance Abuse and Mental Health Services Administration
SEDD: State Emergency Department Databases
SID: State Inpatient Databases
SPARCS: Statewide Planning and Research Cooperative System
TEDS: Treatment Episode Data Set
WHO: World Health Organization

Abstract

PRESCRIPTION DRUG MONITORING PROGRAMS AND OPIOID POISONING:
EVALUATING THE IMPACT OF PRESCRIBER USE MANDATES ON PRESCRIPTION
OPIOID POISONING EMERGENCY DEPARTMENT VISITS

By Sarah A. Almanie, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2018.
Director: David A. Holdford, R.Ph., M.S., Ph.D., FAPhA
Professor
Department of Pharmacotherapy and Outcomes Science

Introduction: Prescription drug monitoring programs (PDMPs) are one strategy established to
curb the prescription opioid abuse epidemic. Prescriber use mandates has emerged as a
promising practice to increase PDMPs impact on prescription opioid abuse; however, evidence
of its effectiveness has not yet been established. Kentucky was the first state to implement
comprehensive prescriber use mandates in July 2012.
Objective: To assess the relationship between prescriber use mandates policy and emergency
department (ED) visits related to prescription opioid poisoning among adults in Kentucky and

North Carolina. Secondary aim: to evaluate the economic impact of prescriber use mandates in
Kentucky.
Methods: A controlled, pre-post study design. Data from the State Emergency Department
Databases (SEDD) and the State Inpatient databases (SID) were used to identify prescription
opioid poisoning ED visits among those ≥ 12 years old. Prevalence rate were estimated.
Prescription opioid poisoning ED visits were characterized based on sociodemographic and
clinical characteristics. Logistic regression was applied to compare occurrences of prescription
opioid poisoning ED visits pre and post prescriber use mandates in Kentucky, and between
Kentucky and North Carolina for the period 2011 to 2014. A cost of illness framework was
applied to estimate direct medical costs associated with prescription opioid poisoning ED visits.
The economic impact of prescriber use mandates was quantified based on logistic regression
coefficient for the interaction term (state*time to implementation).
Results: There were 7,419 and 12,598 prescription opioid poisoning -related ED visits in
Kentucky and North Carolina, respectively. Young and Middle age, male gender, white, having
one or more chronic conditions, and psychiatric conditions (such as depression and drug abuse)
were significantly associated with prescription opioid poisoning ED visits (p-value<0.05). The
odds of having a prescription opioid poisoning ED visit in Kentucky were significantly lower
compared to North Carolina in 2012, 2013, and 2014 compared to 2011 (OR = 0.9, 0.7, and 0.7
respectively). The total estimated direct medical costs were $13.77 and $24.37 million in
Kentucky and North Carolina, respectively. In Kentucky, the economic impact of prescriber use
mandates was estimated at - $2.3 million.
Conclusion: Prescriber use mandates is effective in reducing prescription opioid poisoning ED
visits, and its economic impact is considerable.

Chapter 1

Section 1.1: Introduction
Opioids and their related effects
Opioids are a class of drugs that include the illicit drug heroin as well as legal prescription pain
relievers, including hydrocodone, oxycodone, morphine, and codeine.1 Opioids can be naturally
occurring (morphine), semi-synthetic (heroin), or synthetic (fentanyl). They are further classified
as agonists, partial agonists, and antagonists based on their effect on opioid receptors.2 Opioid
agonists relieve pain by interacting with opioid receptors, thus, inhibiting the transmission of
pain signals (codeine). In contrast, opioid antagonists block opioid receptors and have no
functional response; naloxone is an example of an opioid antagonist that is used to reverse
symptoms of opioid overdose. Opioids with partial agonist activity have some functional
response when binding to opioid receptors (buprenorphine). Three major types of opioid
receptors have been identified: mu, delta, and kappa, which are located in the central nervous
system and the periphery.3
Opioids may also induce a number of behavioral effects, including euphoria, due to activation of
reward regions in the brain.1, 4 This may promote repeated use of opioids for pleasure, rather than
pain relief. Continued opioid use may lead to abuse, dependence, addiction, and other related
behaviors.
1

The literature provides no consistent definition of opioid-related health behaviors like abuse,
dependence, and addiction. According to the American College of Preventive Medicine
(ACPM), abuse is defined as “self-administration of medications to alter one’s state of
consciousness.”5
The World Health Organization (WHO) defines abuse as “persistent or sporadic excessive drug
use inconsistent with or unrelated to acceptable medical practice.”6 Drug abuse is also defined in
the literature as “a disease characterized by continued misuse of drugs even when faced with
drug-related job, legal, health, or family difficulties.”7 Definitions of other related health
behaviors are presented in Table 1.1.
Table 1. 1: Terms and definitions of opioid related behaviors
Term
Opioid use disorder

Definition
“A problematic pattern of opioid use that causes
clinically significant impairment or distress”1

Misuse

“The use of prescription drugs without a
prescription, or in a manner other than as directed
by a doctor”2
“A primary, chronic, neurobiological disease,
with genetic, psychosocial, and environmental
factors influencing its development and
manifestations”3
“Adaptation to a drug that produces symptoms of
withdrawal when the drug is stopped”2
“Redirection of a prescription drug from its lawful
purpose to illicit use; can be done with criminal
intent”4
“Intentional or unintentional use of legitimately
prescribed medication in an un-prescribed manner
for its psychic effect (either experimentation or
recreationally)”5

Addiction

Physical dependence
Diversion

Non-medical use

1. Opioid overdose: prevent opioid use disorder. United States: Centers for Disease Control and Prevention;
October, 2017. Available from: https://www.cdc.gov/drugoverdose/prevention/opioid-use-disorder.html.
2. Opioid overdose: commonly used terms. Centers for Disease Control and Prevention; August, 2017. Available
from: https://www.cdc.gov/drugoverdose/opioids/terms.html.
3. Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American
Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. United
States: American Society of Addiction Medicine; 2001. Available from: https://www.asam.org/docs/defaultsource/public-policy-statements/1opioid-definitions-consensus-2-011.pdf.

2

4. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clinic Proc. 2009;
84(7):593-601.
5. Use, Abuse, Misuse & Disposal of Prescription Pain Medication Clinical Reference United States: the American
College of Preventive Medicine; 2011. Available from: www.acpm.org/?UseAbuseRxClinRef.

Based on the risk of abuse, the Food and Drug Administration (FDA) has classified opioids into
one of the five federal schedules of controlled substances. Heroin is classified in Schedule I,
which contains illegal drugs with the highest tendency of abuse. Prescription opioids, which have
a lower risk of abuse than heroin, are classified in Schedules II to V depending on their specific
risks. Although the use of prescription opioids is associated with abuse risk, opioids are widely
accepted as pain relievers.
Prescription opioid abuse epidemic
The number of prescriptions for opioids in the United States has increased dramatically over the
last two decades. According to the Quintiles IMS (Formerly IMS Health), the number of opioid
prescriptions increased from 76 million in 1991 to 207 million in 2013.8 Each day, more than 65
thousand of opioid prescriptions are dispensed.9 In the United States, the use of prescription
opioids varies largely among states, healthcare providers, and patients’ characteristics.10 The
difference in opioid prescribing rates between states with the highest and lowest prescribing rate
is about three fold. Among medical specialties, primary care physicians are responsible for
almost half of opioid prescriptions dispensed.11 Adults aged 40 years and older, women, and
non-Hispanic white are prevalent users of prescription opioids. The commonly prescribed opioid
analgesics are oxycodone, hydrocodone, morphine, and methadone.
Prescription opioid abuse has increased concurrently over the past two decades. Opioid abuse has
reached epidemic levels in the United States, prompting the US Surgeon General to write a 2016
letter to all American physicians asking for help to solve the epidemic.12 According to the
3

National Survey on Drug Use and Health (NSDUH), about two million Americans abuse
prescription opioids.13 Almost four thousand people initiate non-medical use of prescription
opioids on a single day.9 The prevalence of abuse varies by age, sex, and other factors. Among
people aged 12 years and older, young adults (18-25 years old) are the biggest abusers of
prescription opioids.14 Compared to women, men are more likely to abuse opioid analgesics.14
The risk of abuse increases when patients obtain multiple prescriptions from multiple prescribers
and/or pharmacies, a behavior known as doctor shopping or multiple provider episode (MPE). 15,
16

Other risk factors include high daily dose of opioid [>100 morphine milligram equivalents

(MME)], patients with low income, and presence of a mental illness or a history of drug abuse.17
Prescription opioid abuse and related health and economic outcomes
The prescription opioid abuse epidemic is associated with significant negative health outcomes.
Opioid overdose or poisoning is the most serious health outcome. The Centers for Disease
Control and Prevention (CDC) defines overdose as “injury to the body that happens when a drug
is taken in excessive amounts.”18 Opioids in high doses can lead to respiratory distress and death
due to their impact on respiratory control regions in the brain. The World Health Organization
(WHO) describes opioid overdose as a combination of three symptoms: pinpoint pupils,
unconsciousness, and respiratory depression.19 Opioid overdose is the leading cause of drug
overdose deaths in the United States and was responsible for more than 15 thousands deaths in
2015.20 The rate of opioid analgesic overdose deaths increased by more than fourfold from 2000
- 2014. Currently, half of opioid overdose deaths involve prescription opioids. The risk of opioid
overdose increases with a high daily dose of opioid (>100 MME), use of long acting opioids, and
the concurrent use of benzodiazepines.
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Additional negative health outcomes are associated with the prescription opioid abuse epidemic.
According to the National Poison Data System (NPDS), a comprehensive poisoning surveillance
database in the United States, more than 40 thousand exposure cases involved a single
prescription opioid. Adults, aged 13 years and older, constituted more than 30% of total exposure
cases.21 Moreover, more than 360 thousands emergency department (ED) visits were attributed
to non-medical use of prescription opioids in 2011.22 The negative health impact of prescription
opioid abuse become more serious when abusers of prescription opioids shift to heroin use due to
its lower cost, ready availability in the black market, and higher level of induced euphoria.
According to the Substance Abuse and Mental Health Services Administration (SAMSHA), four
in five new heroin users have previously used prescription painkillers.23
The prescription opioid abuse epidemic has created a substantial economic burden. In a study by
Birnbaum et al. in 2011, the annual cost of prescription opioid abuse in the United States was
estimated at $55.5 billion. Of this cost, 46% was attributed to lost workplace productivity, 45%
to health care costs, and 9% to spending on criminal justice.24 In a more recent study by
Inocencio et al, the total cost of prescription opioid poisoning was estimated at $16 billion.
Emergency department (ED) visits shared 0.5 billion of the total estimated cost.25
The causes of the prescription opioid abuse epidemic are multifactorial. The rapid increase in the
number of prescriptions written for opioids has increased accessibility to these medications.
According to the CDC, about 259 million opioid prescriptions were written in 2012 alone.26 Pill
mills, or operations in which doctors prescribe large quantities of pills for little or no medical
reason, have been one main driver for the massive increase in opioid prescriptions. In addition,
increased social acceptability of prescription opioid use for pain relief and aggressive
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pharmaceutical marketing have facilitated the use of prescription opioids for first-line treatment
of pain.
Combating the prescription opioid abuse epidemic
Controlling the prescription opioid abuse epidemic is complex and requires multifaceted efforts.
The subjectivity of pain presents the first obstacle to limiting opioid prescribing. Patients have
the right to receive adequate pain relief, but the severity of pain and the appropriateness of
opioids to address that pain are difficult to determine and often depend on the prescriber’s
judgment. Doctor shopping behavior, or multiple provider episode (MPE), presents another
obstacle to controlling this epidemic. MPE, defined as “the use of five or more prescribers and
five or more pharmacies within three months”27 makes it difficult for doctors, pharmacists, and
the drug enforcement agencies to identify abusers and target them for interventions. Finally,
efforts to control the opioid abuse epidemic must address the multiple pathways by which
abusers can obtain prescription opioids. These pathways include taking or purchasing
prescription opioids from relatives, friends, or the black market.28 According to the NSDUH,
more than half of non-medical users of prescription opioids obtain them from a friend or relative
for free.28 Due to the complexity of the prescription opioid abuse epidemic, policies or
interventions developed at the federal or state level must ensure a balance between ensuring
access to prescription opioids for patients who need them while minimizing the risk of abuse.
Opioid prescribing guidelines
One method for addressing the prescription opioid abuse epidemic is to decrease access to
opioids for nontherapeutic use. Prescribers are the gate keepers of prescription opioids and thus,
must ensure proper prescribing of opioids to patients. Several guidelines have been developed for
6

prescribing opioids which provide recommendations on dosing threshold, cautious titration, and
risk mitigation strategies. The most recent opioid prescribing guideline was published by the
CDC in 2016 and provides recommendations for prescribing opioids for adults population (≥18
years old) with chronic non-cancer pain in primary care settings.29
Prescription Drug Monitoring Programs (PDMPs)
In 2011, the Federal Government identified PDMPs as one of four key areas of focus to prevent
prescription drug abuse.30 PDMPs are state-run electronic databases that collect information on
the prescribing and dispensing of prescription opioids and other controlled substances. The
pharmacy-reported prescription fill records contained in the PDMPs ease the tracking and
analyzing of prescription data. PDMPs thereby help to identify improper prescribing, dispensing
behavior, and doctor shopping. PDMPs cover controlled substances as defined by federal and
state laws; most PDMPs monitor drug schedules II-V. PDMPs are primarily used by physician
prescribers, nurses, and pharmacists. Other authorized entities, including law enforcement
agencies and regulatory boards, may access prescribing data. States’ PDMPs are operated mainly
by pharmacy boards, departments of health, or law enforcement agencies. A sustained source of
funding is essential to maintain PDMP functioning; state general funds are the major source of
funding. Also, federal grants play an important role in supporting states PDMPs; the most
common federal grant is Harold Rogers PDMP Grant Program.
PDMP use process
The PDMP use process begins when a patient comes to a physician office or other outpatient
setting seeking a prescription for opioids. Before issuing the prescription, the physician must log
in to the PDMP database to retrieve the patient’s schedules II-V prescription history. The
7

checkup step should be done for all new and established patients. If abuse behavior is suspected,
opioids may not be prescribed. Otherwise, the prescription is issued and sent to the pharmacy.
Before dispensing, the PDMP database should be double checked by the pharmacist to ensure
safe and appropriate use of prescription opioids. When inappropriate use of opioids is suspected,
the pharmacist may not dispense the prescription. The pharmacist is responsible for reporting all
dispensed prescriptions for opioids to the PDMP program manager who stores the information
on a database accessible to authorized parties. The transmission of prescribing data from
pharmacy to the state PDMP database is done through an external vendor, where data are
checked for any errors. The PDMP use process cycle continues whenever the same patient seeks
another prescription for opioids. The PDMPs use process is summarized in Figure 1.1

A prescriber
checks a state
PDMPs
system before
issuing a
prescription

Writes a
prescription
and send it to
a pharmacy

A pharmacist
checks the
state PDMPs
system

Dispenses the
prescription

Reports
prescription
data to the
state PDMPs
system

Takes other
actions

No
prescription

Figure 1. 1: PDMP use process
PDMP adoption
PDMPs are currently operational in all states. However, state PDMPs differ in practices
pertaining data collection, analysis, user access, utilization, and user education. A PDMP
practice is defined as “a database operation, or a particular policy that PDMP staff might adopt
8

when carrying out its functions.”31 PDMPs practices can be used to evaluate the effectiveness of
PDMPs.
PDMP effectiveness
The effectiveness of PDMPs has been questioned since their implementation. The impact of
PDMPs on physician prescribing behavior, doctor shoppers, and health outcomes including
overdose deaths and ED visits has been evaluated. The literature reveals inconsistent evidence on
the effectiveness of PDMPs. However, a growing body of evidence suggests that PDMPs are
effective tools.
The effectiveness of PDMPs may be influenced by the degree to which they conform with best
practices related to data collection, analysis, utilization, user access, and education. In 2012, the
Center of Excellence (COE) at Brandies University published a white paper proposing 35
potential best practices for PDMPs.32 Most of the promising best practices proposed in the paper
had no or weak evidence supporting their effectiveness and were suggested based primarily on
expert opinion. As a result, more research on the effectiveness of PDMPs best practices is
needed.
To be effective, PDMPs must be utilized by their intended users, which include prescribing
physicians, nurses, and pharmacists. Currently, utilization of PDMPs is low and highly variable
among different states and health care providers.31, 33-35 Current efforts to improve PDMPs
therefore focus on implementing best practices to maximize their utilization. At the 2016
National Prescription Drug Abuse and Heroin Summit, eight best practices were proposed to
increase the use of PDMPs that focused on PDMPs utilization.36 Recently, the National Alliance
for Model State Drug Laws (NAMSDL) published a report advocating for these PDMP best
practices.31 Nevertheless, support for these practices only comes from case studies of selected
9

states implementing one or more practices. Although its effectiveness is not yet supported by
high-quality evidence, prescriber mandated utilization seems to be the most promising best
practice.
Prescriber use mandates
Prescriber use mandates are defined as “state laws and regulations that require prescribers to
view a patient’s PDMP data under certain circumstances.”31 As of January, 2017, 32 states
enacted laws requiring prescribers to check PDMPs in specific scenarios.37
States differ widely in how they require prescribers to check PDMPs.38, 39 Some states have
comprehensive rules regarding when and how frequently a prescriber should access PDMPs. For
example, in Kentucky, prescribers are required to check PDMPs before prescribing some opioids
and benzodiazepines for all patients and every three months thereafter. New York, Ohio and
Connecticut have similarly comprehensive regulations. In contrast, Tennessee, Oklahoma, and
other states do not require PDMP use for all patients and allow for longer follow-up intervals. In
Delaware, North Dakota, and Utah the use of PDMPs is dependent upon a prescriber’s judgment.
Mandatory use of PDMPs has been opposed by prescribers nationwide for a number of reasons.
Concerns surrounding technical issues with PDMPs systems have created some opposition to
mandatory utilization laws.40, 41 Many physicians assert that checking PDMPs unnecessarily adds
to an already high work load and delays other important duties. Sustained funding for PDMPs is
also a concern, as mandatory use may require additional staff to maintain the workflow of
mandatory utilization.
Most of the currently available evidence of the effectiveness of mandatory PDMPs consists of
analyses from selected states comparing utilization rates and opioid-related outcomes before and
after the implementation of prescriber mandatory use regulations.31, 38 A study by the University
10

of Kentucky found that a prescriber use mandate policy sharply increased in prescriber
utilization of the Kentucky All Schedule Prescription Electronic Reporting (KASPER) PDMP.42
Improvements in opioid prescribing behavior, doctor shopping, and patients’ health outcomes
were also reported. Comparable results were documented for New York and Ohio, states that
implemented similar comprehensive prescriber use mandates.31 Although preliminary studies
suggest that prescriber use mandates are effective, the strength of this evidence is limited by a
lack of comparison with non-prescriber use mandates states. Only one study compared opioid
overdose death rates in mandated states with non-mandated states and found a positive impact.43
In addition to prescribers, pharmacists are other potential users of PDMPs. As of January 2017,
21 states require pharmacists to enroll in state PDMPs, and 11 states mandate pharmacist use of
PDMPs prior to dispensing a controlled substance prescription. Evidence on the effectiveness of
pharmacist PDMPs use mandate policies is lacking and more research is required to establish its
value.
Other PDMP best practices
In addition to prescriber use mandates, NAMSDL report discusses seven more evidence-based
practices that may increase prescriber utilization of PDMPs.31 As the case with prescriber use
mandates, evidence on the effectiveness of these practices is derived from case studies of
selected states. The definitions of these best practices are presented in Table 1.2.
Table 1. 2: Evidence based practices to increase prescriber utilization of PDMPs31
Best practice
Delegate access

Definition
Allowing staff, such as a nurse, to access the
PDMPs database on behalf of a provider

Unsolicited reports

Proactively send reports on prescription opioid
utilization to healthcare providers, law
enforcement agencies, and regulators to flag
suspicious drug use or prescribing behavior
11

Data timeliness

Uploading information into the database at set
intervals, whether in real time, daily,
weekly, or monthly

Streamlined enrollment

Simplifying prescriber enrollment to the PDMPs
database

Educational and promotional initiatives

Efforts that promote the use of PDMPs, such as
educating prescribers on PDMPs access and use

Health information technology (IT) integration

Combining PDMP data with other clinical data
through technologies that are used
to store, communicate, and analyze health
information, such as electronic health
records

Enhanced user interfaces

Implementing user-friendly technologies, such as
dashboards and mobile applications
that provide PDMPs data in easily understandable
formats

Other strategies to curb opioid abuse epidemic
In addition to PDMPs, the report published by the Federal Government discussed three other
plans to curb the prescription opioid abuse epidemic.30 One is to implement educational
programs to increase patients’ awareness of the danger of abusing prescription opioids. In
addition, health care providers should be trained on how to identify and respond to suspicious
drug use behavior. Unused and expired prescription opioids are another risk for abusing opioids.
Patients often keep unneeded medications at home making them readily available for family
members and friends to use. Providing people with proper drug disposal methods is a way to
reduce the risk of abuse. The last proposed plan develops enforcement actions against doctor
shoppers and improper prescribing behavior.
The current research described in this dissertation evaluates the effectiveness of PDMPs by
assessing the impact of mandated prescriber use of PDMPs on emergency department (ED) visits
related to prescription opioid poisoning. This was measured by comparing ED visits within states
12

before and after mandate implementation and between states with and without requirements for
mandatory use. To our knowledge, no previous studies have evaluated the relationship between
mandated prescriber PDMPs utilization and ED visits.
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Section 1.2: Conceptual Framework
This research uses Donabedian’s structure-process-outcome quality framework to evaluate the
effectiveness of PDMPs (Figure 1.2).44 “Structure” refers to the presence of things associated
with a quality initiative such as having a PDMP program and the potential best practices
employed within the program. Simply having a PDMP program is unlikely to result in quality if
people do not follow the policies and procedures within the program. Therefore, “process”
describes the actions taken by program participants like checking the PDMP before prescribing
or dispensing. The assumption is that quality occurs when people follow certain processes,
although this may not be true when the structure is poorly designed and/or the processes are
ineffective. Donabedian’s framework argues although structure and process are important for
measuring quality, “outcomes” or the end result of care are ideal for assessing the quality of
healthcare. Positive health outcomes are desired and therefore will be used to assess the
effectiveness of PDMP interventions.
The existence of PDMPs and policies mandating that prescribers use them (i.e., structure) is
proposed as an intervention to improve their utilization (i.e., process) among prescribers. It is
additionally proposed that this will reduce prescription opioid-related ED visits associated with
opioid poisoning (i.e., outcomes). In addition, the economic impact of prescriber use mandates
will be assessed.

14

Structure

•PDMPs with
prescriber use
mandates

Process

•Utilization of
PDMPs

Figure 1. 2: The Donabedian model
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Outcome

•Prescription opioid
poisoning ED visit
(primary outcome)

Section 1.3: Rationale
Mandated use of PDMPs by prescribers is a relatively new policy. A number of states have
implemented prescriber use mandates, and these mandates contain differing stipulations on the
scenarios requiring PDMPs utilization. These mandates have been enacted with the expectation
that they will increase the low utilization rate of PDMPs and in turn, reduce inappropriate
prescribing and adverse health outcomes associated with prescription opioid abuse. These
expectations are supported by limited evidence of the association between prescriber use
mandates and increased PDMPs utilization as well as reduced opioid prescribing rates, doctor
shopping, and adverse health outcomes.31, 32, 38
PDMPs use mandates are opposed by many prescribers around the country and may be
associated with unintended consequences on their prescribing behaviors.40, 41 Thus, adopting
prescriber use mandates is not a smooth process for policy makers, and stronger evidence of its
effectiveness is needed to promote this policy.
The current literature provides a limited evidence on the impact of prescriber use mandates on
prescription opioid abuse- related health outcomes. More rigorous study designs are needed to
demonstrate or refute the effectiveness of prescriber use mandates. To our knowledge, none of
the evidence has assessed the relationship between PDMPs and prescription opioid poisoningrelated ED visits while specifically considering prescriber use mandates.
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Section 1.4: Objectives
The main objective of this research is to examine the impact of PDMP prescriber use mandates
policy on ED visits related to prescription opioid poisoning among adults in the United States.
The underlying concept of this research is study the relationship between prescriber use
mandates and prescription opioid abuse-related health outcomes. The population of interest is
ambulatory (out-patient) individuals aged 12 years and older who receive their opioids from
prescribers in outpatient settings including physician offices and EDs. Four specific aims fall
under the main objective.
Specific aim I:

A. To identify and select states with laws or regulations mandating prescriber use of
PDMPs.
B. To identify comparison state(s) without mandatory use policies.
Specific aim II:
Among Kentucky and North Carolina residents:

A. To determine the prevalence of prescription opioid poisoning ED visits.
B. To characterize prescription opioid poisoning ED visits based on socio-demographic and
clinical characteristics.
C. To examine associations between patients’ sociodemographic and clinical characteristics
and prescription opioid poisoning ED visits.

Specific aim III:
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A. To compare occurrences of prescription opioid poisoning ED visits pre and post
prescriber use mandates in Kentucky.
B. To compare occurrences of prescription opioid poisoning ED visits in Kentucky and
North Carolina, after prescriber use mandate implementation.

Specific aim IV:

A. To estimate the direct medical costs associated with prescription opioid poisoning ED
visits in Kentucky and North Carolina.
B. To estimate the economic impact of prescriber use mandates in Kentucky.
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Chapter 2

Literature Review on Prescription Drug Monitoring Programs (PDMPs)
A comprehensive literature review on PDMPs was completed in April 2017. A search of
PubMed/MEDLINE (limited to English) and Cumulative Index to Nursing and Allied Health
Literature (CINHAL) was conducted, using different combinations of keywords and Medical
Subject Headings (MeSH) terms. A predetermined inclusion and exclusion criteria were used to
screen for eligible studies. The following inclusion and exclusion criteria were considered in the
literature search:
Inclusion criteria:
The literature search considered original studies that:
a. Assessed the impact of PDMPs implementation on outcomes related to prescriber,
patient, or health outcomes.
b. Assessed PDMPs utilization among prescribers.
c. Evaluated the impact of prescriber use mandates on opioid prescribing, doctor shopping,
or health outcomes.
d. Examined the influence of adopting other PDMPs best practices on PDMPs effectiveness.
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Exclusion criteria:
Studies with one or more of the following criteria were excluded:
a. Conducted outside the United States.
b. Considered veterans or cancer patients as the study population. The current research
considers prescription opioid abuse among the general population. Veterans or cancer
patients have different characteristics and thus, were excluded.
c. Assessed prescribers’ knowledge, opinion, or perception toward PDMPs or PDMPs best
practices.
d. Examined PDMPs utilization solely among pharmacists.
e. Descriptive studies: these include studies that utilize PDMPs data to describe patterns of
opioid abuse, identify risk factors and risky prescriber and patient behaviors.
Search terms used are summarized in Table 2.1. Titles and abstracts of articles were checked for
inclusion and exclusion criteria. The original 885 articles were reduced to 37 after applying
inclusion and exclusion criteria and eliminating duplicates. Similar articles to the included
studies were also reviewed, yielding 5 studies. A total of 42 studies were included for discussion.
The literature search is summarized in Figure 2.1.
Table 2. 1: Search terms history
Search term

Eligible studies
PubMed

CINHAL

Prescription drug monitoring program

42

35

Prescription drug monitoring program AND

3

5

7

3

emergency room visits
Prescription drug monitoring program AND
(prescriber mandate OR mandatory use OR
mandates OR provider mandate)

19

“Analgesics, opioid” [Mesh] AND (prescriber

2

0

mandate OR mandatory use OR mandates OR
provider mandate) AND (monitor OR control
OR manage)
37

Total unique eligible studies

Articles retrieved based on
search terms
n= 885
Excluded articles that did not
meet the inclusion/exclusion
criteria
n= 731
Eligible articles
n= 154

Eliminated duplicates
n= 69

Unique eligible research
articles
n= 85
Excluded reports, reviews,
letters
n= 48
Unique eligible research
articles
n= 37

Figure 2. 1: Flow chart summary of literature search
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Overview of the literature
Prescription opioid abuse has reached epidemic levels in the United States. Concurrently, the
number of opioid overdose deaths and related emergency room visits has dramatically increased.
In response to the epidemic, the federal government released in 2011, the Prescription Drug
Abuse Prevention Plan that includes actions in four major areas to combat the epidemic.
Increased utilization of prescription drug monitoring programs (PDMPs) was one major area.
PDMPs are state run electronic databases that track prescribing and dispensing data and thus,
help identify doctor shoppers and improper prescribing behaviors. The effectiveness of PDMPs
have been assessed through their impact on doctor shoppers, opioid prescribing behavior, and
health outcomes like overdose deaths. The existing literature found mixed evidence on the
effectiveness of PDMPs, however, there is a growing body of literature that supports their
effectiveness. Studies have shown that PDMPs are effective if utilized. A recent report from the
National Alliance for Model State Drug Laws (NAMSDL) indicated that utilization of PDMPs is
low and highly variable among the states and healthcare providers within a state.31 The low and
inconsistent utilization of PDMPs makes it difficult to evaluate their effectiveness.
To be effective, PDMPs must be utilized by prescribers, dispensers, and other intended users.
Correspondingly, many states implemented laws, regulations, or policies that mandate
prescribers and/or dispensers to check the system before issuing a controlled substance
prescription. Case studies from Kentucky, New York, and Ohio showed that prescriber use
mandates increase PDMPs utilization and are effective in reducing doctor shopping and opioid
prescribing.31 However, higher levels of evidence are needed to approve the effectiveness of this
policy.
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The aim of the literature review was to evaluate PDMPs effectiveness with a focus on the impact
of prescriber use mandates. The search terms identified studies in three related areas:
a. Studies that assessed prescriber utilization of PDMPs. These studies were considered,
because PDMPs utilization is part of their effectiveness.
b. Studies that assessed the impact of PDMPs on patient behavior, prescriber behavior, or
health outcomes.
c. Studies that specifically evaluated the impact of prescriber use mandates on patient
behavior, prescriber behavior, or health outcomes.
Part 1: Literature review on prescriber utilization of PDMPs
A total of 17 studies have evaluated prescriber utilization of PDMPs in different medical
settings. Five studies focused on emergency providers’ usage of PDMPs. One study included
only primary care physicians, and another study assessed PDMPs utilization among dentists. The
remaining ten studies evaluated PDMPs utilization among pharmacists, dentists, and/or
physicians in different specialties. Studies are summarized in Table 2.2.
Poon et al. conducted a mixed method study to assess usability of PDMPs among emergency
providers (EPs) in Massachusetts.45 The first part of the study involved quantitative analysis of
PDMPs usability compared to three other commonly performed tasks in the ED. Accessing
PDMPs took a longer time and required more mouse clicks compared to other tasks. In addition,
PDMPs were the most difficult task compared to others (mean = 4.29 on a 1–7 scale). In terms of
frequency of use, PDMPs were less frequently utilized compared to two other tasks (mean = 2.41
on a 1–5 scale). The second part of the study involved semi-structured interviews with EPs to
identify barriers to use PDMPs. Difficulty in accessing the system, retrieving patient’s history,
and analyzing patient information were common barriers.
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In a similar study by Young et al., EPs in Florida were surveyed about their utilization of
PDMPs.46 The findings of the study indicated low and infrequent use of the system. Only 3% of
providers check PDMPs before issuing a controlled substance prescription; almost half of them
check the system only when misuse is suspected. As low as 12% of EPs use PDMPs most of the
time. Among frequent users, the chief complaint when using PDMPs is the frequent time out of
the system (55%). Common barriers among all other users included frequent need to renew the
password (68%) and difficulty in accessing the system (52%).
A third survey was conducted by Fleming et al.47 The study evaluated emergency physicians’
utilization of PDMPs in Texas and included those with PDMP accounts and non-registrants.
Among all physicians, 76% were non-PDMP users; among users, 83% utilized PDMP (≤20%) of
the time.
The fourth survey of EPs was by Wang et al. who investigated PDMPs utilization among
pediatric emergency physicians.48 The study included physicians from 21 states, assessing their
knowledge about the state PDMP and identifying barriers to use the system. Thirty percent of
physicians were not aware of their state PDMPs. Among those who registered with the state
PDMPs, almost 60% rarely use the system and 35% have never used it. However, these findings
may not be nationally representative to pediatric emergency physicians in the United States due
to the small sample size (n= 47). In accordance with previous studies, the most common barrier
to using PDMPs were difficulty to access the system; insufficient time and forgetting to check
the system were also reported as common barriers.
The last survey was conducted by Perrone et al. and assessed PDMPs utilization among medical
toxicologists (MTs).49 The survey utilized a nationally representative sample of MTs (n=205),
most of whom practiced emergency medicine for a significant portion of their clinical practice.
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The survey responses indicated variable knowledge and utilization of PDMPs. Most MTs had
some knowledge about their state PDMPs, but more than 25% did not access it. Among all
surveyed MTs, 50% have used the state PDMPs with 30% of them utilizing it daily. Most
respondents complained about the time lag between data entry and retrieving patient information.
Also, being unaware of the PDMPs existence and lack of registration to the system prevented
MTs from accessing the state PDMPs.
PDMPs utilization was also assessed among primary care physicians. A study by Rutkow et al.
included a national representative sample of primary care physicians in the United States.50
Authors found that approximately one quarter of surveyed physicians were unaware of their state
PDMPs. Fifty three percent of all physicians have used PDMPs. Among those with existing
knowledge of their state PDMPs, 87% have used the system. However, only 23% check the
system when abuse behavior is not suspected. Information on frequency of using PDMPs was
not provided in the study. Among barriers to use the system, the lengthy period of the process
was the most common.
Dentists are another group of prescribers who significantly contributed to the prescription opioid
epidemic. Almost 12% of immediate release opioids are prescribed by dentists.51 A study by
McCauley et al. examined dentists use of PDMPs as an opioid abuse risk mitigation strategy in
South Carolina.52 About 62% have never used the system. Among users, only 12% of dentists
check PDMPs before issuing an initial prescription of opioid each time. For refill prescriptions,
about 15% of dentists use PDMPs each time; however, more than 36% have never used it. Most
dentists were unaware of the PDMPs existence (72%) and one third did not know how to access
the system.
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The remaining studies (n =10) involved prescribers with different specialties to evaluate and
compare their utilization of PDMPs. Most of the studies (n =7) were conducted in single states,
one study compared PDMPs utilization between Connecticut (CT) and Rhode Island(RI), and
two studies included national representative samples.
Three studies focused on PDMPs utilization among prescribers in Oregon.53-55 The first study
compared PDMP users (n=619) to non-users (n=439).53 Most PDMP users were primary care
physicians (56.4%), followed by emergency physicians (17.2%). Among non-users, physicians
in other specialties constituted the largest group (27.5%), followed by surgical specialties
(20.7%). Also, the study identified high and low frequency PDMP users (≥ or < four times in
three month periods, respectively). Among high frequency users, 50% use the system ten or
more times a month, compared to 10% of low frequency users. Almost all physicians reported
checking PDMPs when abuse behavior is suspected and/or early refill is requested. Only one
third of respondents use PDMPs whenever a controlled substance is prescribed.
A mixed method study in Oregon assessed PDMP registration, use, and barriers to use among
clinicians with different specialties.54 In 2013, using Oregon’s PDMP registry, authors found that
25% of all licensed prescribers had PDMP accounts; 45% of accounts were attributed to medical
doctors. Among controlled substance prescribers, 36% were registered with PDMPs. Of these
prescribers, 50% of osteopathic physicians and nurse practitioners had active PDMPs accounts,
compared to 36% of medical doctors. Among medical doctors, the number of PDMPs queries
have been almost doubled from 2012 to 2013. The average number of queries per user have
increased from 14 to 16 queries per month. When surveyed about reasons for not registering and
barriers using PDMPs, prescribers were divided into three groups: frequent users (> one query
per month, n= 358), infrequent users (≤ one query per month + one query to PDMP, n= 261), and
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non-registrants (n= 439). Almost half of non-registrants were not aware that they could register.
Among the three groups, time constraints were reported as the most common barriers to using
PDMPs, followed by an inability to delegate PDMPs access to other medical staff. A sample of
prescribers who were PDMP users was further studied by Leichtling et al.55 In this study,
clinicians were interviewed to identify patterns of PDMP use. Most PDMP users were regular
users with 78% accessing PDMPs ten or more times a month. Authors compared patterns of
PDMP use among short and long term prescribers. Long term prescribers used PDMPs routinely
compared to their counterparts who were less frequent users. However, long term prescribers
checked PDMPs more frequently for new patients than existing patients. Conversely, short term
prescribers depend more on their clinical judgment and suspected abuse behavior, when deciding
to use the system.
A survey by Rittenhouse et al. measured PDMPs utilization among medical doctors, nurse
practitioners, and pharmacists in Arkansas.56 The sample had an equal distribution of the three
groups of providers; similarly, PDMPs utilization was evenly distributed among the three groups
in terms of frequency of accessing the system. Accessing PDMPs varied from daily use (21.1%)
to less than three times a month (26.2%). Most medical doctors and nurse practitioners accessed
PDMPs when abuse behavior was suspected (91% and 87%, respectively); less percentage use
the system with any involvement of controlled substance prescription (36% and 45%,
respectively).
A similar survey in Maryland evaluated PDMPs registration and use among primary care, pain,
and emergency providers (EPs).57 The sample included three groups of providers: registered
users (46%), registered non-users (28%), and non-registrants (26%). PDMP users included
prescribers with at least one PDMPs access in the 18 month period preceding the survey. Among
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non-registrants, about one third were not aware of the state PDMPs or lacked knowledge of how
to register. Among registered non-users and non-registrants with PDMPs access, 69% and 49%
respectively, have ever used the system in their practice. More than 70% of prescribers
(including registered users, non-users, and non-registrants) found the system easy to access. In a
multivariable regression model, physicians who wrote opioid prescriptions for more than 50
patients accessed the PDMPs three times as often as those prescribing opioids for less than ten
patients monthly (IRR = 3.00, 95% CI = (1.07–8.43)). Common barriers to using PDMPs for
registered physicians were: multiple IDs for same the patient, system slowness, and missing data.
No data on frequency of use or drivers to use PDMPs were reported in the study.
An older study in Ohio (2011) revealed a significant difference in PDMPs awareness and
utilization among physicians with different specialties.58 The study found that 84% of all survey
respondents were aware of the Ohio PDMPs; however, only 59% used it. Among all specialties,
pediatric physicians were least aware of the PDMPs (67%). Emergency medicine had the highest
proportion of utilization compared to pediatric physicians (p-value ≤0.001). The study did not
report figures on frequency of utilization. Almost all physicians (91%) reported concerns about
drug abuse that drive accessing the system; no significant difference, in reasons to use PDMPs,
between different specialties were noted.
Another survey in Ohio compared PDMPs utilization among attending and resident physicians
(n=25 and 70, respectively).59 The study found that almost all attending physicians (96%) and
most resident physicians (81%) were aware of the system. However, about one third of attending
physicians and half of the resident physicians do not utilize PDMPs. Most PDMP users utilized
the system to address concerns about prescription drug abuse. Unlike most previous studies, the
current study did not assess frequency of PDMP use among different specialties.
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Green et al. conducted a survey among prescribers in CT and RI.60 The study found significant
differences in PDMPs utilization among prescribers in the two states (44% and 16.3% have ever
used the system, respectively, p-value = <0.0001). Prescribers in CT used the PDMPs more
frequently compared to those in RI (p-value <0.0001). Almost 35% of CT prescribers accessed
the PDMPs weekly or more often, compared to 3.3% in RI. More than two thirds of prescribers
in both states did not use PDMPs, because they were not aware of their existence (68% in CT,
84% in RI). The second reported barrier to using PDMPs in CT and RI was a lack of knowledge
of how to use the system and lack of internet access, respectively.
The last two studies assessed PDMP utilization among nationally representative samples of
prescribers.61, 62 The first study was carried by Fleming et al.61 The study involved PDMP
administrators from 15 states to evaluate prescribers, pharmacists, and law enforcement
personnel utilization of PDMPs. Authors found that prescribers had the highest rate of requests
per population of 100,000, followed by pharmacists and law enforcement personnel. Also, it was
found that availability of online access and fast turnover of PDMP requests increased utilization.
The study did not evaluate frequency of PDMP use among prescribers with different specialties
or assessed barriers to use.
Hildebran et al. conducted a qualitative study including 35 prescribers from nine states.62
Prescribers with different specialties were interviewed to identify patterns of PDMP use. Most
clinicians reported checking PDMPs for clinical purposes, others use it for administrative
requirements. Examples of clinical use included verifying prescription history and coordinating
with other prescribers when suspected prescribing behavior is noted. Consistency for using
PDMPs were varied among specialties. Long term prescribers checked PDMPs more consistently
for their patients compared to emergency providers. Barriers to using PDMPs were also
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identified; patient satisfaction rating was one important barrier. Some organizations evaluated
prescribers based on patient satisfaction; utilizing PDMPs may delay treatment sessions or forbid
an opioid prescription, adversely affecting patient satisfaction. Also, lack of training on how to
access PDMPs was another reported barrier.
Summary of part I literature review:
Studies of PDMPs utilization revealed low and inconsistent use of the system among prescribers
in different states. The literature also documented variation in PDMP use among prescribers with
different specialties. Most of the encountered surveys had a low response rate (≤50%) and small
sample size. Thus, findings of the studies may not be generalized to the whole population of
prescribers. PDMP utilization was assessed in terms of frequency of accessing the system and
reasons that drive access of the system. Studies used different terms to describe PDMP users.
Some studies considered prescribers who used the system at least one time in the past as PDMP
users. Other studies classified prescribers as frequent or infrequent users based on their
frequency of checking the system in a defined period of time. Many studies agreed that most
prescribers check the system when abuse behavior is suspected; fewer prescribers use PDMP
with every controlled substance prescription. Studies also shared common barriers for using
PDMPs including difficulty in accessing the system, lack of knowledge of the system’s
existence, and time constraints. The low and inconsistent utilization among prescribers may
adversely affect PDMP effectiveness. PDMPs must be utilized sufficiently to have a powerful
impact on the prescription opioid abuse epidemic.
The second part of the literature review evaluates the effectiveness of PDMPs through assessing
their impact on prescription opioid abuse risk measures, opioid prescribing, and health outcomes
related to prescription opioid abuse.
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Table 2. 2: Summary of included studies (prescriber utilization of PDMPs)
Author

Study design
and sample

Sample size

Poon et al45
2016

- Mixed
method study

17

- Emergency
physicians
(EPs)

Outcome
measure of
interest
- Time and
number of
mouse clicks
required to
complete the
PDMP task
compared to
three
commonly
performed
tasks in the
ED

Period

Setting and
data source

Related findings

5 months

One large
urban
academic
medical
center in MA

- PDMPs require more time and
greater number of mouse clicks

Florida

- Most EPs (99%) are aware of
PDMPs, 21% rarely use it

- PDMPs are more difficult to
use compared to other tasks

- Ease of use
Young et al46
2017

-Web based
survey

88

- Utilization
of PDMP

5 weeks

-EPs

Fleming et
al47
2014

Wang et al48
2016

- Survey

- Only 3% use it with every CS
prescription
76

- PDMP
utilization

_

- EPs

- Web based
Survey

47

- PDMP
utilization

_

Emergency
medicine
conference in
Texas

-76% do not use PDMPs as a
screening tool

21 states

- 60% rarely use the system

- Most users (83%) utilize
PDMPs ≤ 20% of the time

- 35% have never used it
- Pediatric EPs
Perrone et
al49
2012

-Web based
survey

205

- PDMP
utilization

2 months

35 states

- Medical
toxicologists
(MTs)
Rutkow et al50
2015

- Mail survey

- 50% have ever used PDMPs
- only 30% access it daily
420

- PDMP
utilization

18 weeks

51 states

- Primary care
physicians

McCauley et
al52
2015

-Web based
survey

- More than 25% do not access
PDMPs

- 53% of all physicians have
used PDMPs
-77% check the system only
when abuse behavior is
suspected

86

-PDMP
utilization

- Dentists
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_

SouthCarolina

- 38% have ever used PDMPs

- 27% use PDMPs all the times
for initial and refill opioid
prescriptions
Irvine et al53
2014

-Mail survey
- Clinicians
with DEA
license

Deyo et al54
2014

1,058
(PDMP users
and non-users)

- Mixed
method study

- 612 PDMP
frequent users

- Clinicians
with DEA

- 503
infrequent
users

-PDMP
utilization

_

-Oregon
-PDMP
registry

- PDMPs
registration
and use

_

-Oregon
-PDMP
registry

- Qualitative
telephone
interviews
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- Less than 50% check it for
every new patient or every time
they prescribe a CS
- 25% of all licensed prescribers
had PDMPs accounts
- 36% of CS prescribers were
registered with PDMPs
- Among medical doctors,
number of PDMPs queries have
almost doubled in 2013

- 1,789 nonregistrants
Leichtling et
al55
2017

- 95% access PDMPs when
abuse or diversion is suspected

- Pattern of
PDMP use

_

Oregon

- Most of PDMP users were
regular users
- Long term prescribers used
PDMPs routinely compared to
short term prescribers

-Clinicians
registered with
Oregon PDMP

- Short term prescribers depend
more on their clinical judgment
and suspected abuse behavior, as
a driver to use PDMPs
Rittenhouse
et al56
2015

-Web based
survey

1541

-PDMPs
utilization

30 days

- Medical
doctors, nurse
practitioners,
and
pharmacists
Lin et al57
2016

-Mail survey
- Primary care,
pain, and EPs

405
(105 nonregistrants,
114 registered
non-users, 186
registered
users)

-PDMP
registration
and use

4 months

Healthcare
practices in
all 75
Arkansas
counties

- Maryland
- Maryland
(DHMH)

- PDMPs access varied from
daily access (21.1%) to < 3 times
a month (26.2%)
- Most medical doctors and nurse
practitioners accessed PDMPs
when abuse behavior is
suspected
- 85% of all prescribers with
PDMPs access have ever used
the system in their practice
- Physicians who wrote opioid
prescriptions for more than 50
patients accessed the PDMPs
three times as often as those
prescribing opioids for less than
10 patients monthly (IRR = 3.00,
95 % CI = 1.07–8.43)
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Feldman et
al58
2011

Feldman et
al59
2012

Green et al60
2012

- Survey

95

- Physicians
with different
specialties

- Survey
-Attending and
resident
physicians

-Web based
and mail
survey

- 70 resident
physicians and
25 attending
physicians

1,385
prescribers
(998 in CT and
375 in RI)

-Awareness
and
utilization of
state PDMPs

3 months

-Utilization
of state
PDMPs and
reasons for
accessing the
system

3 months

-PDMPs
utilization

6 months

One
academic
medical
center in
Ohio

-Web based
survey

- One third of attending
physicians and half of resident
physicians do not utilize PDMPs

CT and RI

- Prescribers in CT used PDMPs
more frequently compared to
those in RI (p-value <0.0001)

-Qualitative
study (online
focus groups
and telephone
interviews)

- Most of PDMP users utilized
the system to address concerns
about prescription drug abuse

-More than 60% of prescribers in
both states did not use PDMPs
because they were not aware of
its existence

15

-PDMP
utilization

3 months

15 states

- Operational
PDMPs
Administrators

Hildebran et
al62
2014

- Emergency medicine had the
highest proportion of utilization
compared to pediatric physicians
(p-value ≤0.001)

One
academic
medical
center in
Ohio

- All providers
licensed to
prescribe
scheduled
medications
with an email
address
Fleming et
al61
2013

-84% of all survey respondents
were aware of Ohio PDMPs,
59% used PDMPs

-Prescribers had the highest rate
of requests per 100,000
population
-Availability of online access
and fast turnover of PDMPs
requests increase utilization
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-Pattern of
PDMP use

_

9 states

- Most clinicians reported
checking PDMPs for clinical
purposes, followed by
administrative requirements
- Long term prescribers checked
PDMPs more consistently for
their patients compared to
emergency providers

- Prescribers

CS: controlled substance.
DEA: drug enforcement agency.
DHMH: Department of Health and Mental Hygiene.
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Part II: Literature review on PDMP effectiveness
This part of the literature review is divided into three parts. The first part discusses studies that
evaluate PDMPs impact on prescription opioid abuse risk measures. The second part reviews
studies on the impact of PDMPS on opioid prescribing. The last part discusses studies assessing
the impact of PDMPS on health outcomes related to prescription opioid abuse.
PDMP impact on prescription opioid abuse risk measures:
A total of seven studies assessed the impact of PDMPs on a variety of prescription opioid abuse
risk measures.62-69 The studies compared changes in abuse risk measures by analyzing
longitudinal data or evaluating changes in measures before and after implementing PDMPs. One
of the encountered studies was a randomized clinical trial in a managed care organization. The
remaining studies had a quasi-experimental study design with a control group. Four studies
assessed differences in abuse risk measures between PDMPs and non-PDMPs states. Three
studies examined changes in single states. Following is a review for studies that evaluated
PDMPs effectiveness, arranged in a sequential manner based on date of data collection. Studies
are summarized in Table 2.3.
Reisman et al.63 conducted an ecological study examining the impact of PDMPs on opioid
shipment and inpatient admission rate over the period of 1997 – 2003. The study compared
changes in the two outcome measures between PDMPs (13 states) and non-PDMPs states (36
states). Both groups demonstrated increase in opioid shipment (except for codeine). However, a
significant reduction in the rise of oxycodone shipment was noted in PDMPs states compared to
non-PDMPs states (p-value= 0.019). Also, increase in rate of opioid inpatient admissions was
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lower in PDMPs states compared to non-PDMPs states, however, no information on the
significance of this result was reported.
A study by Brady et al.64 assessed the impact of state PDMPs on per capita dispensing of
opioids. To account for variation in opioid potency, the amount of each drug dispensed was
converted into Morphine Milligram Equivalents (MME). Authors examined the overall effect of
PDMPs on per capita dispensing of opioid as well as state specific impact of PDMPs, using state
quarter as the unit of analysis. The amount of MME dispensed increased significantly over the
study period. However, no significant difference in MME dispensed per capita was found
between state quarters with and without PDMPs (p-value = 0.68). State specific impact of
PDMPs showed a great variation. Nine states had significant reduction in MME dispensed per
capita between state quarters with and without PDMPs. No significant difference was found in
14 states. Eight states had significant increase in MME dispensed. Also, results were not
significant when PDMPs characteristics were considered. Type of PDMPs operating agency,
having statutory requirements for committee oversight of the PDMPs, and having laws that
explicitly do not require prescribers to check the system were not significantly associated with
changes in MME dispensed per capita. Differences in other PDMPs characteristics adopted by
different states may explain variation in states’ specific impact of PDMPs.
Reifler et al.65 (2003 – 2009)
Reifler et al. evaluated PDMPs effectiveness by examining their impact on opioid intentional
exposures and opioid treatment admission rate in PDMPs and non-PDMPs states. The study
utilized data from poison centers and opioid treatment databases which report both measures on a
quarterly basis. Over the period of 2003 – 2009, opioid intentional exposures and opioid
treatment admissions showed an increasing trend over time for PDMPs and non-PDMPs states.
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However, quarterly increase in intentional exposures in PDMPs states was significantly less than
non- PDMPs states (0.2% vs 1.9%, respectively, p-value = 0.036). Opioid treatment admissions
increased per quarter by 2.6% in PDMPs states compared to 4.9% in non-PDMPs states (p-value
0.058). Also, PDMPs characteristics were considered in additional analyses. PDMPs that have
been active for long time, provide data directly to health care providers, and cover controlled
substance at least through schedule IV were considered as superior PDMPs. Increase in opioid
treatment admissions were significantly less in superior PDMPs states compared to others (pvalue= 0.027); however, no significant difference was found for opioid intentional exposure rate
(p-value = 0.086).
Gonzalez et al.66 (2009 – 2010)
A randomized clinical trial by Gonzalez et al. examined the impact of a managed care PDMPs on
prescription opioid abuse measures. Patients with at least three prescribers and three dispensed
prescriptions in a three month period were identified. Prescribers in both groups received letters
indicating an increasing trend of prescription opioid use. Prescribers in the intervention group
received an additional medical report (intervention) providing data for each controlled substance
dispensed during the three month period. Three outcome measures were assessed: change in
number of opioid prescribers, number of pharmacies, and number of opioid prescriptions filled.
The outcome measures were compared between the first month and 12 month following the
intervention. A greater reduction in number of prescribers, number of pharmacies, and number of
prescriptions filled was noted in the intervention group compared to the control group. The study
did not report information on the significance of the observed difference.
Young et al.67 (2010 – 2011)
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Young et al. conducted a study to assess the impact of PDMPs proactive reports on a number of
patient opioid abuse risk measures. In January 2010, Massachusetts PDMPs started to send
proactive reports to prescribers whose patients met the multiple prescriber episode criteria
(utilizing four or more prescribers and four or more pharmacies in a six month period). However,
not all prescribers were notified due to system limitations. The current study utilized a controlled
pre – post study design. The intervention group included patients whose prescribers were sent
proactive reports. The control group was represented by patients who met the multiple prescriber
episode criteria, without informing their prescribers. Participants in the control group were
matched on demographics and baseline prescription history using propensity score matching.
The two groups were assessed for differences in abuse risk measures in the baseline period
(before January 2010); no significant differences were found. However, following proactive
reports, significant reductions in abuse risk measures were reported for the intervention group
relative to the control group. The intervention group had significant reduction in number of
schedule II opioid prescriptions (P < 0.01), number of prescribers visited (P < 0.01), number of
pharmacies used (P < 0.01), dosage units (P < 0.01), total days’ supply (P < 0.01), total MME
(P < 0.01), and average daily MME (P < 0.05) compared to the control group.
Surratt et al.68 (2009 – 2012)
A study in Florida examined changes in prescription opioid diversion rate following a
comprehensive legislation to regulate pain clinic and PDMPs implementation in Florida. Change
in diversion rate per 100,000 population was assessed on a quarterly basis over a three year
period (2009 – 2012). A significant reduction in rate of diverted cases was noted for oxycodone,
methadone, and morphine (p-value: 0.03, 0.001 and 0.05, respectively) following the
implementation of the policies. Diversion rate for other opioids either remained stable over the
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study period or did not significantly change. The study did not isolate the impact of pain clinic
laws (effective in late 2010) from Florida PDMPs (effective in late 2011). Thus, the observed
change in diversion rates cannot be attributed to Florida PDMPs only.
Ali et al.69 (2004 – 2014)
A study by Ali et al. assessed PDMPs impact on non-medical use of prescription opioids
(NMPO), utilizing the National Survey of Drug Use and Health data (2004 – 2014). The study
evaluated the impact of PDMPs existence alone or with prescribers’ mandatory
enrollment/access policy on four outcomes related to NMPO. States with operational PDMPs
and states with an additional requirement of prescribers’ enrollment/access did not significantly
differ from other states in: past year NMPO use, past year prescription opioid dependence, and
past year initiation of NMPO. However, states with PDMPs only or with additional prescriber
enrollment/access requirements had significantly fewer days of NMPO compared to other states
(p-value <0.05 and <0.01, respectively). Also, states with operational PDMPs were associated
with 56% reduction in doctor shopping (≥ two prescribers) compared to non-PDMPs states (pvalue ≤0.05). Further reduction in doctor shopping (80%) was noted in states with additional
requirement of prescriber use mandates (p-value ≤0.05).
Summary of PDMP impact on prescription opioid abuse risk measures:
The literature on PDMPs effectiveness on a variety of prescription opioid abuse risk measures is
inconsistent. Four studies found that having operational PDMPs significantly reduced oxycodone
shipment, prescription opioid intentional exposures, days of prescription opioid supply, and
doctor shopping.63-65, 69 However, PDMPs did not positively impact other abuse risk measures
including per capita dispensing of opioid, treatment admission rate, and last year non-medical
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use of prescription opioids. Three studies were conducted in single states and reported positive
impact of PDMPs on prescription opioid abuse risk measures.66-68
The inconsistency in the reported findings can be related to differences in PDMPs characteristics
adopted by different states. Also, the presence of other policies implemented at similar times to
PDMPs can impact the assessment of PDMPs effectiveness. State level unmeasured confounders
is another contributing factor that should be considered when evaluating differences in outcome
measures among the states.
Table 2. 3: Summary of included studies (PDMP impact on prescription opioid abuse risk
measures)
Author

Study
design and
sample

Sample size

Unit of
analysis

Outcome
measure of
interest

Period

Setting
and data
source

Related findings

Reisman
et al63
2009

- Ecologic
cohort study

- 14 PDMP
states

-State

1997–
2003

-ARCOS

- PDMPs
and nonPDMPs
states

- 36 nonPDMPs
states

- Rate of
prescription
opioid
shipments

- PDMPs and non-PDMPs
states demonstrated increase in
opioid shipment (except for
codeine)

- TEDS

- Rate of
inpatient
admissions
for
prescription
opioid abuse

- A significant reduction in the
rise of oxycodone shipment
was noted in PDMPs states
compared to non-PDMPs states
(p-value= 0.019)
- Increase in rate of opioid
inpatient admissions was lower
in PDMPs states compared to
non-PDMPs states (no p-value)

Brady et
al64
2014

-Ecologic
cohort study
- PDMPs
and nonPDMPs
states

Reifler et
al65
2012

-Ecologic
cohort study

- 2,040 state
quarters
(619 state
quarters
with active
PDMPs)

-State
quarter

- Per capita
dispensing
of opioid
(MME)

1999 2008

-ARCOS

- No significant difference in
MME dispensed per capita was
found between state quarters
with and without PDMPs (pvalue = 0.68)
- State specific impact of
PDMPs showed a great
variation

_

-State
quarter

- Opioid
intentional
exposures
and opioid
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20032009

RADARS

- Opioid intentional exposures
and opioid treatment
admissions showed an

-PDMPs and
non-PDMPs
states

treatment
admission
rate

increasing trend over time for
PDMPs and non-PDMPs states
- Quarterly increase in
intentional exposures in
PDMPs states was significantly
less than non- PDMPs states
(0.2% vs 1.9%, respectively, pvalue = 0.036)
- Opioid treatment admissions
increased per quarter by 2.6%
in PDMPs states compared to
4.9% in non-PDMPs states (pvalue 0.058)

Gonzalez
et al66
2012

Randomized
clinical trial
- Patients
who
received
opioid
prescriptions
from three
or more
prescribers
at three or
more
pharmacies
in a three
month
identification period

Young et
al67
2017

-Controlled
pre-post
- Patients
who
received
schedule II
prescriptions
(with at least
one opioid)
from four or
more
prescribers
at four or
more
pharmacies
in a sixmonth
identification period

Intervention
group (242
patient)

Patient

Change in:

2009 2010

-A
managed
care
organization in
New York

- A greater reduction in number
of prescribers, number of
pharmacies, and number of
prescriptions filled was noted
in the intervention group
compared to the control group
(no p-value)

2010 2011

MA

- Compared to the control
group, the intervention group
had significant reduction in:

- Number of
opioid
prescribers

-Control
group (220
patient)

- Number of
pharmacies
- Number of
opioid
prescriptions
filled

Intervention
group (84
patient)

Patient

- Seven
opioid abuse
risk
measures

- Control
group (504)

- Number of schedule II opioid
prescriptions (P < 0.01)
- Number of prescribers visited
(P < 0.01)
-Number of pharmacies used
(P < 0.01)
- Dosage units (P < 0.01)
-Total days’ supply (P < 0.01)
-Total MME (P < 0.01)
-Average daily MME
(P < 0.05)
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Surratt et
al68
2014

Ali et al69
2017

Longitudinal
ecologic
study

Longitudinal
ecologic
study

- 219

- 507,000

- Year
quarter

-State

- Civilian
population
(12≥ years
old)

- Quarterly
change in
prescription
opioid
diversion
rate per
100,000
population

2009 2012

- Four
outcome
measures
related to
NMPO

2004 2014

- Florida
-RADARS

- Significant reduction in rate
of diverted cases was noted for
oxycodone, methadone and
morphine (p-value: 0.03, 0.001
and 0.05, respectively
- Diversion rate for other
opioids either remained stable
over the study period or did not
significantly change

NSDUH

- Significant association
between PDMPs
implementation and reduction
in ‘doctor shopping’ behavior
- No significant associations
between PDMPs
implementation on nonmedical
use/initiation/dependence of
opioids

ARCOS: Automation of Reports and Consolidated Orders System.
TEDS: Treatment Episode Data Set.
RADARS: Researched Abuse, Diversion and Addiction-Related Surveillance.
MME: Morphine Milligram Equivalents.
NSDUH: National Survey on Drug Use and Health.
NMPO: Non-Medical use of Prescription Opioid.

PDMPS impact on opioid prescribing:
PDMPS impact on opioid prescribing was assessed in eight studies.70 - 77 Five were conducted in
single states; the remaining studies compared opioid prescribing in PDMP and non-PDMP states.
Three studies examined changes in opioid prescribing among emergency providers (EPs), while
others were more general and included prescribers from other ambulatory care settings. Studies
are summarized in Table 2.4.
Three studies evaluated changes in opioid prescribing in Florida. The first study by Rutkow et al.
assessed the impact of pain clinic laws and PDMPS on opioid prescribing and use.70 The study
followed a comparative interrupted times series design over the period 2010 to 2012; Georgia
was selected as the comparator state. Four outcome measures were evaluated: total opioid
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volume, average MME per transaction, number of days supplied, and total number of opioid
prescriptions. Authors found modest, but a statistically significant reduction in monthly opioid
volume and mean MME per transaction in Florida compared to Georgia (p-value <0.05 for both
measures). No significant difference was found in monthly number of days supplied and total
number of opioid prescriptions dispensed. The impact of policies was further examined among
groups of prescribers and patient stratified based on volume of opioid prescribing and use.
Significant reduction in total opioid volume and average MME per prescription was limited for
prescribers and patients with the highest baseline opioid prescribing and use. The study
examined the impact of pain clinic laws and PDMPS jointly and findings supported the
effectiveness of the policies. Nevertheless, the magnitude of the impact was modest and the
statistical significance could be related to the large sample size. Further evidence is needed to
support the effectiveness of PDMPs. Findings of the current study were further analyzed in
another study by Chang et al.71
The new study examined impact of PDMPs implementation and pain clinic laws on high risk
prescribers.71 The latter was defined as prescribers in the top fifth percentile of opioid volume
during four consecutive calendar quarters in the pre-intervention period. The current study
compared seven prescriber related outcomes in Florida and Georgia using a comparative
interrupted times series analysis. The impact of policies was assessed by comparing differences
in level and monthly trend of the outcomes. Among high risk prescribers, the policies had no
significant impact on the level of any of the outcomes. A slight, but statistically significant
increase in monthly trend of average days’ supply was reported (p-value<0.05). In contrast,
significant reduction in the monthly trend of the number of patients receiving opioids, MME per
transaction, total opioid volume, and number of filled opioid prescriptions was found (p-value
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<0.05 and <0.01). Despite this significant impact, opioid prescribing remained highly
concentrated among high risk prescribers after implementation of the policies. In other words,
high risk prescribers continued to account for the high proportion of opioid volume and opioid
prescriptions in the post as the pre-implementation period. The impact of policies on the seven
outcomes were also examined among low risk prescribers and no significant change in level or
trend of the outcomes was documented.
The third study in Florida was conducted among emergency providers (EPs).72 The study utilized
a pre – post study design with a historical control group. Prescribers in the intervention group
were notified of their patients’ prescription history using reports from Florida PDMPs. The
average number of controlled substance prescribed per patient was compared between patients in
the intervention group (in February 2014) and the historical control group (in December 2013).
Results from the Poisson regression model indicated non-significant difference in average
number of controlled substance prescribed per patient between the two groups. Thus, authors
concluded that Florida PDMPs did not influence EPs prescribing of controlled substances.
However, there are clear limitations that could affect findings of the study. Authors did not use
propensity score matching or other statistical methods when selecting the historical control group
and thus, comparison between the two groups might not be acceptable. Also, in the Poisson
regression model, only age, sex and chief complaint were included as confounders, while other
possible confounders were left uncontrolled. The study also investigated PDMPs utilization
among twenty five prescribers in the ED; one third were registered to use PDMPs and more than
two thirds rarely or never accessed the system.
Further assessment of the impact of PDMPs on opioid prescribing in emergency care settings
was conducted in Ohio.73 EPs were surveyed about their likelihood to prescribe opioid analgesics
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for patients presented with non-acute injury. PDMPs data were presented to EPs and prescribers’
likelihood to prescribe opioid was re-assessed after reviewing patients’ prescription fill history.
Among all providers, opioid prescribing decisions were altered for 41% of patients; 61% resulted
in fewer or no opioids prescribed. The study indicated positive impact of PDMPs on opioid
prescribing in the ED; however, two thirds of patients were treated by only four providers. Thus,
findings may not be representative to the general population of EPs.
In North Carolina, Ringwalt et al. examined the relationship between prescribers’ utilization of
PDMPs and opioid prescribing, utilizing PDMPs data for the period between 2009 – 2011.74
Over the study period, an increasing trend in the number of providers with PDMPs queries and
days of access was found. However, the trend of opioid prescriptions and patients filling opioid
prescriptions remained stable. Linear regression models found that increasing prescriber
utilization of PDMPs was not associated with significant reduction in the proportion of patients
or opioid prescriptions filled.
The remaining three studies included prescribers from multiple states and compared differences
in opioid prescribers after PDMP implementation or use.75 - 77
A survey by Pomerleau et al. assessed the impact of PDMPs utilization on opioid prescribing
among EPs.75 The survey included 443 EPs from seven emergency centers across the United
States. About 60% of EPs were registered in the state PDMPs and 50% use it less than once per
shift. The relationship between PDMPs and opioid prescribing was tested in four case scenarios.
Decisions to prescribe opioid in each scenario were compared between PDMP users and nonusers using Chi-square test. No significant association was found between the two groups.
Authors concluded that PDMPs have no impact on opioid prescribing among EPs, which is
contrary to previous studies. To assess the impact of PDMPs on an outcome, regression analysis
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should be used controlling for possible confounders. Using only Chi-square test does not reflect
the actual impact of PDMPs on opioid prescribing and this may explain the non-significant
findings of the current study.
Another study by Bao et al. evaluated PDMPs impact on opioid prescribing in ambulatory care
settings during the period between 2001 – 2010.76 Visits after PDMP implementation were
compared to visits in states without PDMPs. The overall effect of PDMPs on the rate of opioid
prescribing was examined, as well as, the effect of time since implementation. A 30% reduction
in schedule II opioid prescribing was found after PDMPs implementation (p-value<0.001).
However, the reduction in the prescribing of any opioid was not significant. The impact of
PDMPs on schedule II opioid prescribing showed significant results considering time since
PDMP implementation. Furthermore, the reduction in rate of schedule II opioid prescribing
remained significant up to two years after implementation. However, decline in rate of other
opioid prescribing was not significant after six months of implementation.
The last study examined changes in opioid prescribing among Medicare population with part D
coverage.77 The study utilized difference in difference modeling to compare opioid prescribing
pre and post PDMP implementation in states with and without PDMPs. Two independent
variables were included in the models: presence of PDMPs with online access and presence of a
statute that explicitly does not require PDMPs access. The main outcome measure was percent
change in days of opioid supply. Presence of PDMPs with online access was associated with a
significant, but limited decrease in days’ supply for all opioids, oxycodone only, and
hydrocodone only (p-value <0.01). A significant increase in days’ supply for schedule IV was
also found (p-value <0.05). States where a statute did not explicitly require PDMP access were
associated with significant increase in days’ supply for all opioids, hydrocodone only, oxycodone
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only, and schedule IV opioids. Findings of the current study were significant, but limited in
magnitude. The reported significance may also be related to the large sample size and not due to
the actual impact of PDMP.
Summary of PDMP impact on prescribing:
Studies show inconsistent evidence on the impact of PDMPs on opioid prescribing. Studies in
Florida did not isolate the impact of PDMPs from pain clinic laws, so any observed effect cannot
be attributed to PDMPs implementation only. In addition, the positive impact of PDMPs reported
in few studies are either not generalizable, could not be validated, or statistically but not
clinically significant. More evidence is needed to support PDMPs effectiveness. In general, there
is an increasing trend of opioid prescribing in PDMP and non-PDMP states. This suggests that
PDMPs should not be the only policy to combat the prescription opioid abuse epidemic.
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Table 2. 4: Summary of included studies (PDMPs impact on prescribing)
Author

Study design
and sample

Sample
size

Unit of
analysis

Outcome
measure of
interest

Period

Setting and
data source

Related findings

Rutkow et
al70
2015

- Comparative
interrupted
times series

2.6 million

-Patient

- Four
outcomes
measures
related to
opioid
prescribing

2010 2012

- Florida
(intervention
state),
Georgia
(control
state)

- Modest, but,
statistically significant
reduction in monthly
opioid volume and
mean MME per
transaction in Florida
compared to Georgia
(p-value <0.05 for both
measures)

- Patients

- IMS
Health's
LRx
Lifelink
database

Chang et
al71
2016

- Comparative
interrupted
times series
- Prescribers

For Florida:

Prescriber

- High risk
prescribers
(1526)

- Seven
prescriber
related
outcomes

2010 2012

- Low risk
prescribers
(36,939)

- Florida
(intervention
state),
Georgia
(control
state)
- IMS
Health's
LRx
Lifelink
database

- No significant
difference in monthly
number of days
supplied and total
number of opioid
prescriptions dispensed
- Significant reduction
in the monthly trend of:
(- Number of patients
receiving opioids
- MME per transaction
-Total opioid volume,
and
- Number of filled
opioid prescriptions)
in Florida compared to
Georgia
- A slight, but
significant increase in
monthly trend of
average days’ supply
(p-value <0.05)
- No significant
differences among low
risk prescribers

McAllister
et al72
2015

- Pre – post
design
- Patients (≥18
years old)
treated at ED

Interventio
n group
(356
patient)

Patient

- Change in
average
number of CS
prescribed per
ED visit

- Historical
control
group (354
patient)
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2013 and
2014

- ED of a
tertiary care,
urban
university
teaching
hospital in
Florida

- No significant
difference in average
number of controlled
substance prescribed
per patients between the
two groups

Baehren et
al73
2010

- Pre – post
design (using
survey as data
collection
method)

- 179
patient

Prescriber

- 18
provider

-Patients
presented at
the ED with
painful
conditions
Ringwalt
et al74
2015

Longitudinal
ecologic study

_

Per six
months/per
1000
persons

- Change in
opioid
analgesics
prescribing for
patients
presented with
non-acute
injury

June July
2008

-PDMPs
utilization and
its impact on:

2009 2011

Ohio

- 61% resulted in fewer
or no opioids prescribed

NC

- Rate of
patients filling
opioid
prescription

-Web based
survey

443

_

- PDMPs
registration
and use

- Increasing trend in
number of providers
with PDMPs queries
and days of access
- However, no
significant reduction in
proportion of patients
filling opioid
prescriptions or opioid
prescriptions filled

- Rate of
opioid
prescriptions
filled
Pomerleau
et al75
2017

- Opioid prescribing
decisions were altered
in 41% of patients

August –
October
2014

- EPs
- Opioid
prescribing

- Seven
emergency
centers
across the
United
States

- 60% of EPs were
registered in state
PDMPs
- 50% use it less than
once a shift
- PDMPs utilization did
not significantly impact
opioid prescribing

Bao et al76
2016

- Pre – post
design
- Patients (≥
18 years old)
presented to
an office
based visit
with pain

26,275
ambulatory
care office
visits

Visit

- Having at
least one
Schedule II
opioid
analgesic
(dichotomous)
- Having at
least one
opioid of any
kind
prescribed or
continued at a
pain-related
ambulatory
care visit
(dichotomous)
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2001 –
2010

- 24 states
with online
access
PDMPs
- NAMCS

a. Impact of PDMP
existence:
- 30% reduction in
schedule II opioid
prescribing following
PDMPs implementation
(p-value<0.001)
- Non significant
reduction in the
prescribing of any
opioid
b. Impact of PDMP
considering time since
implementation:

- Significant reduction
in schedule II
prescribing up to two
years following
implementation
- Significant reduction
in the prescribing of
any opioid for the first
six months following
implementation

Yarbough
CR77
2017

-Controlled
before and
after
- Medicare
population
with part D
coverage

451,583
physician
year
observations

-Physician

-Percent
change in days
of opioid
supply

2010 –
2013

-ProPublica
- CMS

- States with online
access PDMPs had
significant reduction in
days’ supply for all
opioids (p-value <0.01)
- However, a significant
increase in days’ supply
for schedule IV was
found (p-value <0.05)

IMS Health's LRx Lifelink database: an individual level claims database that represents 65% of retail prescription
transactions in the United States.
MME: Morphine Milligram Equivalents.
CS: controlled substance.
EPs: emergency providers.
NAMCS: National Ambulatory Medical Care Survey.
ProPublica: a non-profit news organization.
CMS: Centers for Medicare and Medicaid Services.

PDMPs impact on prescription opioid related-health outcomes:
The existing literature examined PDMPs impact on prescription opioid related overdose deaths
and emergency room visits. Five studies assessed the impact of PDMPs on overdose deaths,78 - 82
and one evaluated the impact on ED visits.83 The reviewed studies assessed PDMPs effectiveness
by comparing the rate of overdose deaths or ED visits in PDMPs and non-PDMPs states over a
period of time. One study was conducted in Florida and evaluated changes in overdose deaths
following PDMPs implementation. Studies are summarized in Table 2.5.
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An early study by Paulozzi et al. examined PDMPs impact on overdose deaths over the period
1999 – 2005.78 The study compared opioid overdose mortality rate and MME consumption rate
(per 100,000 population) in PDMPs and non-PDMPs states. PDMPs implementation was not
associated with significant reductions in opioid overdose mortality or MME consumption rate
per state-year (p-value = 0.34, 0.55, respectively).
Over a similar period of time, Li et al. conducted a study comparing the number of drug
overdose deaths per state per quarter year (i.e. state-quarter) in 31 PDMPs states and 20 nonPDMPs states during the period 1999 – 2008.79 A state-quarter was coded having PDMP if the
state implemented the PDMP any time during the quarter year. State-quarters with PDMP were
associated with a 11% increase in drug overdose deaths compared to state-quarters without
PDMPs (adjusted risk ratio = 1.11; 95% CI: 1.02–1.21). Also, the impact of PDMPs varied
among the states. PDMP implementation was associated with a significant reduction in drug
overdose mortality in three states, a significant increase in 17 states, and no impact in 11 states.
The impact of PDMPs characteristics was also examined. The increase in overdose mortality was
more pronounced in state-quarters with PDMPs monitored by a pharmacy board or those without
an expectation on practitioners to access the system.
A later study by Patrick et al. evaluated the impact of PDMPs implementation on opioid
overdose deaths in 34 states.80 The study compared the annual rate of deaths per 100,000
population pre and post PDMPs implementation over the period 1999 – 2013. Unlike previous
studies, results from linear regression analysis found a significant decline in the annual rate of
opioid overdose deaths following PDMPs implementation (p-value<0.001). The impact of
PDMPs characteristics was also examined. States with PDMPs that monitor four or more drug
schedules and update data on a weekly basis had a significantly lower rate of opioid overdose
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deaths compared with other state PDMPs (p-value <0.05 and <0.001, respectively). However, no
significant impact of PDMPs registration or use mandates was found.
The significant impact of PDMPs on overdose mortality was also documented in a recent study
by Pardo.81 The study compared the opioid overdose death rate in PDMPs and non-PDMPs
states. Unlike previous studies, the current study considered PDMP strength when assessing its
impact on overdose deaths. PDMP strength was measured based on the adoption of 11
characteristics or policies related to PDMPs operation. A score (a continuous number) was given
for each state-year to represent PDMPs strength for the state-year; stronger PDMPs (i.e. more
policies adopted) received higher scores. States without operational PDMPs received a score of
zero. The regression model also controlled for the type of administrating agency and the
presence of other regulatory policies including naloxone access and pain clinic laws. Results of
the regression model were significant; with every one point increase in the PDMPs score,
overdose deaths decreased by 1.5% (p-value ≤ 0.05). However, when scoring on quartiles, only
PDMPs scores in the third quartiles were associated with a significant reduction in overdose
deaths compared to non-PDMPs states. PDMPs scores in the fourth quartile were not significant.
Findings of the current study suggest that PDMPs strength matters when assessing PDMPs
effectiveness. The non-significant impact of PDMPs with scores in the fourth quartile may
indicate that increasing the number of PDMPs policies may negatively influence the
effectiveness of PDMPs.
Also, a recent study in Florida supports PDMPs effectiveness in reducing overdose mortality.82
The study examined changes in oxycodone-caused deaths following PDMPs implementation.
The study utilized an interrupted time series design and examined changes from 2003 to 2012.
Authors compared the monthly number of oxycodone-caused deaths before and after PDMPs
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implementation in 2010. The model controlled for multiple confounders including pain clinic
laws and other regulatory policies implemented at a similar time to PDMPs. The impact of
PDMPs and the rate of PDMPs query by health care providers on oxycodone-related mortality
were examined. PDMPs were associated with a 25% decline in the number of deaths (p-value =
0.008). Significant results were also reported for the impact of the rate of PDMPs query. With
every increase of one query per health care provider, the number of oxycodone deaths decreased
by 0.23 persons per month (p-value = 0.002). However, the impact of PDMPs on opioid
(excluding oxycodone) caused deaths was not significant (p-value 0.7).
The last study assessed the impact of PDMPs on the prescription opioid related ED visits and the
findings were not significant.83 The study compared the rate of ED visits per quarter year
between PDMPs and non-PDMPs states during the period 2004 – 2011. The main outcome
measure included ED visits related to misuse and non-misuse of prescription opioids. For all
opioid related visits, the rate of ED visits did not significantly differ between states with and
without PDMP (p-value = 0.74). Results for ED visits related to prescription opioid misuse or
abuse were also not significant (p –value = 0.57). Findings of the current study suggest PDMPs
ineffectiveness. However, authors did not consider differences in PDMPs characteristics or
policies among states, which may have a huge impact on the reported findings.
Summary of PDMP impact on health outcomes:
As discussed earlier, old studies that examined the PDMPs impact on prescription opioid
overdose deaths showed mixed evidence of PDMPs effectiveness. Later studies provided more
evidence supporting the positive impact of PDMPs on reducing overdose mortality. Overdose
deaths may not be a good measure for opioid safety; many factors may contribute to death.
Furthermore, documentation for the reason of death may not be accurate and thus, may not truly
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represent deaths due to prescription opioid overdose. Most studies did not consider differences in
PDMP characteristics among states, which may have a profound effect on PDMPs effectiveness.
Only one study considered PDMP strength and the results were significant.
Prescription opioid related ED visits is a better indicator for opioid safety. Only one study
examined PDMP impact on ED visits and the results were not significant. More studies are
needed to examine the impact of PDMPs on ED visits.
Table 2. 5: Summary of included studies (PDMPs impact on prescription opioid related-health
outcomes)
Author

Paulozzi et
al78
2011

Study
design and
sample
- Ecologic
study

Sample
size

Unit of
analysis

357 state
year (247
without
active
PDMPs
and 110
with
PDMPs)

State-year

Outcome
measure of
interest
- Rate of
prescription
opioid
overdose
death

Period

Setting and
data source

Related findings

1999 2005

- PDMPs
and nonPDMPs
states

PDMPs implementation
was not associated with
significant reduction in
overdose death or MME
consumption rate

-CDC
(multiple
cause of
death
mortality
files)

- Rate of
MME
consumption

- ARCOS
Li et al79
2014

- Ecologic
study

2040 state
quarter
(619 with
active
PDMPs)

Statequarter

- Rate of
drug
overdose
deaths

1999 2008

PDMPs (31)
and nonPDMPs (20)
states
-CDC
(multiple
cause of
death
mortality
files)

Patrick et
al80
2016

- Ecologic
study
(interrupted
time-series)

_

State-year

- Annual
rate of
opioidrelated
overdose
deaths (per
100,000
population)
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1999 –
2013

- 34 states
with active
PDMPs
- CDC
(multiple
cause of
death

- Overall,
implementation of
PDMPs was associated
with an 11% increase in
drug overdose mortality
(ARR = 1.11; 95%
CI = 1.02–1.21)
- PDMPs impact on
drug overdose mortality
varied greatly across
states
- Significant decline in
annual rate of opioid
overdose deaths
following PDMPs
implementation (p-value
<0.001)

mortality
files)
Pardo B81
2017

- Ecologic
study

816 state
year

State-year

- Rate of
opioid
overdose
death

1999 2014

- PDMPs
and nonPDMP
states
- CDC
(multiple
cause of
death
mortality
files)

- Significant impact of
PDMPs considering its
strength:
- With every one point
increase in PDMPs
score, overdose deaths
decreased by 1.5% (pvalue ≤ 0.05)

- PDAPS
Delcher et
al82
2015

- Interrupted
time-series

120
monthly
counts of
oxycodonecaused
mortality

Month

- Monthly
counts of
oxycodonecaused
mortality

2003 2012

- Florida
- Florida
MEC

- PDMPS was
associated with 25%
decline in number of
deaths (p-value = 0.008)
- With every increase of
one PDMPS query per
health care provider,
number of oxycodone
deaths decrease by 0.23
persons per month (pvalue = 0.002)
- PDMPS did not
significantly impact
other opioid related
deaths (p-value= 0.7)

Maughan et
al83
2015

- Ecologic
study

_

Quarter
year

-Rate of ED
visits (per
100,000
population)

MME: Morphine Milligram Equivalents.
ARR: adjusted Risk Ratio.
CDC: Centers for Disease Control and Prevention.
ARCOS: Automation of Reports and Consolidated Orders System.
State-quarter: Per state per quarter year.
PDAPS: Prescription Drug Abuse Policy System.
MEC: Medical Examiners Commission.
DAWN: Drug Abuse Warning Network.
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2004 2011

- DAWN

- Rate of prescription
opioid related ED visits
did not significantly
differ between states
with and without
PDMPs (p -value =
0.57)

Part III: literature review on prescriber mandates
As seen in the previous studies (part I and II literature review), the literature provided
inconsistent evidence of the effectiveness of PDMPs. Studies on PDMPs utilization showed low
and irregular use of the system; this negatively impacted the expected benefit of PDMPs.
Prescriber use mandates are a relatively new policy directed to increase PDMPs utilization
among prescribers. The impact of the policy on increasing PDMPs effectiveness (by increasing
its utilization) has not been fully studied. This part of the literature review discusses studies on
prescriber use mandates and its impact on the prescription opioid abuse epidemic.
A total of four studies have investigated the impact of prescriber use mandates on opioid
prescribing and opioid related overdose deaths.84-87 Two studies were conducted in New York
and two studies included multiple states. Studies are summarized in Table 2.6.
Brown et al. conducted a study to examine the impact of the Internet System for Tracking OverPrescribing (I-STOP) on opioid prescribing and related morbidity.84 I-STOP is an extension of
New York PDMPs with the additional requirement of prescriber use mandates. The study
examined changes in the trend of opioid prescriptions filled per year, quarterly MME supply, and
opioid related overdoses before and after I-STOP implementation. Following the introduction of
I-STOP, quarterly MME supply significantly increased (p-value= 0.006), although the number of
opioid prescriptions filled appeared to have a negative trend. More data points are required to
confirm the impact of I-STOP on reducing the number of opioid prescriptions filled. Prescription
opioid related overdose (as measured by number of ED visits and inpatient admissions) showed
an increasing trend before I-STOP implementation and leveled off following I-STOP. However,
differences in slope between pre and post I-STOP periods were not significant (p-value =0.37).
The study findings indicated that I-STOP did not significantly change the opioid prescription
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trend in NY. A leveling off in prescription opioid morbidity following I-STOP is promising
given the national increasing trend of opioid morbidity and mortality.
In addition to the previous study, Rasubala et al. assessed the impact of I-STOP on dentists
prescribing of opioids.85 The study examined changes in the odds of opioid prescribing in the
period following I-STOP implementation compared to the pre-I-STOP period. Results were
significant; the odds of receiving an opioid analgesic decreased by almost 60% following ISTOP compared to the pre-I-STOP period (OR = 0.42, 95% CI: 0.35, 0.51, p-value <0.05). Also,
there was a significant reduction in the total number of opioid prescriptions following I-STOP
implementation (p-value <0.05). A number of study limitations have been noted. The regression
model was not clear and results were not shown. Authors did not control for confounders like
demographics or, if they did so, the included covariates were not reported in the study.
In a more generalizable study, Dowell et al. evaluated the impact of PDMPs prescriber
mandatory access and pain clinic laws in 38 states and the District of Colombia.86 The study
compared rate of opioid prescribing (in MME per state resident) and overdose deaths in states
with prescriber use mandates and pain clinic laws and those without the policies over the period
2006 - 2013. A significant reduction in the rate of opioid prescribing and overdose deaths was
observed in states with both policies compared to controls (p-value <0.05). States who
implemented pain clinic laws also adopted prescriber use mandates at similar times and thus, the
impact of prescriber mandates only could not be isolated.
A more recent study by Wen et al. examined the impact of prescriber mandates on the rate of
opioid prescribing among Medicaid enrollees for the period 2011- 2014.87 The study
differentiated mandates into registration mandates only, use mandates only, and registration and
use mandates. The main outcome measure was the total number of opioid prescriptions filled per
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100 enrollees per quarter year. Results from linear regression models indicated that states with
PDMPs registration mandates had a significant reduction in the rate of schedule II opioid
prescribing compared to states without any mandates (p-value <0.05). Significant reductions in
the rate of schedule II opioid prescribing were also reported for states with PDMPs registration
and use mandates (p-value <0.05). However, PDMP use mandates only had a limited impact on
the rate of schedule II opioid prescribing (results were not significant at a 0.05 level of
significance). Further analysis differentiated weak and strong (i.e. comprehensive mandates
without prescriber judgment) mandates, however, no significant impact of any type of mandates
was found.
As seen in the previous studies, prescriber use mandates have a limited impact on opioid
prescribing and prescription opioid related overdose deaths. More studies are needed to prove the
effectiveness of the new policy.
Table 2. 6: Summary of included studies (PDMPs prescriber use mandates)
Author

Brown et
al84
2017

Study
design and
sample

Interrupted
time series

Sample
size

Unit of
analysis

Outcome
measure
of interest

Period

Setting
and data
source

Related findings

_

- Year
quarter

- Changes
in trend
of:

2010 2015

- NY

-Following ISTOP
implementation:

- ARCOS

-Year
- Quarterly
MME
supply

- BNNYSDOH
- SPARCS

- Quarterly
Opioid
related
morbidity
- Yearly
opioid
prescriptio
ns filled
per year
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- Significant increase in
quarterly MME (P-value=
0.006)
- Prescription opioid related
morbidity leveled off (no
significant difference from
pre-ISTOP period)
- Number of opioid
prescription filled showed a
negative trend

Rasubala
et al85
2015

- Pre – post
design

6204
visits

Dentist
visit

-Odds of
receiving
opioid

- Dentists
- Number
of opioid
prescriptio
n

(12/ 2012–
02/2013)
and
(12/ 2013 –
02/ 2014)

- A dental
urgent care
in NY
- Patient
records

- Following ISTOP
implementation:
- Odds of receiving an opioid
analgesic decreased by
almost 60% (OR = 0.42,
95% CI: 0.35, 0.51)
- Significant reduction in
total number of opioid
prescriptions (Chi-square
test, p-value <0.05)

Dowell et
al86
2016

- Ecologic
study
(difference
in
difference
model)

312
state
year

State
year

-Rate of
opioid
prescribin
g-g (in
MME per
state
resident)

2006 –
2013

- Rate of
prescription opioid
overdose
deaths (per
100,000
state
resident)

Wen et
al87
2017

- Ecologic
study
-Medicaid
enrolls

736
state
quarter

Year
quarter

-Rate of
opioid
prescribeng (per
100
enrollee
per quarter
year)

-Prescriber
mandates
and nonprescriber
mandates
states (total
39 states)

- Significant reduction in
rate of opioid prescribing
and overdose deaths was
observed in states with
prescriber mandates
compared to controls (pvalue <0.05)

- CDC
(multiple
cause of
death
mortality
files)
- IMS
Health’s
National
Prescription Audit
2011- 2014

- CMS
(Medicaid
State Drug
Utilization
Files)

- Significant reductions in
rate of schedule II opioid
prescribing for state PDMPs
with both registration and
use mandates (p-value
<0.05).
– No significant reduction in
rate of schedule II opioid
prescribing for state with use
mandates only

ARCOS: Automation of Reports and Consolidated Orders System.
BNE-NYSDOH: Bureau of Narcotics Enforcement- New York State Department of Health.
SPARCS: Statewide Planning and Research Cooperative System.
MME: Morphine Milligram Equivalents.
CDC: Centers for Disease Control and Prevention.
CMS: The Centers for Medicare and Medicaid Services.
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Overview of the literature
Prescription Drug Monitoring Programs (PDMPs) have been adopted by all states (except
Missouri). However, the effectiveness of these systems has not been fully demonstrated. Earlier
studies provided inconsistent evidence on PDMPs effectiveness. However, there is a growing
body of literature to support their positive impact on the prescription opioid abuse epidemic.
Studies have shown that PDMP utilization is low and variable among healthcare providers; this
may explain the inconsistent findings reported in the literature. In addition, studies examining the
impact of PDMPs on prescription opioid related health outcomes have selected overdose death as
the outcome measure even though it may not be a good indicator for PDMP effectiveness. Only
one study has selected ED visits as a measure for prescription opioid safety, and results were not
significant.
In the proposed research, PDMPs effectiveness will be examined in terms of their impact on
prescription opioid poisoning related ED visits. Also, the impact of prescriber use mandates on
increasing PDMPs utilization will be considered. The connection between prescriber use
mandates and their impact on ED visits can be explained by the Donabedian model discussed in
Chapter 1.
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Chapter 3

Methods and results for specific aim 1:
A. To identify and select states with laws or regulations mandating prescriber use of
PDMPs.
B. To identify and select comparison state(s) without mandatory use policies.

Section 3.1-Methods
Data source
Three data sources were used to identify states with or without PDMPs prescriber use mandate
policies, the Center of Excellence (COE) at Brandeis University, the National Alliance for Model
State Drug Laws (NAMSDL), and the Prevention Status Report (PSR) from the CDC. The COE
at Brandeis University is the first comprehensive source of information on PDMPs.88 Established
in 2010, the COE is a joint project between the Bureau of Justice Assistance (BJA) and Brandeis
University, and it was created to evaluate PDMPs effectiveness. One major use of the CEO data
is to disseminate information on PDMPs best practices or policies in order to enhance their
effectiveness in combating the prescription opioid abuse epidemic.
The NAMSDL is another valuable source of information on PDMPs.89 NAMSDL is a non-profit
organization that drafts model drug and alcohol laws, policies, and regulations. NAMSDL also
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compares state policies and regulations related to alcohol and substance abuse prevention and
treatment. For example, in December 2016, NAMSDL published a report on eight evidence
based practices to optimize prescriber utilization of PDMPs.31 The report discussed states’
adoption of the policies and preliminary findings on their impact on prescription opioid abuse as
well as prescriber use mandates policy. Compared to the COE, the NAMSDL provided more
information on the type of prescriber use mandates adopted by the states. States were classified
based on the level of prescriber requirements to check the PDMPs.
Lastly, the PSR was utilized. First published by the CDC in February 2012, PSR provides
information on states adoption of PDMPs prescriber use mandates.90 The PSR focuses on two
PDMP policies: state requirement for prescriber comprehensive PDMP use and timely data
submission to PDMP. The CDC used a three-level rating scale (green, yellow, red) to describe
the extent of state adoption of these policies. The rating scale is based on data from the COE at
Brandeis University and NAMSDL supported by emerging evidence and/or expert opinion. The
green rating is the highest level rating and is given to states with comprehensive prescriber use
mandates, defined as “requiring prescribers to consult the PDMP before initially prescribing
opioids and benzodiazepines, and at least every three months thereafter.”90 The latest PSR
assessment of state adoption of prescriber use mandates was conducted on October 31, 2015;
however, it does not provide information on timing of policy implementation. Table 3.1
describes the three-level rating scale.
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Table 3. 1: Requirements for comprehensive use of state PDMPs90
Rating

State PDMP use requirement

Green

Prescribers are required to consult the PDMP before initial
opioid and benzodiazepine prescriptions and at least every three months thereafter

Yellow Prescribers are required to consult the PDMP before initial opioid prescriptions and again
within one year
Red

Prescribers are not required to consult the PDMP before initial opioid prescriptions,
OR such a requirement does exist but there is no required subsequent check and/or the policy
includes subjective standards or broad exceptions

Selection of eligible states
Using the COE, NAMSDL and PSR, an overall assessment of states adoption of PDMPs
prescriber use mandates was conducted. As of 2017, the COE classified 39 states as “mandate
states”. As of 2015, the NAMSDL identified 13 states with requirements for comprehensive
prescriber use and 15 states with requirements for prescribers to check the system in narrower
circumstances; the remaining 22 states were classified as non-mandates states.31 Comprehensive
prescriber use mandates require all prescribers to check the state PDMPs with just a few
exceptions. Based on the PSR, only four states were classified as comprehensive prescriber use
mandates, four states had non-comprehensive mandates, and all other states were non-mandated.
For the current study, the selection of mandates and non-mandates states was based on the threelevel rating scale. States with green rating (comprehensive prescriber use mandates) were
considered as gold standards and represented the intervention state(s) in order to examine the full
impact of the prescriber use mandates policy. Comparator states were selected from states who
received a red rating. The HCUP State Emergency Department Databases (SEDD) and the State
Inpatient Databases (SID) provide information on treat and release ED visits and ED visits that
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resulted in hospital admission. The SEDD and the SID are the only available databases that
provide ED visits on the state level and were selected as the source of data for the current
study.91
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Section 3.2-Results
States with prescriber use mandates policy
States require prescribers to check PDMPs based on specific scenarios — which varies
significantly based on the situation. In July 2012, Kentucky was the first state that implemented a
comprehensive prescriber use mandate policy followed by New York, Ohio, and Connecticut.
New Jersey, Oklahoma, Rhode Island, and Tennessee received a yellow rating from the CDC
while all other states were rated red. States with comprehensive mandate policies were
considered as intervention states. To select an intervention state, the state should have available
data on prescription opioid poisoning ED visits at least one year before and one year after the
policy implementation. Out of the four states that received green rating from the CDC, only
Kentucky and New York have ED visits data available in the HCUP. However, the latest
available data for New York were in 2014 and the mandates policy was implemented in August
2013. The after mandates period was not sufficient to examine the impact of the policy. Thus,
Kentucky was selected as the intervention state. The comparator state was selected from states
that received red rating in the PSR. The selection was based on geographic proximity to
Kentucky and availability of data in the HCUP. ED visits data were not available for the seven
neighboring states. The closest state with available data was North Carolina, which was selected
as the comparator state. Table 3.2 summarizes information on states adoption of prescriber use
mandates policy and availability of ED visits data in the HCUP.
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Table 3.2: States adoption of prescriber use mandates policy and availability of ED visits data in
the SEDD and the SID92
State

Kentucky

Intervention
vs.
comparator
statea
Intervention

7/20/2012

2008 2015

2000 2015

New York

Intervention

8/27/13

2006 2014

1999 2014

Not
eligible

Ohioc,d

Intervention/
comparator
Intervention

4/1/15
10/1/2015

West
Virginiad
Virginiad

Comparator

-

Comparator

-

Tennesseed

Comparator

-

Indianad

Comparator

-

Missourid

Comparator

-

Illinoisd

Comparator

-

North
Carolina

Comparator

-

Not
available
Not
available
Not
available
Not
available
Not
available
Not
available
Not
available
Not
available
2000 2015

Not
available
Not
available
2000 2014
Not
available
Not
available
Not
available
Not
available
Not
available
2007 2015

Not
eligible
Not
eligible
Not
eligible
Not
eligible
Not
eligible
Not
eligible
Not
eligible
Not
eligible
Eligible

Connecticutd

a.
b.
c.
d.

Effective
date of
policyb

Data in the Data in the
SEDD
SID

Eligibility
for the
current
study
Eligible

Rationale

Implemented
comprehensive mandates
and has available ED
visits data before and
after 2012
ED visits data are not
available one year after
August 2013
ED visits data are not
available
ED visits data are not
available
ED visits data are not
available in the SEDD
ED visits data are not
available
ED visits data are not
available
ED visits data are not
available
ED visits data are not
available
ED visits data are not
available
- A non-mandates state.
-Geographically close to
Kentucky
- Has available ED visits
data one year before and
one year after 2012

States with green rating were considered as intervention states, states with red rating were considered as
reference.
NAMSDL report.
Ohio is a neighboring state to Kentucky and it implemented mandates policy in 2015, thus, it could be
considered as intervention state (if ED data were available) or a comparator state.
A neighboring state to Kentucky.
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Chapter 4

Methods and results for specific aim 2:
Among Kentucky and North Carolina residents:
A. To determine the prevalence of prescription opioid poisoning ED visits.
B. To characterize prescription opioid poisoning ED visits based on socio-demographic
and clinical characteristics.
C. To examine associations between patients’ sociodemographic and clinical
characteristics and prescription opioid poisoning ED visits.

Section 4.1-Methods
Study Setting
All prescription opioid poisoning ED visits in Kentucky and North Carolina for the years 2011 to
2014.
Data source
Data from the State Emergency Department Databases (SEDD) and the State Inpatient Databases
(SID) were used for the current study.91 Both SEDD and SID are part of the family of databases
and software tools developed for the Healthcare Cost and Utilization Project (HCUP). The
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SEDD is a longitudinal dataset that contains information on emergency visits at hospitalaffiliated EDs that do not result in hospitalization, and clinical, socio-demographic, and resource
utilization information. Currently, 22 states release their ED data through the SEDD; however,
not all variables are available for each year data was collected.
To analyze all ED visits, data from the SEDD need to be combined with the SID. The SID
records ED visits that result in hospital admissions and contains information about patients
initially seen in the ED and then admitted to the hospital. The SID includes inpatient discharges
from community hospitals per state per year. Currently, 31 states have their inpatient data
available through the SID. Similar to the SEDD, the SID includes clinical, socio-demographic,
and resource utilization variables for each inpatient discharge. Both the SEDD and the SID for
Kentucky and North Carolina were used in the current study.
Sample
The inclusion and exclusion criteria considered to determine the final study samples are listed
below. Figure 4.1 illustrates the sample selection process.
Inclusion criteria:
a. Patients had to be at least 12 years of age.
b. ED visits with all listed diagnosis of prescription opioid poisoning were considered.
There are up to 25 diagnosis variable in the SEDD and the SID (DX1 to DX25), an
indicator variable of prescription opioid poisoning event was created using all 25
variables.
c. Intentional, unintentional, and prescription opioid poisoning events with undetermined
intent were considered. Patients may have the intention to abuse prescription opioid,
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however, they may develop a poisoning event unintentionally. Since there is no clear
guidance on how to classify intention of opioid poisoning, all intentions were considered
for this study. The variables (ECODE1 to ECODE7) were utilized to identify poisoning
intention.
Exclusion criteria:
a. Prescription opioid poisoning ED visits for patients with cancer were excluded. Cancer
patients are considered a special population due to severity of pain and complexity of
their medical condition. PDMPs are intended to capture doctor shoppers; therefore,
including cancer patients does not reflect the population of interest. Single level Clinical
Classifications Software (CCS) was used to identify patients with cancer diagnosis. A list
of CCS for cancer is available in Appendix A.
b. Opioid poisoning ED visits for patients who were not residents in Kentucky or North
Carolina. Prescriber use mandates policy is state specific and thus, including nonresidents may bias the evaluation of the policy.
c. Fatal prescription opioid poisoning events. Death might not be a good indicator for
prescription opioid poisoning because many factors can contribute to a patient’s death.
d. Heroin related poisoning events because illicit drugs are not covered under PDMPs.
Identification of prescription opioid poisoning events
Opioid poisoning events were identified using the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes. External Cause of Injury codes (E-codes)
are an extension of ICD-9-CM codes used to specify intent of opioid poisoning. Description of
ICD-9-CM codes and E-codes related to opioid poisoning is available in Table 4.1.
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Table 4. 1: ICD-9-CM codes and E-codes for opioid poisoning
ICD-9-CM code
965.00
965.02
965.09

Description
Poisoning by opium (alkaloids), unspecified
Poisoning by methadone
Poisoning by other opiates

E-code

Description

E850.1
E850.2
E950.0
E980.0

Accidental poisoning by methadone
Accidental poisoning by other opiates and related narcotics
Suicide and self-inflicted poisoning by analgesics, antipyretics, & antirheumatics
Poisoning by analgesics, antipyretics & antirheumatics, undetermined whether
accidentally or purposely inflicted
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Number of ED visits (SID) in NC
from 2011 to 2014

Number of ED visits (SID) in KY
from 2011 to 2014

(N=2,152,796)

(N= 1,167,966)

Number of all ED visits (combined
SEDD and SID) in NC from 2011 to
2014

Number of all ED visits (combined
SEDD and SID) in KY from 2011 to
2014

(N=18,102,397)

(N=9,364,242)

Exclude ED
visits for
patients <12
years old

(N= 8,190,898)

(N=15,674,886)

Exclude ED
visits for
cancer
patients

Exclude ED
visits for
patients <12
years old

Exclude ED
visits for
cancer
patients
(N=15,030,316)

(N= 7,842,812)

Exclude ED
visits for
nonresidents

Exclude ED
visits for
nonresidents
(N=14,410,161)

Exclude ED
visits
resulted in
patient
death

(N= 7,442,262)

c

c
(N= 7,408,933)

(N= 14,346,788)

Total ED
visits with
prescription
opioid c
poisoning

c

c

(N= 7,419)b

(N= 12,598)a

Exclude ED
visits
resulted in
patient
death
Total ED
visits with
prescription
opioid
poisoning c

Figure
Figure 4.1:
4. 1: Sample
Sample flow
flow chart
chart for
for specific
specific aim
aim 22
a.

Final sample size for NC from 2011 to 2014, b. Final sample size for KY from 2011 to 2014, c. based on
ICD-9-CM codes in Table 4.1
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Variables
Clinical Variables
In the SEDD and the SID, the variable (DXn) represents patient’s diagnosis based on ICD-9-CM
codes. There are up to 25 listed diagnosis for each patient discharge abstract (DX1 to DX25). An
indicator variable was created to identify prescription opioid poisoning event using all listed
diagnoses. For the SID, the first listed diagnosis is the principle diagnosis responsible for
hospital admission; however, in the SEDD, the first listed diagnosis is the main condition,
symptom, or problem responsible for the ED visit. The first listed diagnosis in the SEDD and the
SID cannot be substituted, if missing, with the second, third, or any following diagnosis.
However, starting from the first secondary diagnosis, the diagnoses are shifted to eliminate blank
secondary diagnoses.
Number of chronic conditions was recoded into six categories based on the Agency for the
Healthcare Research and Quality (AHRQ) classification.93 Number of chronic conditions was
selected because it is a risk factor for opioid poisoning. The more chronic conditions the patient
has, the higher is the risk of having a prescription opioid poisoning event.
Other risk factors for opioid poisoning include pre-existing conditions of psychoses, depression,
alcohol, and drug abuse. Indicator variables for each condition was created based on ICD-9-CM
codes. An indicator variable for each condition was created using all listed diagnoses (DX1 to
DX25). A description of ICD-9-CM codes for depression, psychoses, alcohol abuse, and drug
abuse is available in Table 4.2.
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Table 4. 2: ICD-9-CM codes for depression, psychoses, alcohol abuse, and drug abuse94
Comorbidity

ICD-9-CM code

Depression

296.2, 296.3, 296.5, 300.4, 309.x, 311

Psychoses

293.8, 295.x, 296.04, 296.14, 296.44, 296.54, 297.x, 298.x

Alcohol abuse

265.2, 291.1, 291.2, 291.3, 291.5, 291.6, 291.7, 291.8, 291.9, 303.0, 303.9, 305.0, 357.5,
425.5, 535.3, 571.0, 571.0, 571.1, 571.2, 571.3, 980.x, V11.3

Drug abuse

292.x, 304.x, 305.2, 305.3, 305.4, 305.5, 305.6, 305.7, 305.8, 305.9, V65.42

Sociodemographic variables
Age was categorized into five groups based on the literature related to opioid poisoning.95, 96
Other sociodemographic variables available in the SEDD and the SID include gender, race,
ethnicity, insurance, median household income, and patient’s location (urban/rural). A
description of all original variables and recoded variables used in this study is available in Table
4.3.
Table 4. 3: Description of variables included for specific aim 2
Variable name in the
SEDD and the SID
DX1 – DX25

Description

NCHRONIC

Number of chronic
conditions

New-nchronic

DX1 – DX25

ICD-9-CM codesb

Depression

DX1 – DX25

ICD-9-CM codesb

Psychoses

DX1 – DX25

ICD-9-CM codesb

Alcohol

ICD-9-CM codesa

Name of the recoded
variable in this study
Poisoning_indicator
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Description
1 = yes
0 = no
0 = no chronic conditions
1= 1 chronic condition
2= 2 chronic conditions
3= 3 chronic conditions
4= 4 chronic condition
5 ≥ 5 chronic conditions
1 = yes
0 = no
1 = yes
0 = no
1 = yes

DX1 – DX25

ICD-9-CM codes

AGE

Age in years

New_age

FEMALE

Indicator of sex

New_female

RACE

Race and ethnicity

New_race

PAY1

Expected primary payer

New_pay1

MEDINCSTQ

Median household
income state quartile
for patient ZIP Code

New_medincstq

PL_UR_CAT4

Patient location: urbanrural 4 categories

New_pl_ur_cat4

a.
b.

b

Drug_abuse

0 = no
1 = yes
0 = no
1 = (12 -17)
2= (18-15)
3= (26-34)
4= (35-50)
5 >50
1 = female
2= male
1 = white
2= black
3= Hispanic
4= other
1 = Medicare
2 = Medicaid
3= private insurance
4= self-pay
5= others
1= first quartile(poor)
2= second quartile
(lower-average)
3= thirds quartile (higheraverage)
4= fourth quartile (rich)
1= urban
2= rural

Description of ICD-9CM codes for opioid poisoning considered in the study is available in Table 4.1.
Description of ICD-9CM codes for depression, psychoses, alcohol abuse and, drug abuse is available in
Table 4.2.

Statistical analyses
Prevalence
Annual prevalence of prescription opioid ED visits in Kentucky and North Carolina were
estimated using the following equation:
Prevalence = number of prescription opioid poisoning ED visits per state per year
Estimate of the resident population in that state/year
Number of prescription opioid poisoning ED visits were obtained from the SEDD and the SID.
Estimates of the resident population in Kentucky and North Carolina are available from the
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United States Census Bureau.97 Estimates for residents of 12 years of age and older were
calculated and used for this study. Also, total four years (2011 -2014) prevalence in Kentucky
and North Carolina was reported using the following equation: 98
Total prevalence = total number of prescription opioid poisoning ED visits in each state over the
period 2011-2014
Estimate of the average resident population in that state over the same period
Annual prevalence rates by age group were also calculated and compared to examine changes in
prescription opioid poisoning ED visits among different age groups:
Prevalence by age group = number of prescription opioid poisoning ED visits in each age group
per state
Estimate of the resident population in that age group/state
Prevalence estimates of prescription opioid poisoning ED visits among all ED visits in Kentucky
and North Carolina were calculated as follows:
Prevalence among all ED visits = number of prescription opioid poisoning ED visits per state per
year
Total number of all ED visits in that state/year
Descriptive statistics
Descriptive statistics were used to describe basic sociodemographic and clinical characteristics
of prescription opioid poisoning ED visits in each state over the 2011 – 2014 period. Age as a
continuous variable was described by mean and standard deviation; frequencies and percentages
were used to describe all categorical variables reported in Table 4.3. Prescription opioid
poisoning ED visits were described by age group and intent of poisoning. Bivariate analyses
using Chi-square test and/or Fisher’s exact test were applied to examine associations between
patients’ sociodemographic and clinical characteristics and prescription opioid poisoning ED
visits in each state. This study was qualified for exemption by Virginia Commonwealth
University Institutional Review Board (IRB) (ID: HM20009965).
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Section 4.2-Results
Aim 2A: To determine the prevalence of prescription opioid poisoning ED visits in Kentucky
and North Carolina.
Kentucky
Over the four-year period, a total of 7,419 prescription opioid poisoning ED visits were reported
among people aged 12 years and older. The total (four year) prevalence rate of prescription
opioid poisoning ED visits was 199.6 per 100,000 population. The prevalence of prescription
opioid poisoning ED visits by year is reported in Table 4.4. There was 26.1% decrease in the
prevalence of prescription opioid poisoning ED visits from 2011 to 2014.
The total and annual prevalence rate of prescription opioid poisoning ED visits among different
age groups was examined (Table 4.5). The total prevalence rate was higher in adults 26-34 years
old and 35-50 years old, 68.4 and 65.5 per 100,000 population, respectively, compared to other
age groups. There was an overall reduction in the annual rate of prescription opioid poisoning
ED visits in people ≤ 50 years of age. The decrease in the annual prevalence rate was greater
among 18 to 25 years old and 26 to 34 years old compared to other age groups. On the other
hand, there was 0.7% increase in the prevalence of prescription opioid poisoning ED visits
among people greater than 50 years old from 2011 to 2014.
The annual prevalence rate of prescription opioid ED visits among all ED visits is reported in
Table 4.6. There was 26.1% reduction in annual rate of non-fatal prescription opioid ED visits
from 2011 – 2014.
North Carolina
Over the four-year period, a total of 12,598 prescription opioid poisoning ED visits were
reported among people aged 12 years and older. Total (four years) prevalence rate of prescription
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opioid poisoning ED visits was 151.94 per 100,000 population. The prevalence of prescription
opioid poisoning ED visits by year is reported in Table 4.4. There was 3.2% increase in the
prevalence of prescription opioid poisoning ED visits from 2011 to 2014.
The total and annual prevalence rate of prescription opioid poisoning ED visits among different
age groups was assessed (Table 4.7). The total prevalence rate was higher in adults 26-34 years
old and 35-50 years old, 43.18 and 42.12 per 100,000 population, respectively, compared to
other age groups. The annual prevalence rate of prescription opioid poisoning ED visits
increased in children 12 to 17 years old, adults 26 to 34 years, and >50 years. On the other hand,
there was reduction in annual prevalence rate of prescription opioid poisoning ED visits in adults
18 to 25 years old and 35 to 50 years.
The annual prevalence rate of prescription opioid ED visits among all ED visits is reported in
Table 4.6. The annual prevalence rate of prescription opioid ED visits (per 100,000 ED visits)
was stable over the years 2011 – 2014.
Table 4. 4: Annual prevalence rate of prescription opioid-poisoning ED visits (per 100,000
population) by state
State
2011
2012
2013
2014
Percent change 2011 - 2014

KY
59.31
54.94
41.67
43.82
-26.12

Note: KY= Kentucky; NC = North Carolina
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NC
36.29
37.68
39.49
37.45
3.20

Table 4. 5: Annual and total prevalence rate of prescription opioid poisoning ED visits (per
100,000 population) by age group in Kentucky
Age
(in years)

2011

2012

2013

2014

Total
prevalence
rate

11.71

Percent
change
2011 2014
-38.40

12 - 17

19.00

14.00

12.56

18 - 25
26 - 34
35 - 50
>50

62.15
94
78
43

58.3
77
69
46.5

32.2
48.3
58
39

34
54.2
56.3
43.3

-45.3
-42.3
-27.8
0.7

46.50
68.43
65.46
43.00

14.25

Table 4. 6: Annual prevalence rate of prescription opioid poisoning ED visits (per 100,000 ED
visits) by state
State
2011
2012
2013
2014
Percent change 2011 - 2014

KY
117
109.4
87.2
86.5
-26.1

NC
86.8
87.1
90.5
86.8
0

Note: KY= Kentucky; NC = North Carolina

Table 4. 7: Annual and total prevalence rate of prescription opioid poisoning ED visits (per
100,000 population) by age group in North Carolina
Age
(in years)

2011

2012

2013

2014

12 - 17
18 - 25
26 - 34
35 - 50
>50

12.7
41.9
43.0
41.1
34.3

14.0
38.6
39.7
42.4
39.2

11.1
37.2
45.5
44.6
41.6

14.7
38.3
44.5
40.3
41.2

Percent
change
2011 2014
15.7
-8.6
3.5
-1.9
20.1

Total
prevalence
rate
13.12
39.00
43.18
42.12
39.14

Aim 2B: To characterize prescription opioid poisoning ED visits based on socio-demographic
and clinical characteristics.
Kentucky
Sociodemographic characteristics
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The mean age was 43 years (SD=15.9). More than two thirds of prescription opioid ED visits
were related to adults 35 to 50 years old and >50 years. Children 12 to 18 years old were the
least group among all age groups. More females were involved compared to males (54.1% and
45.9%, respectively). The majority of prescription opioid poisoning ED visits involved whites
(93.9%). About one third of prescription opioid poisoning ED visits were related to people with
low income. Most of ED visits were paid by Medicare or Medicaid (29.1% and 27.0%,
respectively). Descriptions of all sociodemographic are reported in Table 4.8.
Clinical characteristics
Prescription opioid poisoning ED visits were more common in people with at least one chronic
condition. One third of prescription opioid poisoning ED visits involved people with five or
more chronic conditions. About one quarter of ED visits were related to patients diagnosed with
depression. Other psychiatric conditions like psychoses, drug abuse, and alcohol abuse were
rarely reported (Table 4.8).
Table 4. 8: Sociodemographic and clinical characteristics of prescription opioid poisoning ED
visits in Kentucky from 2011 – 2014
Sociodemographic variable
Age (in years)
0-17
18-25
26-34
35-50
>50
Gender
Male
Female
Race
White
Black
Hispanic
Other
Primary expected payer
Medicare
Medicaid

N (%)
195 (2.63)
902 (12.16)
1393 (18.78)
2445 (32.96)
2484 (33.48)
3406 (45.91)
4013 (54.09)
6967 (93.91)
262 (3.53)
113 (1.52)
77 (1.04)
2150 (29.09)
1994 (26.98)
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Private insurance
Self-pay
Other
Median household income
Poor
Lower average
Higher average
Rich
Patient location
Urban
Rural
Clinical variable
No. of chronic conditions
0
1
2
3
4
≥5
Psychoses
Yes
No
Alcohol abuse
Yes
No
Drug abuse
Yes
No
Depression
Yes
No

1294 (17.51)
1411 (19.09)
543 (7.35)
2487 (34.42)
1789 (24.76)
1647 (22.79)
1303 (18.03)
3838 (51.90)
3557 (48.10)
N (%)
834 (11.24)
1092 (14.72)
1095 (14.76)
953 (12.85)
829 (11.17)
2616 (35.26)
3 (0.04)
7416 (99.96)
61 (0.82)
7358 (99.18)
6 (0.08)
7413 (99.92)
1815 (24.46)
5604 (75.54)

Sociodemographic and clinical characteristics were further examined by age group. Results are
summarized in Tables 4.9. Prescription opioid poisoning ED visits were more common in males
35 to 50 years old and in females >50 years. Although females were the predominant group
across all ages, males had a higher percentage among young adults (18-25 and 26-34 years old).
Among white, black, Hispanic, and others prescription opioid poisoning ED visits were more
common in adults 35 to 50 years old and >50 years compared to other age groups. Low income
patients had the highest proportion of prescription opioid poisoning ED visits among all age
groups; however, they were most common in middle age adults (35 to 50 years old). With the
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exception of patients 35 to 50 years old, urban areas had higher prevalence of prescription opioid
poisoning ED visits as compared to rural. Medicaid was the most common primary payer for
patients 12 to 17 years old and 35 to 50 years (60% and 31.6%, respectively). Among young
adults (18- 25 and 26-34 years old), private insurance was the most prevalent payer (31.8% and
34.1%, respectively). Medicare was the primary source of payment for two thirds of prescription
opioid ED visits for patients >50 years old.
Among patients with zero to three chronic conditions, one third of prescription opioid poisoning
ED visits were related to people 35 to 50 years old. Two thirds of patients 35 to 50 years old had
five or more chronic conditions. Prescription opioid poisoning ED visits for patients with
depression and alcohol abuse were more common in those 35 to 50 years old and > 50 years.
Table 4. 9: Sociodemographic and clinical characteristics of prescription opioid poisoning ED
visits by age group in Kentucky from 2011 – 2014
Characteristics

Gender
Male
Female
Race
White
Black
Hispanic
Other
Primary expected
payer
Medicare
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor
Lower average
Higher average
Rich

0 – 17

18 – 25

95 (1.28)
100 (1.35)

523 (7.05)
379 (5.11)

164 (2.21)
22 (0.30)
6 (0.08)
3 (0.04)

Age (in years)
n (%)
26 – 34

35 – 50

>50

742 (10.00)
651 (8.77)

1102 (14.85)
1343 (18.10)

944 (12.72)
1540 (20.76)

817 (11.01)
55 (0.74)
16 (0.22)
14 (0.19)

1309 (17.64)
39 (0.53)
27 (0.36)
18 (0.24)

2326 (31.35)
64 (0.86)
33 (0.44)
22 (0.30)

2351 (31.69)
82 (1.11)
31 (0.42)
20 (0.27)

0 (0.00)
115 (1.56)
58 (0.78)
17 (0.23)
5 (0.07)

22 (0.30)
219 (2.96)
255 (3.45)
284 (3.84)
114 (1.54)

104 (1.41)
432 (5.84)
194 (2.62)
472 (6.39)
183 (2.48)

576 (7.79)
769 (10.40)
415 (5.61)
508 (6.87)
169 (2.29)

1448 (19.59)
459 (6.21)
372 (5.03)
130 (1.76)
72 (0.97)

63 (0.870
41 (0.57)
37 (0.51)
52 (0.72)

264 (3.65)
210 (2.91)
192 (2.66)
213 (2.95)

492 (6.81)
318 (4.40)
307 (4.25)
242 (3.35)

866 (11.98)
585 (8.10)
525 (7.27)
393 (5.44)

802 (11.10)
635 (8.79)
586 (8.11)
403 (5.58)
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Patient location
Urban
Rural
No. of chronic
conditions
0
1
2
3
4
≥5
Alcohol abuse
No
yes
Drug abuse
No
yes
Depression
No
yes
Psychoses
No
yes

105 (1.42)
90 (1.22)

535 (7.23)
361 (4.88)

735 (9.94)
649 (8.78)

1187 (16.05)
1249 (16.89)

1276 (17.25)
1208 (16.34)

66 (0.89)
55 (0.74)
36 (0.49)
18 (0.24)
9 (0.12)
11 (0.15)

159 (2.14)
221 (2.98)
227 (3.06)
137 (1.85)
91 (1.23)
67 (0.90)

209 (2.82)
301 (4.06)
292 (3.94)
208 (2.80)
164 (2.21)
219 (2.95)

235 (3.17)
343 (4.62)
348 (4.69)
363 (4.89)
281 (3.79)
875 (11.79)

165 (2.22)
172 (2.32)
192 (2.59)
227 (3.06)
284 (3.83)
1444 (19.46)

195 (2.63)
0 (0.00)

901 (12.14)
1 (0.01)

1385 (18.67)
8 (0.11)

2421 (32.63)
24 (0.32)

2456 (33.10)
28 (0.38)

195 (2.63)
0 (0.00)

901 (12.14)
1 (0.01)

1392 (18.76)
1 (0.01)

2442 (32.92)
3 (0.04)

2483 (33.47)
1 (0.01)

151 (2.04)
44 (0.59)

718 (9.68)
184 (2.48)

1123 (15.14)
270 (3.64)

1842 (24.83)
603 (8.13)

1770 (23.86)
714 (9.62)

195 (2.63)
0 (0.00)

902 (12.16)
0 (0.00)

1392 (18.76)
1 (0.01)

2445 (32.96)
0 (0.00)

2482 (33.45)
2 (0.03)

Also, sociodemographic and clinical characteristics were described by intent of poisoning.
Results are summarized in Tables 4.10. Accidental prescription opioid poisoning constituted
51% of all visits. On the other hand, intentional represented more than half visits in children 12
to 17 years old (53.5%). Among all other age groups, accidental prescription opioid poisoning
was more common. Females had a higher proportion of accidental and intentional opioid
poisoning as compared to males (58.1%, 54.5%) and (41.9%, 45.6%), respectively.
Table 4. 10: Sociodemographic and clinical characteristics of prescription opioid poisoning ED
visits by intent of poisoning in Kentucky from 2011-2014
Characteristics N (%)

Intent of poisoning
Intentional
(N= 1678)

Unintentional
(N= 3370)
Age (in years)
0 – 17
18 – 25
26 – 34

47 (0.71)
348 (5.26)
535 (8.08)

92 (1.39)
251 (3.79)
324 (4.89)
80

Undetermined
(N=1571)
33 (0.50)
203 (3.07)
349 (5.27)

35 – 50
>50
Gender
Male
Female
Race
White
Black
Hispanic
Other
Primary expected payer
Medicare
Medicaid
Private insurance
Self-pay
Other
Median household income
Poor
Lower average
Higher average
Rich
Patient location
Urban
Rural
No. of chronic conditions
0
1
2
3
4
≥5
Alcohol abuse
No
Yes
Drug abuse
No
Yes
Depression
No
Yes
Psychoses
No
Yes

1006 (15.20)
1434 (21.66)

626 (9.46)
385 (5.82)

550 (8.31)
436 (6.59)

1535 (23.19)
1835 (27.72)

703 (10.62)
975 (14.73)

782 (11.81)
789 (11.92)

3174 (47.95)
113 (1.71)
50 (0.76)
33 (0.50)

1544 (23.33)
82 (1.24)
35 (0.53)
17 (0.26)

1497 (22.62)
41 (0.62)
16 (0.24)
17 (0.26)

1225 (18.58)
835 (12.66)
526 (7.98)
565 (8.57)
210 (3.18)

328 (4.97)
465 (7.05)
414 (6.28)
329 (4.99)
130 (1.97)

390 (5.91)
509 (7.72)
215 (3.26)
349 (5.29)
104 (1.58)

1052 (16.33)
853 (13.24)
772 (11.99)
614 (9.53)

498 (7.73)
424 (6.58)
389 (6.04)
328 (5.09)

661 (10.26)
328 (5.09)
311 (4.83)
211 (3.28)

1828 (27.71)
1534 (23.25)

876 (13.28)
797 (12.08)

665 (10.08)
897 (13.60)

381 (5.76)
466 (7.04)
457 (6.90)
382 (5.77)
351 (5.30)
1333 (20.14)

130 (1.96)
254 (3.84)
281 (4.25)
258 (3.90)
223 (3.37)
532 (8.04)

192 (2.90)
256 (3.87)
245 (3.70)
198 (2.99)
173 (2.61)
507 (7.66)

3346 (50.55)
24 (0.36)

1667 (25.19)
11 (0.17)

1549 (23.40)
22 (0.33)

3367 (50.87)
3 (0.05)

1677 (25.34)
1 (0.02)

1569 (23.70)
2 (0.03)

2625 (39.66)
745 (11.26)

1062 (16.04)
616 (9.31)

1275 (19.26)
296 (4.47)

3370 (50.91)
0 (0.00)

1677 (25.34)
1 (0.02)

1570 (23.72)
1 (0.02)

North Carolina
Sociodemographic characteristics
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The mean age was 44.5 years (SD =17.2). Prescription opioid poisoning ED visits were more
common in adults >50 years old (39%). Children 12 to 18 years old had the least proportion of
prescription opioid ED visits among all other age groups. More females were involved compared
to males (56.6% and 43.4%, respectively). The majority of prescription opioid poisoning ED
visits involved whites (81.4%). About one third of prescription opioid poisoning ED visits were
related to people with low income. Medicare was the most common primary payer (29.2%)
followed by private insurance (23.8%), self-pay (22.5%), and Medicaid (21.4%). More than two
thirds of prescription opioid poisoning ED visits belonged to patients living in urban areas.
Description of all sociodemographic is reported in Table 4.11.
Clinical characteristics
Prescription opioid poisoning ED visits were more common in people with at least one chronic
condition. More than one third of prescription opioid poisoning ED visits involved people with
five or more chronic conditions. About one quarter of ED visits were related to patients
diagnosed with depression. Other psychiatric conditions including psychoses, drug abuse and
alcohol abuse constituted ≤1% of total prescription opioid poisoning ED visits (Table 4.11).
Table 4. 11: Sociodemographic and clinical characteristics of prescription opioid poisoning ED
visits in North Carolina from 2011-2014
Sociodemographic variable
Age (in years)
0-17
18-25
26-34
35-50
>50
Gender
Male
Female
Race
White
Black
Hispanic

n (%)
403 (3.20)
1723 (13.68)
1973 (15.66)
3587 (28.48)
4911 (38.99)
5465 (43.39)
7131 (56.61)
10212 (81.44)
1600 (12.76)
226 (1.80)
82

Other
Primary expected payer
Medicare
Medicaid
Private insurance
Self-pay
Other
Median household income
Poor
Lower average
Higher average
Rich
Patient location
Urban
Rural
Clinical variable
No. of chronic conditions
0
1
2
3
4
≥5
Psychoses
Yes
No
Alcohol abuse
Yes
No
Drug abuse
Yes
No
Depression
Yes
No

502 (4.00)
3663 (29.18)
2680 (21.35)
2984 (23.77)
2823 (22.49)
403 (3.21)
3806 (31.23)
3433 (28.17)
3088 (25.34)
1861 (15.27)
8213 (65.78)
4272 (34.22)

1137 (9.03)
1738 (13.80)
1815 (14.41)
1708 (13.56)
1524 (12.10)
4676 (37.12)
11 (0.09)
12587 (99.91)
128 (1.02)
12470 (98.98)
44 (0.35)
12554 (99.65)
3044 (24.16)
9554 (75.84)

Description of sociodemographic and clinical characteristics by age group is available in Table
4.12. Prescription opioid poisoning ED visits were more common in males and females >50
years old (33.8% and 42.9%, respectively). Although females were the predominant group across
all ages, males had a higher proportion among young adults (18-25 and 26-34 years old). Among
white, black, and others prescription opioid poisoning ED visits were more common in adults 35
to 50 years old and >50 years compared to other age groups. Hispanics had similar proportions
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among all adult age groups (i.e. ≥18 years old). Among patients with high income, one quarter of
prescription opioid poisoning involved children 12 to 18 years old. Medicaid was the most
common primary payer for patients 12 to 17 years old and 35 to 50 years (51.7% and 26.5%,
respectively). Among young adults (18- 25 and 26-34 years old), private insurance was the most
prevalent primary payer (38.3% and 48.3%, respectively). Medicare was the primary source of
payment for about half of prescription opioid ED visits for patients >50 years old.
Prescription opioid ED visits with one chronic condition were more common in children 12 to 17
years old, adults 18 to 25 years, and 26 to 34 years. About two thirds of patients 35 to 50 years
old had five or more chronic conditions. Prescription opioid poisoning ED visits with existing
diagnosis of depression, alcohol abuse, and drug abuse were more common in patients > 50 years
old (Table 4.12).
Table 4. 12: Sociodemographic and clinical characteristics of prescription opioid poisoning ED
visits by age group in North Carolina from 2011 to 2014
Characteristics

Gender
Male
Female
Race
White
Black
Hispanic
Other
Primary expected
payer
Medicare
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor

0 – 17

18 – 25

188 (1.49)
215 (1.71)

940 (7.46)
782 (6.21)

267 (2.13)
85 (0.68)
24 (0.19)
26 (0.21)

Age (in years)
n (%)
26 – 34

35 – 50

>50

1035 (8.22)
938 (7.45)

1453 (11.54)
2134 (16.94)

1848 (14.67)
3062 (24.31)

1329 (10.60)
259 (2.07)
48 (0.38)
73 (0.58)

1641 (13.09)
225 (1.79)
50 (0.40)
52 (0.41)

2907 (23.18)
452 (3.60)
51 (0.41)
161 (1.28)

4067 (32.43)
579 (4.62)
53 (0.42)
190 (1.52)

0 (0.00)
208 (1.66)
154 (1.23)
23 (0.18)
17 (0.14)

34 (0.27)
419 (3.34)
526 (4.19)
657 (5.23)
78 (0.62)

131 (1.04)
486 (3.87)
331 (2.64)
945 (7.53)
64 (0.51)

801 (6.38)
946 (7.54)
845 (6.73)
872 (6.95)
111 (0.88)

2697 (21.49)
621 (4.95)
1128 (8.99)
325 (2.59)
133 (1.06)

114 (0.94)

453 (3.72)

562 (4.61)

1065 (8.74)

1611 (13.22)
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Lower average
Higher average
Rich
Patient location
Urban
Rural
No. of chronic
conditions
0
1
2
3
4
≥5
Alcohol abuse
No
Yes
Drug abuse
No
Yes
Depression
No
Yes
Psychoses
No
Yes

94 (0.77)
89 (0.73)
101 (0.83)

469 (3.85)
449 (3.68)
300 (2.46)

557 (4.57)
487 (4.00)
298 (2.45)

996 (8.17)
887 (7.28)
521 (4.28)

1317 (10.81)
1176 (9.65)
641 (5.26)

289 (2.31)
112 (0.90)

1197 (9.59)
512 (4.10)

1322 (10.59)
628 (5.03)

2349 (18.82)
1205 (9.65)

3055 (24.47)
1815 (14.54)

117 (0.93)
143 (1.14)
64 (0.51)
44 (0.35)
20 (0.16)
15 (0.12)

245 (1.94)
450 (3.57)
397 (3.15)
283 (2.25)
171 (1.36)
177 (1.41)

242 (1.92)
403 (3.20)
391 (3.10)
338 (2.68)
235 (1.87)
364 (2.89)

278 (2.21)
432 (3.43)
528 (4.19)
530 (4.21)
523 (4.15)
1296 (10.29)

255 (2.02)
310 (2.46)
435 (3.45)
513 (4.07)
574 (4.56)
2824 (22.42)

403 (3.20)
0 (0.00)

1721 (13.66)
2 (0.02)

1970 (15.64)
3 (0.02)

3546 (28.15)
41 (0.33)

4829 (38.33)
82 (0.65)

401 (3.18)
2 (0.02)

1716 (13.62)
7 (0.06)

1966 (15.61)
7 (0.06)

3579 (28.41)
8 (0.06)

4891 (38.83)
20 (0.16)

312 (2.48)
91 (0.72)

1351 (10.72)
372 (2.95)

1567 (12.44)
406 (3.22)

2692 (21.37)
895 (7.10)

3632 (28.83)
1279 (10.15)

403 (3.20)
0 (0.00)

1723 (13.68)
0 (0.00)

1971 (15.65)
2 (0.02)

3580 (28.42)
7 (0.06)

4909 (38.97)
2 (0.02)

Sociodemographic and clinical characteristics were further analyzed based by intent of opioid
poisoning. Results are reported in Table 4.13. More than half of non-fatal prescription opioid
poisoning were accidental. Intentional prescription opioid poisoning ED visits were more
common among children 12 to 17 years old. In contrast, accidental poisoning was more
common for all adult age groups. Female had a higher proportion of ED visits across all intent as
compared to men.
Table 4. 13: Sociodemographic and clinical characteristics of prescription opioid poisoning ED
visits by intent of poisoning in North Carolina from 2011 – 2014
Characteristics

Intent of poisoning
n (%)
Intentional
(N=3065)

Unintentional
(N=6130)
Age (in years)
85

Undetermined
(N=1822)

0 – 17
18 – 25
26 – 34
35 – 50
>50
Gender
Male
Female
Race
White
Black
Hispanic
Other
Primary expected payer
Medicare
Medicaid
Private insurance
Self-pay
Other
Median household income
Poor
Lower average
Higher average
Rich
Patient location
Urban
Rural
No. of chronic conditions
0
1
2
3
4
≥5
Alcohol abuse
No
Yes
Drug abuse
No
Yes
Depression
No
Yes
Psychoses
No
Yes

130 (1.18)
693 (6.29)
871 (7.91)
1580 (14.34)
2855 (25.92)

180 (1.63)
564 (5.12)
557 (5.06)
1044 (9.48)
720 (6.54)

61 (0.55)
292 (2.65)
346 (3.14)
527 (4.78)
596 (5.41)

2756 (25.02)
3372 (30.61)

1219 (11.07)
1846 (16.76)

845 (7.67)
977 (8.87)

5023 (45.79)
725 (6.61)
84 (0.77)
271 (2.47)

2393 (21.81)
491 (4.48)
64 (0.58)
107 (0.98)

1509 (13.76)
205 (1.87)
38 (0.35)
60 (0.55)

2137 (19.48)
1222 (11.14)
1359 (12.38)
1214 (11.06)
173 (1.58)

520 (4.74)
715 (6.52)
924 (8.42)
772 (7.04)
119 (1.08)

474 (4.32)
430 (3.92)
331 (3.02)
537 (4.89)
46 (0.42)

1906 (17.84)
1680 (15.73)
1452 (13.59)
907 (8.49)

875 (8.19)
819 (7.67)
754 (7.06)
526 (4.92)

572 (5.35)
485 (4.54)
480 (4.49)
227 (2.12)

3861 (35.32)
2230 (20.40)

2116 (19.36)
913 (8.35)

1167 (10.68)
643 (5.88)

616 (5.59)
812 (7.37)
763 (6.93)
764 (6.93)
741 (6.73)
2434 (22.09)

184 (1.67)
459 (4.17)
540 (4.90)
496 (4.50)
443 (4.02)
943 (8.56)

194 (1.76)
297 (2.70)
303 (2.75)
235 (2.13)
189 (1.72)
604 (5.48)

6076 (55.15)
54 (0.49)

3043 (27.62)
22 (0.20)

1800 (16.34)
22 (0.20)

6108 (55.44)
22 (0.20)

3055 (27.73)
10 (0.09)

1814 (16.47)
8 (0.07)

4906 (44.53)
1224 (11.11)

1988 (18.04)
1077 (9.78)

1467 (13.32)
355 (3.22)

6129 (55.63)
1 (0.01)

3056 (27.74)
9 (0.08)

1822 (16.54)
0 (0.00)
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Aim 2C: To examine associations between patients’ sociodemographic and clinical
characteristics and prescription opioid poisoning ED visits in Kentucky and North Carolina.
Bivariate analyses were performed using Chi-square test to examine the relationship between
various sociodemographic/clinical characteristics and prescription opioid poisoning ED visits. In
Kentucky, with the exception of patient location and psychoses, all variables were statistically
significant (p-value<0.0001). The largest coefficients were associated with number of chronic
conditions, depression, and age (Chi-square = 5514.9, 5233.3, and 444.7, respectively). In North
Carolina the results were similar, where with the exception of only psychoses, all variables were
significantly associated with prescription opioid poisoning ED visits. The largest coefficients
were associated with number of chronic conditions, race, and depression (Chi-square = 10840.8,
8994.5, and 2980.6, respectively).
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Chapter 5

Methods and results for specific aim 3:
A. To compare occurrences of prescription opioid poisoning ED visits pre and post
prescriber use mandates in Kentucky.
B. To compare occurrences of prescription opioid poisoning ED visits in Kentucky and
North Carolina, after prescriber use mandate implementation.
Section 5.1-Methods
Study design
Controlled pre-post study design. Kentucky and North Carolina represented the intervention state
and the control (comparator) state, respectively. Figure 5.1 describes the study design.

Kentucky
Before

Intervention
(Comprehensive
prescriber use mandates)
effective in July 2012

Kentucky
After
Compare
North Carolina
after

North Carolina
Before

Figure5.1
5. 1:
Controlled
pre-post
study
design
Figure
Controlled
pre-post
study
design
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Study settings
Prescription opioid poisoning ED visits in Kentucky and North Carolina for the period 2011 to
2014.
Data source
The SEDD (treat and release ED visits) and the SID (ED visits that resulted in hospital admission)
for Kentucky and North Carolina. See section 4.1
Sample
Prescription opioid poisoning ED visits in Kentucky were compared between the years (2011,
2012), (2011, 2013), and (2011, 2014). In addition, comparisons were made between Kentucky
and North Carolina utilizing the same sets of years. Sample selection process for specific aim 3A
and 3B, including exclusion criteria is illustrated in Figure 5.2 and 5.3, respectively.
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Number of hospital admissions with evidence of ED
visits (SID) in KY

Number of ED visits (SEDD) in KY
2011(N=2,133,987), 2012 (N=2,136,069),

2011 (N=299,484), 2012 (N=294,358),

2013 (N=2,036,780), 2014 (N=2,154,440)

2013 (N=285,070), 2014 (N=289,054)

Number of all ED visits (combined SEDD and SID) in KY
2011 (N=2,433,471), 2012 (N=2,430,427),
2013 (N=2,321,850), 2014 (N=2,443,494)

Combine the years: (2011 and 2012), (2011 and 2013), (2011 and 2014)

(N=4,863,898)

(N=4,755,321)

(N=4,876,965)

Exclude ED visits for patients <12 years of age
2011 and 2012 (N=4,121,655), 2011 and 2013 (N=4,036,712), 2011 and 2014 (N=4,158,623)

Exclude ED visits for cancer patients
2011 and 2012 (N=3,956,679), 2011 and 2013 (N=3,867,454), 2011 and 2014 (N=3,985,977)

Exclude ED visits for non-residents
2011 and 2012 (N=3,750,307), 2011 and 2013 (N=3,667,967), 2011 and 2014 (N=3,782,854)

Exclude ED visits resulted in patient death
2011 and 2012 (N=3,733,535)a, 2011 and 2013 (N=3,651,453)b, 2011 and 2014 (N=3,765,843)c

Figure 5.
2: Sample flow chart for specific aim 3A (Kentucky only)
5.2:
a.

Final sample size for the years 2011 and 2012, b. Final sample size for the years 2011 and 2013
c. Final sample size for the years 2011 and 2014
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Number of all ED visits (combined SEDD and SID) in KY
2011 (N=2,433,471), 2012 (N=2,430,427), 2013 (N=2,321,850), 2014 (N=2,443,494)

Number of all ED visits (combined SEDD and SID) in NC
2011(N=4,278,071), 2012(N=4,500,472), 2013 (N=4,591,023), 2014 (N=4,732,831)

Number of all ED visits in KY and NC
2011(N=6,711,542), 2012(N=6930,899), 2013 (N=6,912,873), 2014 (N=7,176,325)

Combine the years: (2011 and 2012), (2011 and 2013), (2011 and 2014)

(N=13,642,441)

(N=13,624,415)

(N=13,887,867)

Exclude ED visits for patients <12 years of age
2011 and 2012 (N=11,698,646), 2011 and 2013 (N=11,713,122), 2011 and 2014 (N=11,968,130)

Exclude ED visits for cancer patients
2011 and 2012 (N=11,248,304), 2011 and 2013 (N=11,237,165), 2011 and 2014 (N=11,476,345)

Exclude ED visits for non-residents

(N=)

(N=)

(N=)

2011 and 2012 (N=10,741,599), 2011 and 2013 (N=10,737,167), 2011 and 2014 (N=10,964,285)

Exclude ED visits resulted in patient death
2011 and 2012 (N=10,691,826)a, 2011 and 2013 (N=10,688,407)b, 2011 and 2014 (N=10,915,644)c

Figure5.3:
5. 3:Sample
Sampleflow
flowchart
chartfor
forspecific
specificaim
aim3B
3B(Kentucky
(Kentuckyand
andNorth
NorthCarolina)
Carolina)
Figure
a. Final sample size for the years 2011 and 2012, b. Final sample size for the years 2011 and 2013
c.

Final sample size for the years 2011 and 2014
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Variables
Main predictor and outcome variables for specific aims 3A and 3B are listed in Table 5.1. Other
sociodemographic and clinical variables considered for specific aim 3 are similar to specific aim
2 (Table 4.3). The unit of analysis is the ED visit.
Table 5. 1: Main predictor and outcome variables for specific aims 3A and 3B
Aim
3A

Main predictor
variable
Post

3B

Mandates*post

Type of variable

Outcome variable

Dichotomous variable:
Poisoning_indicator
1 = post mandates
(i.e. second half of 2012,
2013, and 2014),
0 = pre-mandates
(i.e. 2011 and first half of
2012)
Interaction term of two
Poisoning_indicator
dichotomous variables.
Mandates:
1= Kentucky, 0= North
Carolina.
Post: 1= post mandates
(i.e. second half of 2012, 2013
and, 2014),
0 = pre-mandates
(i.e. 2011 and first half of
2012)

Type of variable
Dichotomous
variable:
1 = yes, 0= no

Dichotomous
variable
1 = yes, 0= no

Statistical analyses
Specific aim 3A:
Multivariable logistic regression analysis was used to examine the impact of prescriber use
mandates on prescription opioid poisoning ED visits in Kentucky. A stepwise selection with 0.05
level of significance was used to identify confounders to include in the final model. Three
models were created to compare ED visits before and after prescriber use mandates
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implementation in Kentucky. The mandates policy became effective in July 2012, the first set of
comparison was made for the years 2011 and 2012. The subsequent set of comparisons included
the years (2011, 2013) and (2011, 2014).
Specific aim 3B:
Multivariable logistic regression was used to assess changes in prescription opioid poisoning ED
visits relative to prescriber use mandates, in Kentucky and North Carolina. A difference in
difference (DID) framework was applied to analyze the casual effect of prescriber use mandates
policy on prescription opioid poisoning ED visits. The DID framework is a common analytical
technique used to evaluate the impact of policy change.99, 100 It estimates the difference in
changes of an outcome variable over time between the intervention and control group. Three sets
of comparison models were conducted including the years (2011, 2012), (2011, 2013), and
(2011, 2014). Each model compared the occurrences of prescription opioid poisoning ED visits
in Kentucky and North Carolina. The main outcome measure was the occurrence of prescription
opioid poisoning ED visit (a binary variable). The main predictor variable was an interaction
term of state with time relative to policy implementation. The logistic regression analysis with
DID framework can be explained by the following equation:
Logit (poisoning_indicator=1) = β0 + β1 mandates + β2 post+ β3 (mandates*post) + β(4 – n) X(4 –n)
- Mandates is a dummy variable for prescriber mandates (1= Kentucky, 0= North Carolina).
- Post is a dummy variable for post mandates period (1= post mandates (i.e. second half of 2012,
2013 and, 2014), 0= pre-mandates (i.e. 2011 and first half of 2012)).
- β3 is the DID estimator which represents the true effect of mandates:
β3= (KY post - KY pre) - (NC post - NC pre).
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- X (4 – n) are the potential confounders considered in the final model, n = number of confounders.
Scenario analyses
Scenario analyses were performed for specific aim 3B to test the impact of two inclusion criteria
on the final estimates:
a. Including only ED visits with prescription opioid poisoning listed as the first diagnosis
(variable: DX1). This ensured that prescription opioid poisoning was the main diagnosis
or chief compliant responsible for the ED visit or the hospital stay and thus, eliminate
overestimation of the study sample.
b. Including only ED visits with unintentional prescription opioid poisoning. The population
of interest was patients who abuse prescription opioid and developed a poisoning event as
a result of the abuse behavior. Thus, suicide attempts and poisoning events with
undetermined intent may not reflect the intended population.
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Section 5.2-Results

Aim 3A: To compare occurrences of prescription opioid poisoning ED visits pre and post
prescriber use mandates in Kentucky.
Three logistic regression models were conducted to examine the impact of prescriber use
mandates on occurrences of prescription opioid poisoning ED visits. Table 5.2 summarizes
results of the logistic regression analysis for the years 2011 and 2012. The final model included
the variables listed in Table 5.2 and the interaction term of age with number of chronic
conditions. All covariates had a significant relationship with opioid poisoning ED visits (i.e. pvalue<0.05). Holding all other variables constant, the odds of having an opioid poisoning ED
visit in 2012 was 11% (95% CI= 6.0% - 17.0%) less compared to 2011.
Table 5. 2: Adjusted logistic regression for prescription opioid poisoning ED visits in (KY 20112012)

OR

Year
2011*
2012
Age (in years)
12 -17
18 -25
26 -34
35 -50
>50*
Sex
Female*
Male
Race
White*
Black
Hispanic
Other

95% CI
Lower limit Upper limit

Wald
Chi-Square (pvalue)

0.89

0.83

0.94

10.9668 (0.0009)

2.57
2.87
3.27
2.34
-

1.06
2.06
2.68
2.06
-

6.22
4.01
3.98
2.65
-

4.3458 (0.0371)
38.6180 (<.0001)
139.0875 (<.0001)
177.6008 (<.0001)
-

1.23

1.16

1.31

42.4909 (<.0001)

0.30
0.57
0.95

0.25
0.38
0.71

0.35
0.87
1.26

190.9968 (<.0001)
6.7231 (0.0095)
0.1326 (0.7157)
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Primary expected payer
Medicare*
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor*
Lower average
Higher average
Rich
No. of chronic
conditions
0
1
2
3
4
5*
Drug abuse
No
Yes*
Depression
No
Yes*

1.29
0.97
1.35
1.46

1.17
0.88
1.22
1.28

1.42
1.07
1.50
1.66

24.4983 (<.0001)
0.3761 (0.5397)
31.9044 (<.0001)
32.8242 (<.0001)

0.87
0.77
0.85

0.80
0.71
0.78

0.94
0.84
0.94

11.1926 (0.0008)
38.2778 (<.0001)
11.4361 (0.0007)

0.19
0.26
0.38
0.49
0.78
-

0.15
0.21
0.31
0.40
0.66
-

0.23
0.33
0.46
0.60
0.94
-

210.6224 (<.0001)
142.2541 (<.0001)
87.3323 (<.0001)
50.1801 (<.0001)
7.3415 (0.0067)
-

0.05
-

0.01
-

0.20
-

16.8625 (<.0001)
-

0.40
-

0.37
-

0.44
-

518.7315 (<.0001)
-

Note: OR= odds ratio; CI= confidence interval
* Reference category

The following models for years 2011, 2013 and 2011, 2014 included the same covariates as the
final model above. The second logistic regression model compared occurrences of prescription
opioid poisoning ED visits between the years 2011 and 2013. Results of the adjusted analysis are
summarized in Table 5.3. All covariates were statistically significant (i.e. p-value <0.05).
Holding all other variables constant, the odds of having an opioid poisoning ED visit in 2013
was 33% (95% CI= 28.0% - 37.0%) less compared to 2011.
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Table 5. 3: Adjusted logistic regression for prescription opioid poisoning ED visits (KY 20112013)

OR

Year
2011*
2013
Age (in years)
12 -17
18 -25
26 -34
35 -50
>50*
Sex
Female*
Male
Race
White*
Black
Hispanic
Other
Primary expected payer
Medicare*
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor*
Lower average
Higher average
Rich
No. of chronic
conditions
0
1
2
3
4
5*
Drug abuse
No
Yes*

95% CI
Lower limit Upper limit

Wald
Chi-Square (pvalue)

0.67

0.63

0.72

140.1676 (<.0001)

3.90
2.16
3.02
2.41
-

1.84
1.45
2.30
2.12
-

8.27
3.21
3.53
2.74
-

12.5565 (0.0004)
14.3199 (0.0002)
91.1886 (<.0001)
180.7251 (<.0001)
-

1.20

1.12

1.28

28.0746 (<.0001)

0.33
1.20
0.70

0.27
0.95
0.45

0.39
1.53
1.10

155.9573 (<.0001)
2.3506 (0.1252)
2.4134 (0.1203)

1.20
0.90
1.35
1.28

1.08
0.80
1.21
1.11

1.34
1.00
1.50
1.48

11.3530 (0.0008)
4.0724 (0.0436)
28.8509 (<.0001)
11.8466 (0.0006)

0.90
0.84
0.94

0.82
0.77
0.86

0.98
0.92
1.04

6.0363 (0.0140)
14.0983 (0.0002)
1.4479 (0.2289)

0.20
0.26
0.36
0.51
0.82
-

0.16
0.20
0.28
0.42
0.69
-

0.25
0.33
0.44
0.63
0.99
-

180.8271 (<.0001)
127.9302 (<.0001)
83.0225 (<.0001)
41.2326 (<.0001)
4.2864 (0.0384)
-

0.05
-

0.01
-

0.20
-

17.1835 (<.0001)
-

Depression
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No
Yes*

0.40
-

0.37
-

0.43
-

470.7818 (<.0001)
-

Note: OR = odds ratio; CI = confidence interval
*Reference category

The third regression model compared occurrences of prescription opioid poisoning ED visits
between the years 2011 and 2014. Results of the adjusted analysis are summarized in Table 5.4.
All covariates were statistically significant (i.e. p-value <0.05) except for drug abuse. Holding all
other variables constant, the odds of having an opioid poisoning ED visit in 2014 was 35.0%
(95% CI= 30.0%- 39.0%) less compared to 2011.
Table 5. 4: Adjusted logistic regression for prescription opioid poisoning ED visits (KY 20112014)

OR

Year
2011*
2014
Age category (years)
12 -17
18 -25
26 -34
35 -50
>50*
Sex
Female*
Male
Race
White*
Black
Hispanic
Other
Primary expected payer
Medicare*
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor*

95% CI
Lower limit Upper limit

Wald
Chi-Square (pvalue)

0.65

0.61

0.70

86.9103 (<.0001)

2.61
2.17
2.53
2.06
-

1.16
1.51
2.05
1.81
-

5.85
3.13
3.12
2.34
-

5.3772 (0.0204)
17.2781 (<.0001)
74.8696 (<.0001)
124.9205 (<.0001)
-

1.21

1.13

1.29

31.5105 (<.0001)

0.33
0.94
0.73

0.28
0.70
0.51

0.39
1.27
1.05

160.7185 (<.0001)
0.1589 (0.6901)
2.8720 (0.0901)

1.33
0.96
1.42
1.38

1.20
0.86
1.26
1.19

1.47
1.06
1.60
1.61

31.4368 (<.0001)
0.6929 (0.4052)
33.5470 (<.0001)
17.5406 (<.0001)

-

-

-

-
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Lower average
Higher average
Rich
No. of chronic
conditions
0
1
2
3
4
5*
Drug abuse
No
Yes*
Depression
No
Yes*

0.86
0.78
0.92

0.79
0.71
0.83

0.94
0.85
1.01

11.7200 (0.0006)
32.3057 (<.0001)
3.3122 (0.0688)

0.19
0.24
0.33
0.46
0.70
-

0.15
0.19
0.27
0.37
0.59
-

0.24
0.30
0.42
0.56
0.85
-

200.2151 (<.0001)
148.4039 (<.0001)
98.5405 (<.0001)
57.2555 (<.0001)
13.8377 (0.0002)
-

0.51
-

0.19
-

1.36
-

1.8345 (0.1756)
-

0.40
-

0.37
-

0.44
-

470.2845 (<.0001)
-

Note: OR= odds ratio; CI= confidence interval
*Reference category

Aim 3B: To compare occurrences of prescription opioid poisoning ED visits in Kentucky and
North Carolina, after prescriber use mandate implementation
Logistic regression model (KY and NC 2011-2012)
All variables listed in Table 4.3 were considered for inclusion in the model. The selection of
these variables was based on the existing literature, which supports their association with opioid
abuse. The logistic regression model was used to assess changes in prescription opioid poisoning
ED visits relative to prescriber use mandates, in Kentucky and North Carolina for the years 2011
and 2012. A stepwise selection with 0.05 level of significance was applied. The stepwise
selection works by removing or adding variables during the various steps of model building. The
stepwise selection resulted in a model not including the interaction term (state*post), the state
variable, and the variables: psychoses, alcohol abuse, and patient location. This means that these
variables were not significantly associated with prescription opioid poisoning ED visits.
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The interaction term (state*post) and the state variable were forced as regressors in the final
model. Variables sometimes need to be forced into regression equations because they are
necessary to conduct the analysis. The resultant model experienced poor fit (Pearson Goodnessof-Fit Statistic: Value/DF=1.76, p-value <0.0001).
To enhance model fit, a PROC GENMOD procedure was used with logit link function; the
resultant models did not show any improvement. The PROC GENMOD procedure conducts a
generalized linear model, which is a large class of models containing logistic regression model
and others. The advantage of PROC GENMOD is the possibility of using other links to improve
the fit of the model. Also, adding interaction terms of age with all other covariates did not
improve model fit. However, single inclusion of the interaction term of age with number of
chronic conditions showed a better model fit (based on -2 Log L).
The final model included the variables listed in Table 5.5 and an interaction term of age with
number of chronic conditions. All covariates, including the main predictor variable, were
significantly associated with prescription opioid poisoning ED visit (i.e. p-value <0.05). Holding
all other variables constant, the odds of having an opioid poisoning ED visit in Kentucky
compared to North Carolina is 9% (95% CI= 1% - 16%) less in 2012 compared to 2011. Hence,
there is a 9% reduction in likelihood of prescription opioid poisoning ED visit going from 2011
to 2012 in Kentucky, controlling for North Carolina in the model. To recall, prescriber use
mandates policy was implemented in Kentucky in July 2012; thus, the reduction in the odds of
having an opioid poisoning ED visit may be related to the policy.
The odds of having an opioid poisoning ED visit varied according to other model variables. The
odds were significantly higher among 18 to 25 years old, 26 to 34 years, and 35 to 50 years
compared to those >50 years old; however, no significant difference in these odds for children 12
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to 17 years old compared to adults >50 years. Males were 1.2 (95% CI= 1.1 - 1.2) more likely to
experience an opioid poisoning ED visit compared to females. Black and Hispanic were 69.5%
(95% CI= 67.2% – 71.6%) and 54.1% (95% CI= 44.3% - 62.3%) less likely to have an opioid
poisoning ED visit compared to white. The odds of an opioid poisoning ED visit were
significantly lower among patients with median household income in the second and third
quartile compared to those in the first quartile. Medicaid and self-pay patients had 1.1(95% CI=
1.1 - 1.2) and 1.1 (95% CI=1.05 - 1.20) higher odds of an opioid poisoning ED visit compared to
Medicare patients. On the other hand, the odds of an opioid poisoning ED visit were 9% (95%
CI= 3.1% - 14.4%) less when the primary payer is a private insurance compared to Medicare.
Patients not diagnosed with depression or did not have a previous history of drug abuse were
58% (95% CI= 56.0% - 60.0%) and 84% (95% CI= 73.0% - 90.0%) less likely to develop an
opioid poisoning ED visit compared to their counterparts. Patients with no chronic conditions
were 80% (95% CI= 77% - 83%) less likely to have an opioid poisoning ED visit compared to
those with five or more chronic conditions. Similarly, these odds were significantly lower for
patients with one to four chronic conditions as compared to those having five or more chronic
conditions. The association of the number of chronic conditions with opioid poisoning ED visits
varied by age. The odds of an opioid poisoning ED visit for patients with no chronic conditions
were not significantly different in patients 35 to 50 years old compared to > 50 years. On the
other hand, these odds were significantly lower in other age groups compared to those >50 years
old. Among patients with five or more chronic conditions, the odds of an opioid poisoning ED
visit were significantly different in adults 18 to 25 years old, 26 to 34 years, and 35 to 50 years
compared to > 50 years; however, these odds were not significantly different in children 12 to 17
years compared to adults >50 years. The odds of an opioid poisoning ED visit for patients with
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one to four chronic conditions were significantly different comparing all age groups to > 50
years old.
Table 5. 5: Adjusted logistic regression for prescription opioid poisoning ED visits (KY and NC
2011-2012)

OR

Year
2011*
2012
State
KY
NC*
Mandates*post:
KY*2012
Age (in years)
12 -17
18 -25
26 -34
35 -50
>50*
Sex
Female*
Male
Race
White*
Black
Hispanic
Other
Primary expected payer
Medicare*
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor*
Lower average
Higher average
Rich
No. of chronic
conditions
0
1

95% CI
Lower limit Upper limit

Wald
Chi-Square (pvalue)

0.97

0.92

1.02

1.5355 (0.2153)

1.14
-

1.08
-

1.21
-

19.6692 (<.0001)

0.91

0.84

0.99

4.7572 (0.0292)

1.41
3.47
2.86
2.15
-

0.67
2.86
2.50
1.98
-

2.97
4.21
3.27
2.33
-

0.8156 (0.3665)
158.6206 (<.0001)
230.9870 (<.0001)
330.761 (<.0001)
-

1.16

1.11

1.21

50.7203 (<.0001)

0.31
0.46
1.04

0.28
0.38
0.93

0.33
0.56
1.17

1031.9464 (<.0001)
61.1671 (<.0001)
0.4599 (0.4977)

1.14
0.91
1.13
1.31

1.07
0.86
1.05
1.19

1.22
0.97
1.20
1.44

15.9351 (<.0001)
8.8403 (0.0029)
12.1622 (0.0005)
30.7756 (<.0001)

0.90
0.94
0.96

0.85
0.89
0.91

0.95
0.99
1.02

16.9101 (<.0001)
5.4201 (0.0199)
1.5666 (0.2107)

0.20
0.30

0.17
0.27

0.23
0.35

469.431 (<.0001)
314.1063 (<.0001)
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2
3
4
5*
Drug abuse
No
Yes*
Depression
No
Yes*

0.42
0.61
0.76
-

0.38
0.55
0.68
-

0.48
0.68
0.85
-

200.2062 (<.0001)
82.0078 (<.0001)
25.6835 (<.0001)
-

0.16
-

0.10
-

0.27
-

48.8300 (<.0001)
-

0.42
-

0.40
-

0.44
-

1140.7458 (<.0001)
-

Note: OR = odds ratio; CI= confidence interval
* Reference category

Results of the adjusted analysis for the years 2011 and 2013 are summarized in Table 5.6. All
covariates were statistically significant (i.e. p-value <0.05). Holding all other variables constant,
the odds of having an opioid poisoning ED visit in Kentucky compared to North Carolina is 30%
(95% CI= 24% - 35%) lower in 2013 compared to 2011. So, these odds were reduced by threefold compared to the reduction in 2012. The odds of having an opioid poisoning ED visit were
significantly higher among all other age groups compared to those >50 years old. Males were
1.14 (95% CI= 1.1 - 1.2) more likely to experience an opioid poisoning ED visit compared to
females. Black and Hispanic were 67.5% (95% CI= 65.2% - 69.7%) and 37.4% (95% CI=26.6%
- 46.6%) less likely to have an opioid poisoning ED visit compared to white. The odds of an
opioid poisoning ED visit were 8.0% (95% CI= 3.0% - 12.0%) lower for patients with median
household income in the second quartile compared to those in the first quartile. Medicaid and
self-pay patients had 1.2 (95% CI= 1.1 - 1.3) and 1.14 (95% CI= 1.1 - 1.2) higher odds of an
opioid poisoning ED visit compared to Medicare patients. On the other hand, the odds of an
opioid poisoning ED visit were 8.3% (95% CI=2.4 % - 13.8%) less when the primary payer is a
private insurance compared to Medicare. Patients not diagnosed with depression or did not have
a previous history of drug abuse were 55.0% (95% CI= 53.0% - 58.0%) and 83.0% (95% CI=
75.0% - 88.0%) less likely to develop an opioid poisoning ED visit compared to their
counterparts. Patients with no chronic conditions were 83% (95% CI= 80% - 85%) less likely to
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have an opioid poisoning ED visit compared to those with five or more chronic conditions.
Similarly, these odds were significantly lower for patients with one to four chronic conditions as
compared to those having more than five chronic conditions.
The association of the number of chronic conditions with opioid poisoning ED visits varied by
age. The odds of an opioid poisoning ED visit for patients with no chronic conditions were not
significantly different in patients 26 to 34 years old and 35 to 50 years compared to > 50 years.
In contrast, these odds were significantly lower among other age groups compared to the
reference age group. Among patients with four chronic conditions, the odds of an opioid
poisoning ED visit were not significantly different in children 12 to 17 years old compared to
adults >50 years; however, these odds were significantly higher in all age groups compared to
those >50 years old. Among patients with five or more chronic conditions, the odds of an opioid
poisoning ED visit were not significantly different in adults 18 to 25 years old compared to > 50
years; however, these odds were significantly higher in children 12 to 17 years old, adults 26 to
34 years, and 35 to 50 years compared to adults >50 years. The odds of an opioid poisoning ED
visit for patients with one to three chronic conditions were significantly higher comparing all age
groups to > 50 years old.
Table 5. 6: Adjusted logistic regression for prescription opioid poisoning ED visits (KY and NC
2011-2013)

OR

Year
2011*
2013
State
KY
NC*
Mandates*post:

95% CI
Lower limit Upper limit

Wald
Chi-Square (pvalue)

0.97

0.92

1.02

1.6341 (0.2011)

1.15
-

1.08
-

1.21
-

21.8591 (<.0001)
-
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KY*2013
Age (in years)
12 -17
18 -25
26 -34
35 -50
>50*
Sex
Female*
Male
Race
White*
Black
Hispanic
Other
Primary expected payer
Medicare*
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor*
Lower average
Higher average
Rich
No. of chronic
conditions
0
1
2
3
4
5*
Drug abuse
No
Yes*
Depression
No
Yes*

0.70

0.65

0.76

69.5745 (<.0001)

2.39
2.66
2.73
2.09
-

1.38
2.16
2.39
1.93
-

4.13
3.28
3.12
2.26
-

9.6482 (0.0019)
83.6690 (<.0001)
222.8204 (<.0001)
322.1580 (<.0001)
-

1.14

1.09

1.19

38.4994 (<.0001)

0.33
0.63
1.00

0.30
0.53
0.88

0.35
0.73
1.13

987.9433 (<.0001)
33.3024 (<.0001)
0.0000 (0.9971)

1.18
0.92
1.14
1.26

1.10
0.86
1.06
1.14

1.26
0.98
1.22
1.39

24.2162 (<.0001)
7.3700 (0.0066)
14.1759 (0.0002)
19.6974 (<.0001)

0.92
0.98
1.00

0.88
0.93
0.94

0.97
1.04
1.07

8.7359 (0.0031)
0.3267 (0.5676)
0.0013 (0.9716)

0.17
0.27
0.38
0.54
0.71
-

0.15
0.24
0.33
0.48
0.64
-

0.20
0.31
0.43
0.66
0.79
-

508.7096 (<.0001)
356.7509 (<.0001)
242.8057 (<.0001)
119.5279 (<.0001)
39.6031 (<.0001)
-

0.17
-

0.12
-

0.25
-

86.4097 (<.0001)
-

0.445
-

0.423
-

0.469
-

970.2113 (<.0001)
-

Note: OR = odds ratio; CI= confidence interval
* Reference category

The last model compared occurrences of prescription opioid poisoning ED visits in Kentucky
and North Carolina for the years 2011 and 2014. Results of the adjusted analysis are summarized
in Table 5.7. All covariates were statistically significant (i.e. p-value <0.05). Holding all other
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variables constant, the odds of having an opioid poisoning ED visit in Kentucky compared to
North Carolina is 29.8% (95% CI= 24.0% - 35.0%) lower in 2014 compared to 2011. Thus, no
further reduction in these odds was noticed in 2014 as compared to 2013.The odds of having an
opioid poisoning ED visit were significantly higher among all other age groups compared to
those >50 years old. Males were 1.15 (95% CI= 1.1 - 1.2) more likely to experience an opioid
poisoning ED visit compared to females. Black and Hispanic were 69.5% (95% CI= 67.2% 71.6%) and 37.5% (95% CI=26.9% - 46.6%) less likely to have an opioid poisoning ED visit
compared to white. The odds of an opioid poisoning ED visit were not significantly different
among patients with median household income in the third and fourth quartile compared to those
in the first quartile. Medicaid and self-pay patients had 1.2 (95% CI= 1.1 - 1.3) and 1.2 (95% CI=
1.1 - 1.3) higher odds of an opioid poisoning ED visit compared to Medicare patients. On the
other hand, the odds of an opioid poisoning ED visit were 6.2% (95% CI=0.0% - 11.8%) less
when the primary payer is a private insurance compared to Medicare. Patients not diagnosed
with depression or did not have a previous history of drug abuse were 56.0% (95% CI= 53.0% 58.0%) and 73.0% (95% CI= 59.0% - 82.0%) less likely to have an opioid poisoning ED visit
compared to none. Patients with no chronic conditions were 81% (95% CI= 78% - 83%) less
likely to have an opioid poisoning ED visit compared to those with five or more chronic
conditions. Similarly, these odds were significantly lower for patients with one to four chronic
conditions as compared to those having five or more chronic conditions. The association of the
number of chronic conditions with opioid poisoning ED visits varied by age. The odds of an
opioid poisoning ED visit for patients with no chronic conditions were significantly lower in
patients 12 to 17 years old, 18 to 25 years, 26 to 34 years, and 35 to 50 years compared to > 50
years. Among patients with one to four chronic conditions, the odds of an opioid poisoning ED
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visit were significantly higher in all age groups compared to adults >50 years. However, for
patients with five or more chronic conditions, these odds were not significantly different in all
age groups compared to those >50 years old.
Table 5. 7: Adjusted logistic regression for prescription opioid poisoning ED visits (KY and NC
2011-2014)

OR

Year
2011*
2014
State
KY
NC*
Mandates*post:
KY*2014
Age (in years)
12 -17
18 -25
26 -34
35 -50
>50*
Sex
Female*
Male
Race
White*
Black
Hispanic
Other
Primary expected payer
Medicare*
Medicaid
Private insurance
Self-pay
Other
Median household
income
Poor*
Lower average
Higher average
Rich

95% CI
Lower limit Upper limit

Wald
Chi-Square (pvalue)

0.92

0.87

0.97

10.5260 (0.0012)

1.14
-

1.08
-

1.21
-

19.6814 (<.0001)
-

0.70

0.65

0.76

69.4210 (<.0001)

1.99
2.72
2.48
1.93
-

1.17
2.23
2.18
1.78
-

3.38
3.31
2.83
2.09
-

6.5185 (0.0107)
98.6129 (<.0001)
182.7046 (<.0001)
259.3394 (<.0001)
-

1.15

1.10

1.20

44.4086 (<.0001)

0.31
0.63
0.99

0.28
0.53
0.88

0.33
0.73
1.12

1074.5333 (<.0001)
34.3520 (<.0001)
0.0223 (0.8813)

1.22
0.94
1.20
1.28

1.15
0.88
1.12
1.15

1.30
1.00
1.29
1.43

37.4521 (<.0001)
4.1854 (0.0408)
26.6587 (<.0001)
21.1647 (<.0001)

0.946
0.962
0.996

0.898
0.912
0.937

0.997
1.015
1.059

4.2286 (0.0397)
2.0029 (0.1570)
0.0135 (0.9076)
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No. of chronic
conditions
0
1
2
3
4
5*
Drug abuse
No
Yes*
Depression
No
Yes*

0.19
0.25
0.36
0.51
0.68
-

0.167
0.22
0.32
0.46
0.61
-

0.22
0.29
0.41
0.57
0.76
-

499.3691 (<.0001)
389.0633 (<.0001)
270.0749 (<.0001)
138.9470 (<.0001)
51.2393 (<.0001)
-

0.27
-

0.18
-

0.41
-

37.3729 (<.0001)
-

0.44
-

0.42
-

0.47
-

989.6249 (<.0001)
-

Note: OR= odds ratio; CI= confidence interval
*Reference category

Scenario analyses
a. Including ED visits with prescription opioid poisoning listed as the first diagnosis (DX1):
The adjusted analyses were conducted including only ED visits with prescription opioid
poisoning listed as the first diagnosis using the variable DX1. All regression models had
better fit compared to the baseline models as indicated by lower value of -2 Log L. This
means that the ability to predict the observed outcome is better in these models compared
to the base case models. Also, results of the scenario analyses for models that compared
years 2013 and 2014 to 2011 indicated significant reduction in prescription opioid
poisoning ED visits in Kentucky compared to North Carolina. However, results of the
scenario analysis reported no significant difference in the likelihood of prescription
opioid poisoning ED visits between years 2011 and 2012 for Kentucky and North
Carolina.
b. Considering only unintentional prescription opioid poisoning ED visits:
The adjusted analyses were conducted considering only ED visits with unintentional
prescription opioid poisoning. All models experienced good fit based on Pearson
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Goodness-of-Fit Statistic. Also, the models had better fit compared to the baseline models
as indicated by lower value of -2 Log L. Holding all other variables constant, the odds of
having an opioid poisoning ED visit was not significantly different in Kentucky than
North Carolina comparing the years 2011 and 2012. However, these odds were
significantly lower comparing 2013 and 2014 to 2011.
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Chapter 6

Methods and results for specific aim 4:
A. To estimate the direct medical costs associated with prescription opioid poisoning ED
visits in Kentucky and North Carolina.
B. To estimate the economic impact of prescriber use mandates in Kentucky.

Section 6.1 Methods
Conceptual framework
Opioid poisoning is a life-threatening condition characterized mainly by respiratory depression;
but, it is reversible. Patients who develop an opioid poisoning event need to be transferred to the
ED for immediate medical intervention, although some patients may refuse medical help for fear
of legal issues or the use of an opioid antagonist available to the community. Most patients
transferred to the ED are treated and released. Others may be admitted to the hospital for further
medical supervision. In some cases, patients die during the ED visit or the hospital stay.
Figure 6.1 illustrates the conceptual model for patients who develop an opioid poisoning event.
Costs are incurred in every step of the model. From a societal perspective, they include direct,
indirect, and intangible costs. Direct costs are associated with delivery of care, including all cost
that incur while treating patients in the ED or during hospital admission.
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Direct non-medical costs include services that help in the provision of care such as transportation
cost. Indirect costs are associated with loss of productivity due to illness (e.g. absenteeism).
Intangible costs are hard to measure in monetary value, but include feeling, dissatisfaction, and
confusion.
The economic burden of prescription opioid poisoning was assessed from a societal perspective.
When a societal perspective is used, three main types of costs are typically considered: direct
costs, indirect costs, and intangible costs. However, the current study was interested in output
costs resulting from resource utilization associated with prescription opioid poisoning ED visits.

Treated and released
Transferred to the ED by
ambulance or other means

Died
Died

Admitted to the
hospital

Patient
develops
opioid
poisoning

Treated by
naloxone or other
opioid antagonist
available in the
community

Not transferred to the ED

Discharged
alive

Died

Figure
Conceptual
patientswho
whodevelop
developopioid
opioidpoisoning
poisoning
Figure6.1:
6. 1:
Conceptualmodel
modelfor
fortreating
treating patients
Study design
Data from current literature was used to develop a cost of illness framework (Figure 6.1). In the
model, direct medical costs of prescription opioid poisoning (associated with ED visits) were
investigated. Costs associated with inpatients stays, indirect, and intangible costs were not
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considered. Direct medical costs associated with ED visits were estimated over one-year period
using a bottom up approach. In this approach, the average unit cost (i.e. costs per ED visit) is
multiplied by its prevalence (i.e. number of ED visits). Yearly healthcare inflation rates were
used to convert all cost estimates to 2018 monetary values.
Study setting
Prescription opioid poisoning ED visits (including ED visits that resulted in hospital admission)
in Kentucky and North Carolina for the years 2011 to 2014.
Data source
The SEDD (treat and release ED visits) and the SID (ED visits that resulted in hospital admission)
for Kentucky and North Carolina. See section 4.1.
Sample
Inclusion and exclusion criteria can be found in section 4.1. The final sample size for Kentucky
and North Carolina for the years 2011 – 2014 is reported in Table 6.1.
Table 6. 1: Final sample size for specific aim 4
State

Sample size (n)
2011

Kentucky

2189

North
Carolina

2949

2012

2037

Total

2013

2014

1553

1640

7,419

3292

3256

12,598

3101

Direct medical costs
Direct medical costs considered in this study were costs of utilizing the ED (including treat and
release ED visits and ED visits that resulted in hospital stays), physician ED service costs, and
ambulance service costs. The current study focuses on ED visits related to prescription opioid
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poisoning and thus, estimated costs associated with ED visits. Costs of inpatient stays is another
type of direct medical costs associated with prescription opioid poisoning; however, these costs
were not considered in this study. Also, due to data limitation, costs associated with other direct
medical costs such as physician office cost, were not considered.
Costs of ED visit
Treat and Release
Total ED visits costs were estimated by multiplying average cost per ED visit by the number of
ED visits in Kentucky and North Carolina over four years period. Prescription opioid poisoning
ED visits were identified using ICD-9-CM codes listed in Table 4.1. Prescription opioid
poisoning ED visits in any listed diagnosis were considered. Costs per ED visit included cost of
utilizing the ED and physician fee. Cost of utilizing the ED was obtained using the variable
(TOTCHG), which represents total charge per visit. Physician fee costs were estimated by
linking CPT-4 procedure codes to the publicly available Medicare Physician Fee Schedule
(MPFS). The latter was created by the Centers for Medicare and Medicaid Services (CMS) and
contain payment information for services provided by enrolled healthcare professionals. There
are up to 25 CPT-4 procedure code recorded for each ED visit in the SEDD. However, only
CPT-4 codes that describe physician visit to the ED were considered for the estimation of ED
physician costs; these are 99281, 99282, 99283, 99284, and 99285. The latter was used to
describe an ED visit for the evaluation and management of a patient, which requires these three
key components: a comprehensive history, a comprehensive examination, and Medical decision
making of high complexity.101 These characteristics may describe physician visit to the ED for
an opioid poisoning case and thus, the code 99285 was used for the cost analysis. This was
applied for all prescription opioid poisoning ED visits and the total physician fee costs were

113

calculated. The physician fee cost and the average cost of utilizing the ED were used to estimate
total treat and release ED visits related costs.
Costs of ED visits that ended with hospital admissions
This section explains the methods used to estimate costs of ED visits that resulted in hospital
admissions; however, costs of hospital admissions were not calculated in this study. ED visits
that ended in hospital stays were obtained from the SID databases. To recall, the SID provide
information on ED visits that ended with inpatient stays. Information on these ED visits are not
available in the SEDD. Inpatient stays with evidence of ED visits related to prescription opioid
poisoning were identified using ICD-9-CM codes listed in Table 4.1. Prescription opioid
poisoning ED visits in any listed diagnosis were considered. To identify the charge of each ED
visit, revenue center codes from the detail charge files were utilized. There are up to ten revenue
codes (450 – 459) that can be reported on a discharge record that indicate ED services. Each
revenue code has a corresponding charge; multiple revenue codes may be recorded for the same
visit. To estimate total charge per ED visit, all revenue codes with their corresponding charges
for that ED visit were considered. Unlike the SEDD, the SID do not provide CPT-4 codes. To
estimate ED physician fee costs, CPT-4 code (99285) was used. The physician fee cost and the
average cost of utilizing the ED were used to estimate total costs of ED visits that resulted in
hospital stays.
Ambulance service costs
Ambulance service costs represent direct medical costs that might be incurred in prescription
opioid poisoning ED visits. The proportion of ED visits that require ambulance service was
assumed to be 38.2% based on a national study of ambulance transport for mental health
problems.102 This proportion was applied to all ED visits (i.e. treat and release ED visits and ED
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visits that resulted in hospital stays) to estimate the number of ED visits that require ambulance
assistance. Ambulance service costs were obtained from the Ambulance Fee Schedule (AFS),
which was created by the CMS in 2002 and updated annually. AFS provides payment
information on state level. HCPCS codes for ambulance services were used to identify payment
amount listed in the AFS. HCPCS code considered in this study and its associated payment
amount is listed in Table 6.2. Total ambulance service cost was obtained by aggregating cost of
ground ambulance services for all ED visits requiring ambulance service. Total ambulance
service costs were estimated for Kentucky and North Carolina over a four-year period.
Table 6. 2: HCPCS code for ambulance services and its reimbursement (in 2018 USD)
HCPCS
code
A0427

a.
b.

Payment amounta,b ($)

Description

Ambulance service, advanced life support,
emergency transport, level 1 (ALS 1 – emergency)

KY
375.77

NC
397.54

Obtained from the 2018 AFS for the corresponding state.
Based on the equation: base rate* Geographic Practice Cost Index (GPCI)* Relative Value Units (RVU).
For KY payment amount = 224.74* 0.88* 1.9 = $375.77; NC payment amount = 224.74 * 0.931*1.9 =
$397.54

Total direct medical costs of ED visits
The total direct medical costs associated with ED visits were calculated by summing total direct
medical costs of treat and release ED visits and ED visits that resulted in hospital admissions.
Cost to Charge Ratio (CCR)
The SEDD and the SID provide total charge of an ED visit or a hospital stay. Also, the SID
provide total charge of ED visits that ended with hospital admissions. Charges represent what
hospitals bill for services, and they are higher than the actual cost of services or the amount paid
for hospitals. The HCUP developed cost to charge ratios (CCRs) for the SID to help converting
charge data to cost estimates. The CCR calculation is based on all-payer, inpatient cost and
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charge information from the detailed reports by hospitals to the CMS. Both hospital specific and
state average all payer inpatient CCR are provided. Most payers require a bundled bill for
patients admitted to the hospital through the emergency department. Thus, the CCRs for the SID
were utilized to convert charge of ED visits that ended with hospital admissions to cost
estimates. The CCR file for each year was linked to the hospital linkage file using the variable
(DSHOSPID); the result was linked to the SID file using hospital identifier variable (HOSPID).
Total charge per ED visit that resulted in hospital admission was multiplied by the corresponding
CCR (specific to each state/year) to obtain the cost estimate. When available, hospital specific all
payer inpatient CCR, APICC was used to estimate total cost per visit. Otherwise, group average
all-payer inpatient CCR, GAPICC was used.
The HCUP do not provide CCRs specific to each hospital in the SEDD. However, it conducted a
study including eight states and estimated average CCR for treat and release ED visits in these
states.103 The report grouped hospitals based on hospital characteristics such as hospital
ownership and location and provided CCR for each group. Also, weighted average CCR for all
hospitals was estimated. The latter was used in this study because hospital ownership and
hospital region variables are not available in the SEDD.
Method for estimating the economic impact of prescriber use mandates in Kentucky
The economic impact of prescriber use mandates in Kentucky was evaluated in terms of direct
medical costs associated with ED visits considered in specific aim 4A. This was accomplished
by calculating the odds ratio (OR) of the interaction term (mandates*post). The latter is called
difference in difference estimator (DID) and it represents the difference in the change of opioid
poisoning ED visits between Kentucky and North Carolina following policy implementation.
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The DID was used to quantify the difference in the number of opioid poisoning ED visits in KY
in the pre- and post-mandates periods. This can be explained by the following equation:
Logit (poisoning_indicator=1) = β0 + β1 mandates + β2 post+ β3 (mandates*post) + β(4 – n) X(4 –n)
- Mandates is a dummy variable for prescriber mandates (1= Kentucky, 0= North Carolina).
- Post is a dummy variable for post mandates period (1= post mandates (i.e. second half of 2012,
2013 and, 2014), 0= pre-mandates (i.e. 2011 and first half of 2012)).
- (Mandates * post) is an interaction term between the variables mandates and post.
- β3 is the DID estimator which represents the true effect of mandates:
β3= (KY post - KY pre) - (NC post - NC pre).
NC pre = β0
NC post = β0 + β2
KY pre = β0 + β1
KY post = β0 + β1 + β2 + β3
(KY post - KY pre) = β3 + β0 + β2 - β0 = β2 + β3 (suppose that β2 = -0.0333, β3 = -0.3556, postmandates is 2013, and pre-mandates is 2011)
Thus, (KY post - KY pre) = -0.3889, OR = e-0.3889 = 0.68 (i.e. there is a 32% reduction in
likelihood of opioid poisoning ED visits going from 2011 to 2013, controlling for NC in the
model). Thus, there are (0.32 * number of opioid poisoning ED visits in 2011) fewer ED visits in
2013 as compared to 2011. The economic impact of prescriber use mandates in 2013 was
quantified by multiplying the average cost per ED visit by the difference in the number of opioid
poisoning ED visits between the years 2011 and 2013 (i.e. 0.32 * number of opioid poisoning
ED visits in 2011). The same method was applied to estimate the economic impact of the policy
in 2012 and 2014.
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Sensitivity analyses
Sensitivity analyses were performed for Kentucky. Scenario analysis was conducted to test the
impact of including ED visits with prescription opioid poisoning listed as the first diagnosis on
the estimated total direct medical costs. One way-sensitivity analyses were performed to test the
robustness of the base case cost estimates. These analyses included varying values of average
CCR used to estimate cost of treat and release ED visits, the proportion of ED visits requiring
ambulance run, and cost of ground ambulance run. Also, the estimate of the interaction term for
each model was included in the one-way sensitivity analyses. Table 6.3 provides summary of
ranges considered for each value.

Table 6. 3: Ranges of values used in one-way sensitivity analysis
Parameter

Value in base case analysis

CCR
Proportion of ED visits requiring
ambulance services
Cost of ground ambulance run
β3d of the interaction term
(mandates*post)

0.514a
38.2%

a.
b.
c.
d.

$375.77
(KY, 2012) = -0.0892
(KY, 2013) = -0.3556
(KY,2014) = -0.3532

Values used in one-way
sensitivity analysis
± 95% CIb
± 25%
$316.43c
±95% CI

Weighted average CCR for all hospitals reported in the HCUP study was used because hospital ownership
and hospital region variables were not available in the SEDD.
Estimated from the mean and standard deviation (SD) using the equation: mean± 1.96*SD.
= (224.74* 0.88*1.6) which represents payment amount (in 2018 USD) for HCPCS code: A0429
(ambulance service, basic life support, emergency transport (BLS – emergency)).
β3 for each regression model was used.
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Section 6.2 Results
Aim 4A: To estimate the direct medical costs associated with prescription opioid poisoning in
Kentucky and North Carolina.
Kentucky
There were a total of 7,419 prescription opioid poisoning ED visits over the period 2011 – 2014.
Treat and release ED visits constituted 46% of total ED visits; the remaining ED visits (54%)
resulted in hospital stays. The total (four years) average cost for a treat and release ED visit was
estimated at $2,711.61 (see Appendix B for calculations) and the total mean cost for an ED visit
that resulted in hospital stay was evaluated at $869.18 (see Appendix B for calculations). The
annual average costs of a treat and release ED visit, ED visit that resulted in hospital stay, and
physician fee cost are summarized in Table 6.4. The total (four year) ED related costs were
estimated at $12.71 million (Table 6.4). About 73.0% of these costs were attributed to treat and
release ED visits and 27.0% were related to ED visits that resulted in hospital stays. The total
(four year) ambulance service costs of all ED visits were estimated at approximately one million
dollars (Table 6.5). The total direct medical costs of prescription opioid poisoning ED visits were
evaluated at $13.77 million (Table 6.6).
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Table 6. 4: Prescription opioid poisoning related-ED costs in Kentucky (in 2018 USD)
Average cost of utilizing the ED per year (SE)a,b

2011

2012

2013

Number of ED visits
per year (n)
2014

2011 2012 2013 2014

Total average cost per
yearc
(in million)
2011 2012 2013 2014

Total (four
years)
average
costse
(in million)

Treat and 2,469.08 (69.33) 2,445.31 (68.14) d 2,500.21 (76.32) 2,749.53 (105.29) 970 911 712 835
2.56 2.38 1.90 2.44
release
ED visits
ED visits 628.50 (20.81)
682.31 (25.88)
699.49 (28.05)
784.09 (33.44)
1,219 1,126 841 805
0.97 0.96 0.73 0.77
that
resulted
in
hospital
admission
Total
3.53 3.34 2.63 3.21
12.71
average
costs of
all ED
visits per
yearf
a. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits.
b. Exclude physician fee cost which = $170.58.
c. Total average cost per year= average cost of ED visit per year (i.e. average cost of utilizing the ED in that year+ physician fee cost) * number of ED
visits in that year (n).
d. The estimated average cost was missing for one observation.
e. Total (four years) average costs = total average cost of all ED visits in 2011($3.53 million) + total average cost of all ED visits in 2012 ($3.34 million) +
total average cost of all ED visits in 2013 ($2.63 million) + total average cost of all ED visits in 2014 ($3.21 million) = $12.71 million.
f. Total average costs of all ED visits per year= total average costs of treat and release ED visits + total average costs of ED visits that resulted in hospital
admission in that year.
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Ambulance service costs
Over the four years period, 1,310 treat and release ED visits and 1,517 ED visits that ended with
hospital admissions were assumed to have involved ground ambulance transportation. The total
(four year) ambulance services costs of all ED visits were estimated at approximately one million
dollars (Table 6.5). About 46.2% of these costs were attributed to treat and release ED visits and
53.8% were related to ED visits that resulted in hospital stays. The annual and total costs of
ambulance services are summarized in Table 6.5.
Table 6. 5: Annual and total (four years) costs of ground ambulance services in Kentucky (in
2018 USD)
Total costs per yearb,c
(in million)

Number of ED visits
requiring ambulance
service per year (n)a

Total (four
years)
costsd
(in million)

2011 2012 2013 2014
2011 2012 2013 2014
Treat and
371 348 272 319
0.14 0.13 0.1 0.12
release ED
visits
ED visits
466 430 322 308
0.17 0.16 0.12 0.12
that
resulted in
hospital
admission
Total costs
0.31 0.29 0.22 0.24
1.06
of
ambulance
services
for all ED
visits per
year
a. Number of ED visits requiring ambulance service per year = (38.2%) * No. of ED visits in that year.
b. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED
visits.
c. Total average cost per year= cost per ambulance run ($375.77) * number of ED visits requiring ambulance
services in a year.
d. Total (four years) costs = total costs of ambulance services for all ED visits in 2011($0.31 million) + total
costs of ambulance services for all ED visits in 2012 ($0.29 million) + total costs of ambulance services for
all ED visits in 2013 ($0.22 million) + total costs of ambulance services for all ED visits in 2014 ($0.24
million) = $1.06 million.
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Total direct medical costs of ED visits
Total (four year) direct medical costs associated with ED visits were estimated at $13.77 million.
About 29.1% of these costs were attributed to ED visits that ended with hospital admissions and
70.9% were related to treat and release ED visits. The annual and total direct medical costs for
the period 2011 to 2014 are summarized in Table 6.6.
Table 6. 6: The annual and total direct medical costs of prescription opioid poisoning ED visits
in Kentucky (in 2018 USD)

2011

2012

2013

2014

Total (four year) direct medical
costs (in millions)d

Total average costs of all ED visits
3.53
3.34
2.63
3.21
per yeara
Total ambulance service costs for
0.31
0.29
0.22
0.24
all ED visits per yearb
Total direct medical costs per
3.84
3.63
2.85
3.45
13.77
yearc
a. Estimated in Table 6.4.
b. Estimated in Table 6.5.
c. Total direct medical costs per year = total average costs of all ED visits + total ambulance service costs in
that year.
d. Total (four year) direct medical costs = total direct medical costs in 2011 ($3.84 million) + total direct
medical costs in 2012 ($3.63 million) + total direct medical costs in 2013 ($2.85 million) + total direct
medical costs in 2014 ($3.45 million) = $13.77 million.

North Carolina
There were a total of 12,598 opioid poisoning related ED visits over the period 2011 – 2014.
Treat and release ED visits constituted 44.8% of total ED visits; the remaining ED visits (55.2%)
resulted in hospital stays. Over the four years period, the average cost for a treat and release ED
visit was estimated at $ 2,766.67 (see Appendix B for calculations), and the mean cost for an ED
visit that resulted in hospital stay was evaluated at $1,011.94 (see Appendix B for calculations).
The annual average cost of a treat and release ED visit, ED visit that resulted in hospital stay, and
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physician fee cost are summarized in Table 6.7. The total (four years) ED related costs were
estimated at $22.46 million (Table 6.7). About 96.9% of these costs were attributed to treat and
release ED visits and 30.1% were related to ED visits that resulted in hospital stays. The total
(four year) ambulance service costs of all ED visits were estimated at $1.9 million (Table 6.8).
The total direct medical costs of prescription opioid poisoning ED visits were evaluated at
$24.37 million (Table 6.9).
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Table 6. 7: Prescription opioid poisoning related- ED costs in North Carolina (in 2018 USD)
Average cost of utilizing the ED per year (SE)a,b

2011

2012

2013

Number of ED visits per
year (n)
2014

2011 2012 2013 2014

Total average cost per
yearc
(in million)
2011 2012 2013 2014

Total (four
years)
average
costsd
(in million)

Treat and 2,251.19e (53.90) 2,588.65f (84.61) 2,648.11f (62.04) 2,896.95g (124.87) 1,306 1,361 1,414 1,565
3.16 3.76 3.99 4.80
release
ED visits
ED visits
765.26 (5.76) 832.34 (11.18) 850.04 (9.85) 918.35(11.60)
1,643 1,740 1,878 1,691 1.54 1.74 1.92 1.55
that
resulted
in
hospital
admission
Total
4.70 5.50 5.91 6.35
22.46
average
costs of
all ED
visits per
yearh
a. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits.
b. Exclude physician fee cost which = $170.44.
c. Total average cost per year= average cost of ED visit per year (i.e. average cost of utilizing the ED in that year+ physician fee cost) * number of ED visits in
that year (n).
d. Total (four years) average costs = total average cost of all ED visits in 2011($4.70 million) + total average cost of all ED visits in 2012 ($5.50 million) + total
average cost of all ED visits in 2013 ($5.90 million) + total average cost of all ED visits in 2014 ($6.35 million) = $22.46 million.
e. The estimated average cost was missing for three observations. f. The estimated average cost was missing for four observations.
g. The estimated average cost was missing for six observations.
h. Total average costs of all ED visits per year= total average costs of treat and release ED visits + total average costs of ED visits that resulted in hospital
admission in that year.
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Ambulance service costs
Over the four years period, 2,157 treat and release ED visits and 2,656 ED visits that ended with
hospital admissions were assumed to have involved ground ambulance transportation. The total
(four years) ambulance services costs of all ED visits were estimated at $1.92 million. About
44.8% of these costs were attributed to treat and release ED visits and 55.2% were related to ED
visits that resulted in hospital stays. The annual and total costs of ambulance services are
summarized in Table 6.8.
Table 6. 8: Annual and total (four years) costs of ground ambulance services in North Carolina
(in 2018 USD)

Number of ED visits requiring
ambulance service per year (n)a

Total costs per yearb,c
(in million)

Total (four
years) costsd
(in million)

2011 2012 2013 2014
2011 2012 2013 2014
Treat and release
499 520 540 598
0.20 0.21 0.21 0.24
ED visits
ED visits that
628 665 717 646
0.25 0.26 0.29 0.26
resulted in hospital
admission
Total costs of
0.45 0.47 0.50 0.50
1.92
ambulance services
for all ED visits per
year
a. Number of ED visits requiring ambulance service per year = (38.2%) * No. of ED visits in that year.
b. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits.
c. Total average cost per year= cost per ambulance run ($397.54) * number of ED visits requiring ambulance
services in a year.
d. Total (four years) costs = total costs of ambulance services for all ED visits in 2011($0.45 million) + total costs of
ambulance services for all ED visits in 2012 ($0.47 million) + total costs of ambulance services for all ED visits in
2013 ($0.50 million) + total costs of ambulance services for all ED visits in 2014 ($0.50 million) = $1.92 million.

Total direct medical costs of ED visits
Total (four years) direct medical costs associated with ED visits were estimated at $24.37
million. About 32.0% of these costs were attributed to ED visits that ended with hospital
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admissions and 68.0% were related to treat and release ED visits. The annual and total direct
medical costs for the period 2011 to 2014 are summarized in Table 6.9.
Table 6. 9: The annual and total direct medical costs of prescription opioid poisoning ED visits
in North Carolina (in 2018 USD)

Total average costs
of all ED visits per
yeara
Total ambulance
service costs for all
ED visits per yearb
Total direct
medical costs per
yearc

2011

2012

2013

2014

4.70

5.50

5.90

6.35

0.45

0.47

0.50

0.50

5.15

5.97

6.40

6.85

Total (four
year) direct
medical costs
(in millions)d

24.37

a. Estimated in Table 6.7.
b. Estimated in Table 6.8.
c. Total direct medical costs per year = total average costs of all ED visits + total ambulance service costs in that
year.
d. Total (four year) direct medical costs = total direct medical costs in 2011 ($5.15 million) + total direct medical
costs in 2012 ($5.97 million) + total direct medical costs in 2013 ($6.40 million) + total direct medical costs in 2014
($6.85 million) = $24.37 million.

Specific aim 4B: To estimate the economic impact of prescriber use mandates in Kentucky.
From 2011 to 2014, there was a 22.14% reduction in direct medical costs associated with
prescription opioid poisoning ED visits. Following prescriber use mandates implementation, the
total reduction of direct medical costs associated with ED visits was estimated at about $2.31
million. Table 6.10 summarizes the impact of the policy on the number of opioid poisoning ED
visits and the associated direct costs by year.
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Table 6. 10: The impact of prescriber use mandates policy on the number of opioid poisoning ED
visits and the associated direct costs (in 2018 USD, millions)
Pre-mandates
2011
2,189
3.84
-

2012
1,948
3.48b
0.36

Post-mandates
2013
2014
1,488
1,423
2.74
2.99
1.1
0.85

No. of opioid poisoning ED visitsa
Total direct medical costs
Change in total direct medical
costs from 2011 to post mandatesc
Percent change in total direct
- 9.38
- 28.65
- 22.14
medical costs from 2011 to post
mandates
a. No. of opioid poisoning ED visits for the years 2012, 2013, and 2014 were estimated based on the DID
estimator equation (see Section 5.1 under specific aim 3B) as follow:
KYpost – KYpre = β2 + β3 (where β2 is the estimate for the variable post (i.e. post-mandates) and β3 is the
DID estimator). For the year 2012:
KY2012 – KY2011= - 0.0326 + (- 0.0892)
= -0.1218, OR = e-0.1218 = 0.89, then, no. of opioid poisoning ED visits in 2012 = 0.89 * no. of opioid
poisoning ED visits in 2011 (2,189)
= 1,948 ED visits in 2012. The same calculations will be applied to estimate no. of opioid poisoning ED
visits in 2013 and 2014.
b. Total direct medical costs for 2012 were estimated as follow: no. of opioid poisoning ED visits = 1,948
(treat and release ED visits constituted 44.7% of total ED visits and hospital ED visits that resulted in
hospital admission constituted 55.3% of total ED visits (Table 6.4). Thus, there are 871 treat and release
ED visits and 1077 ED visits that resulted in hospital admission. Total average costs of treat and release ED
visits = (871 * $2,615.89) = $2.28 million, total average costs of ED visits that resulted in hospital
admission= (1077 * $852.89) = $0.92 million, total costs of ambulance services for all ED visits = 1,948 *
38.2% = 744; $375.77 * 744 = $0.28 million. Total direct medical costs in 2012= 2.28 + 0.92 + 0.28 =
$3.48 million. The same calculations will be applied to estimate total direct medical costs for 2013 and
2014.
c. Change in direct medical costs from 2011 to post mandates = total direct medical costs in 2012 (2013, or
2014) - total direct medical costs in 2011 ($3.84 million).

Sensitivity analyses
Scenario analysis and one-way sensitivity analyses were conducted to test the robustness of the
base case cost estimates in KY.
Scenario analysis (including only ED visits with first listed diagnosis of prescription opioid
poisoning):
There were 2,322 treat and release ED visits and 2,266 ED visits that resulted in hospital
admission, with first listed diagnosis of prescription opioid. Considering these ED visits, the total
(four years) direct medical cost of prescription opioid poisoning in KY was estimated at $8.45
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million (compared to $13.77 million in the base case analysis). Results of the scenario analysis

are summarized in Table 6.11
One-way sensitivity analyses:
One-way sensitivity analyses were conducted by varying the proportion of average CCR of treat
and release ED visits, ED visits requiring ambulance run, cost per ground ambulance run, and the
estimate of the interaction term for each regression model. Varying the proportion of CCR over
95% CI range resulted in approximately ± $7.7 million effect on the total (four years) estimated
costs. When the proportion of ED visits with ambulance service varied between (28.65% and
47.75%), the total (four years) direct medical costs ranged from $13.5 million to $14 million.
Reducing ambulance cost to $316.43 decreased the total direct costs by $70 thousands. When the
estimate of the interaction term for all models varied over 95% CI, the total reduction in direct
medical costs in post mandates period compared to 2011 ranged from $1.6 million to $3.14
million. Results of the one-way sensitivity analyses are summarized in Table 6.12 and 6.13.
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Table 6. 11: Direct medical costs of ED visits associated with prescription opioid poisoning listed as first diagnosis in Kentucky (in
2018 USD)
Average cost of utilizing the ED per year (SE)a,b

2011

2012

2013

Number of ED visits
per year (n)
2014

2011 2012 2013 2014

Total average cost per
yearc
(in million)
2011 2012 2013 2014

Total
(four
years)
average
costsd
(in
million)

Treat and 2,283.06 (81.87) 2,236.33e (73.34) 2,298.63 (79.03) 2,505.04 (122.92)
633 602 502 584
1.55 1.45 1.24 1.56
release ED
visits
ED visits
649.92f (15.88) 701.72 (15.31) 707.40 (17.66) 791.71e (20.12)
|686 671 470 436
0.56 0.59 0.41 0.42
that
resulted in
hospital
admission
Total
0.19 0.18 0.14 0.15
ambulance
service
costs for
all ED
visits per
yearg
Total
2.30 2.22 1.79 2.13
8.44
direct
medical
costs of all
ED visits
per yearh
a. The SEDD and the SID do not need to be weighted because it provides a census (not an estimate) of ED visits.
b. Exclude physician fee cost which = $170.58.
c. Total average cost per year= average cost of ED visit per year (i.e. average cost of utilizing the ED in that year+ physician fee cost) * number of ED
visits in that year (n).
d. Total (four years) average costs = total average cost of all ED visits in 2011($2.30 million) + total average cost of all ED visits in 2012 ($2.22 million) +
total average cost of all ED visits in 2013 ($1.79 million) + total average cost of all ED visits in 2014 ($2.13 million) = $8.44 million.
e. The estimated average cost is missing for one observation.
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f.
g.
h.

The estimated average cost is missing for two observations.
Total ambulance service costs for all ED visits per year = no. of ED visits requiring ambulance service in that year * cost per ambulance run ($375.77).
Total average costs of all ED visits per year= total average costs of treat and release ED visits + total average costs of ED visits that resulted in hospital
admission in that year.

Table 6. 12: One-way sensitivity analyses on the total estimated direct medical costs in Kentucky (in 2018 USD)
Parameter

a.
b.

Base
case
value

Base case
estimated
total
direct
medical
costs (in
million)
13.77
13.77

Value or range tested

Change in
estimated
total direct
medical costs
(in million)

CCR
0.514
95% limit (0.06 - 0.97)
(6.10 - 21.50)
Proportion
38.2%
± 25% (28.65%, 47.75%) (13.52, 14.05)
of ED visits
requiring
ambulance
run
Cost of
$375.77
13.77
$316.43b
13.71
ground
ambulancea
Estimated from the mean and SD using the equation: mean± 1.96*SD (0.232)
Payment amount (in 2018 USD) for HCPCS code: A0429 (ambulance service, basic life support, emergency transport (BLS – emergency)).

Table 6. 13: One-way sensitivity analysis on the impact of prescriber use mandates (in 2018 USD)
Parameter

a.

Base
case
value

Range tested

Total direct medical costs in
post mandates period (per
year)

Change in total direct
medical costs from
2011a

β3 associated with
the interaction term
(mandates * post):
(KY, 2012)
95% limit (-0.009 - -0.169)
(3.20 - 3.75)
(0.09 - 0.64)
-0.0892
(KY, 2013)
-0.3556
95% limit (- 0.272 - -0.439)
(2.50 - 2.98)
(0.86 - 1.34)
(KY, 2014)
-0.3532
95% limit (-0.270 - -0.436)
(2.71- 3.22)
(0.62- 1.13)
Change in total direct medical costs from 2011 = total direct medical costs in 2012 (2013, or 2014) - total direct medical costs in 2011 ($3.84 million).
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Chapter 7

Section 7.1: Discussion
This is the first study to examine the impact of a PDMP prescriber use mandate policy on
prescription opioid poisoning ED visits in the United States. The existing literature assessed the
effectiveness of PDMPs in terms of their impact on prescribing behavior, opioid consumption,
doctor shopping, and opioid-related morbidity (see Chapter 2). The framework used for this
research was the Donabedian model (Figure 1.2). In addition, this study estimates the direct
medical costs associated with prescription opioid poisoning ED visits and the economic impact
of prescriber use mandates.
This research focused on the impact of comprehensive prescriber use mandates.90 Difference in
difference (DID) framework was used to examine the impact of the policy on prescription opioid
poisoning ED visits. The DID model is a well-known statistical methodology used for policy
impact evaluation.77, 86, 99, 100 This study was further strengthened by conducting three
comparison models for the years 2012, 2013, and 2014 as compared to 2011.
Prevalence of prescription opioid poisoning ED visits and associated characteristics
This study found that the prevalence rate of prescription opioid poisoning ED visits in 2014 was
43.82 per 100,000 residents for Kentucky and 37.45 per 100,000 residents for North Carolina. In
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the same year, the Agency for Healthcare Research and Quality (AHRQ) estimated the national
rate of opioid related ED visits to be 177.7 per 100,000 residents.104 However, this national
estimate included all heroin and non-heroin related ED visits for all age groups. National data
from another study was utilized to calculate the rate of non-heroin related ED visits in 2014;105
the estimated national rate is lower compared to Kentucky and North Carolina (= 25.60 per
100,000 residents).
From 2010 to 2014, the national age adjusted rate of non-heroin related ED visits decreased by
4%.105 Also, a recent report by the CDC found that the rate of opioid overdose ED visits among
those aged 11 years and older decreased by 15% in Kentucky, and increased by 30% in North
Carolina from July 2016 to September 2017.106 Our study estimated 26.1% reduction in the rate
of prescription opioid poisoning ED visits in Kentucky and 3.2% increase in North Carolina
from 2011 to 2014.
Sociodemographic characteristics of prescription opioid poisoning ED visits described in our
study were similar to the existing literature; prescription opioid poisoning ED visits were more
prevalent in people aged 35- 50 years old and >50 years compared to other age groups. 105, 107 In
addition, our study reported a higher proportion of visits occurring in urban areas, higher rates of
opioid related ED visits among females, and white, non-Hispanics had the highest visit rates.105,
108-110

Medicare was the largest payer for unintentional opioid poisoning; the latter can be caused

by poly-pharmacy, which is more common in elderly. This finding is supported by previous
studies.108, 111 Lastly, consistent with Monnat et al.,112 our study found non-significant
relationship between patient location and opioid related ED visits.
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Impact of prescriber use mandates on prescription opioid poisoning ED visits
This study found evidence to support prescriber use mandates and how this differed in Kentucky
and North Carolina. Prescriber use mandates implemented in Kentucky in July 2012 were
associated with a moderate, but significant reduction in prescription opioid poisoning ED visits
in 2012 as compared to 2011, controlling for North Carolina in the model. An even greater
reduction in opioid related ED visits was seen in 2013. The impact of the policy has leveled off
in 2014, as no further reduction was seen in prescription opioid poisoning ED visits. However,
this does not ensure the sustainability of the policy impact; more data points are required to
examine a pattern in the observed data.
Results of this study expands the growing body of evidence on PDMP effectiveness. It differs
with Maughan et al. who did not find a statistically significant difference in prescription opioid
misuse related ED visits between states with and without PDMPs.83 One explanation for the nonsignificant results reported by the authors was the low and variable utilization of PDMPs by
prescribers at the time of their study.46-50, 52-62 PDMP use was much greater in Kentucky during
the period of our study.
The few studies specific to prescriber use mandates are generally supportive of them. In New
York, prescription opioid related ED visits leveled off following prescriber use mandate
implementation.84 New York also saw a significant reduction in opioid prescribing after
prescriber use mandates.85 A national study by Dowell reported significant reduction in
prescription opioid related deaths following prescriber use mandates.86 Only one study found
non-significant impact of prescriber use mandates on opioid prescribing.87
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Economic impact of prescriber use mandates policy
The current study is the first to estimate the economic impact of prescriber use mandates on nonfatal prescription opioid poisoning ED visits. Existing studies evaluated costs of opioid related
ED visits using national estimates and included fatal and non-fatal ED visits. To date, four
studies have estimated costs of opioid related ED visits utilizing national ED visits data.
Inocencio et al. assessed direct and indirect costs associated with opioid misuse, abuse, and/or
poisoning in the United States. The average estimated cost of a prescription opioid related ED
visit was $2,337 in 2017 U.S. dollars.25 Another study by Yokell et al. estimated average charges
of prescription opioid overdose ED visit at $4,454 to $5,043, which would be comparable to
Inocencio’s cost figures after applying a cost to charge adjustment.110 Tadros et al. costs were
also comparable to Inocencio’s.108 A study using 2007 data found lower average charges for drug
poisoning related ED visit of $2,700.113 To our knowledge, only one study reported state level
costs of opioid related ED visits and hospital admissions; in Florida, the total estimated costs of
ED visits and inpatient stays was $208 million over one-year period (2010 – 2011).114
In the current study, the average cost treat- and release ED visits were estimated at $2,500 in
Kentucky and $2,600 in North Carolina. These estimated costs are comparable to the average
costs reported by Incencio et al.25 In addition, the average charges per visits estimated in our
study were similar to those reported by prior studies.108, 110 The current study estimated total
direct medical costs of prescription opioid poisoning ED visits to be $13.77 and $24.37 million
in Kentucky and North Carolina, respectively, over the period 2011 - 2014. Treat and release ED
visits contributed to most of costs in both states.
Surprisingly, the average costs of treat- and release ED visits were more than triple compared to
the average cost of ED visits that resulted in hospital stays ($2500 vs. $700 for Kentucky and
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$2600 vs. $840 for North Carolina). These findings can be explained through the severity of
opioid cases. Patients who were seen in the ED and admitted to the hospital would have more
severe cases and thus, require more procedures to be done in the ED. Most payers require
bundled payments for patients who were first seen in the ED and then admitted to the hospital.
Based on this model, the current study used inpatient CCRs to estimate costs of ED visits that
ended in hospital stays. This may explain the low cost of ED visits that resulted in hospital
admissions as compared to treat and release ED visits. No other studies have evaluated costs of
emergency department services for inpatient stays; therefore, the current findings cannot be
supported by any existing evidence. Payments for physician fees used in the current study were
the highest documented payment in the MFS for ED services — which may inflate the total
estimated direct costs. However, the CPT-4 code selected for use in this study appropriately
describes ED services for opioid overdose. Sensitivity analysis was performed to test the
robustness of the total estimated costs in Kentucky. Varying the CCR for treat and release ED
visits over its 95% CI range had the largest impact on the total cost estimate (± 7 million effect).
This was expected due to the large variation in CCR values between hospitals and states
estimated in the HCUP report.103

The current study evaluated the economic impact of the PDMP policy considering only direct
medical costs. Following prescriber use mandates implementation, the reduction of total direct
medical costs from 2011 to 2014 was estimated at $2.31 million. The estimated reduction in
costs was doubled from 2012 to 2013 and leveled off in 2014 (Figure 7.1). It could be that the
policy impact reached its maximum level a year after its implementation (i.e. in 2013) and thus,
no further reduction in costs was noted in 2014. This may indicate that the policy need to be
updated to increase its effect, or other policies should be implemented to synergize its impact. It
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is worth to note that the estimated reduction in costs following the policy implementation does
not reflect savings in cost. Abusers of prescription opioids may shift to heroin and thus, costs
associated with abusing heroin and other non-prescription opioids may increase on the other side.
A study by Dart et al. on trends on opioid analgesic abuse found a reduction in prescription
opioid abuse and a concurrent increase in heroin abuse in the United States from 2010 to 2013.115
The relationship between prescription opioid abuse and heroin abuse was further supported by
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Figure 7. 1: Economic impact of prescriber use mandates on prescription opioid poisoning ED
visits in Kentucky (in 2018 USD)

Findings of this study provide information surrounding the effectiveness of comprehensive
prescriber use mandates in reducing prescription opioid poisoning ED visits. However, the
impact of the policy cannot be isolated from pain clinic regulations, which were part of the
House Bill 1 (HB1) legislation implemented in Kentucky in 2012. Also, Kentucky and North
Carolina differ in the adoption of other policies, which could impact the assessment of prescriber
use mandates (Table 7.1).
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In 2011, North Carolina implemented a state-wide program called Project Lazarus. The program
aimed to combat the prescription opioid abuse epidemic and related health outcomes. When first
initiated in Wilkes county in 2008, Project Lazarus reduced overdose deaths and opioid abuse
related ED visits by 69% and 15%, respectively.117 Despite the initiative in North Carolina, our
study found a significant reduction in prescription opioid poisoning ED visits in Kentucky
compared to North Carolina. This finding further supports the effectiveness of prescriber use
mandates.

It is important to note that the prescriber use mandate policy does not necessarily ensure
prescribers’ utilization of PDMPs. Many prescribers oppose the use of PDMPs and, it is not
feasible to verify prescriber’s use of the system. In addition, as of 2016, only 30 states explicitly
provide civil and/or criminal immunity to prescribers and dispensers for accessing, failing to
access, or reporting data to PDMPs.118 As mentioned earlier, there are seven other PDMPs
practices proposed to increase PDMPs utilization.31 Also, other practices that increase PDMPs
effectiveness should be considered.32 These policies and practices should work hand in hand with
prescriber use mandates to curb the prescription opioid abuse epidemic.
Table 7. 1: PDMPs practices and other related policies in Kentucky and North Carolina
KY
2011 2012 2013 2014
Proactive reports
to prescribers
Delegate access
Naloxone
distribution*
Schedules
monitored
Operational
PDMP
Require prescriber
to be trained

NC
2011 2012 2013 2014

II - V

II- V

1999

2007
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before using
PDMP
Pain clinic law
Proactive reports
on prescriber (to
law enforcement
agency)

Yes (part of HB1)
Yes (part of HB1)

Note:
means the policy was not implemented;
means the policy was not implemented
* Effective in 3/2015 in Kentucky; Effective in 6/2016 in North Carolina; HB1= house bill1

Limitations
This study is the first to examine the impact of prescriber use mandates policy on prescription
opioid poisoning ED visits using a controlled pre-post study design. However, the study has
several limitations.
The intended population were abusers who obtain their prescription opioids from doctors.
Unfortunately, the data did not provide information to verify this. Physicians are one leading
source of prescription opioids, however, there are other sources from which patients can obtain
prescription opioids. According to National Survey on Drug Use and Health (NSDUH), half of
non-medical users (50.5%) obtained their opioid from a friend or relative for free, 22.1% got it
from one doctor, and 11% bought it from a friend or relative.119 Improperly stored prescription
opioid in households represents another source for abuse that was not captured in the current
study. A study by Lewis et al. (2014) reported stockpiling of unused opioids by 65% of patients
with only 6.3% dispose unused opioids.120 Stockpiling opioids was associated with recreational
use of these medications in 34% of patients. A similar study by Bates et al. (2011) investigated
unused narcotics among discharged patients who underwent surgery.121 In this study, 67% of
patients stockpiled unused narcotics. Therefore, educating patients and providing them with
proper drug disposal methods is necessary to reduce the risk of abuse.
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Prescription opioid poisoning is not limited to prescription opioid abusers. Polypharmacy,
defined as taking five or more medications, 122 can be a leading cause. Polypharmacy is common
in elderly due to having multiple medical conditions. The current study found that more than one
third of opioid-related ED visits were attributed to patients >50 years old, however, the
possibility of polypharmacy as an underlying cause cannot be determined. Furthermore, this
study could not control for patient’s living condition (i.e. homelessness), marital status,
education, and employment which are potential confounders. Evidence from the existing
literature supports the relationship between these variables and opioid abuse; 123, 124 however, no
information on these variables were available in the SEDD and the SID for the period of the
study. Other data limitations are related to the ICD-9-CM codes; there are no specific codes that
identify prescription opioid poisoning and thus, the analyses of this study may overestimate the
occurrences of prescription opioid poisoning ED visits.
Other state level unobserved factors may affect the findings of this study. There may be local
policies or interventions that were implemented at similar time to prescriber use mandates, which
could impact the estimated effect of the policy. These may include other opioid-related
prescriber mandates, regulations of naloxone access, and others.
Lastly, findings of the current study may not be generalizable to all states. This is related to two
factors, first, differences among the states in conditions under which a prescriber is required to
check the state PDMP. This research focused on comprehensive prescriber use mandates
adopted in Kentucky. To recall, comprehensive prescriber use mandates require all prescribers to
consult the PDMP before initial opioid and benzodiazepine prescriptions and at least every three
months thereafter.90 Therefore, it represents the highest level of prescriber use mandates
compared to other states. Second, in addition to prescriber use mandates, Kentucky HB1
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legislation included regulations for pain clinics.125 As a result, the reduction in opioid-related ED
visits found in this study may not be attributed to prescriber use mandates only.
Study implications
The current study supports the effectiveness of prescriber use mandates in reducing the number
of prescription opioid-related ED visits, also, the economic impact of the policy is considerable.
These findings can be of a great importance to policy makers. States without prescriber use
mandates policy should consider its adoption. To maximize prescriber use of PDMPs, other
policies or practices should also be considered. Prescribers and other intended users of PDMPs
should be educated about the importance of using the system and how to use it appropriately. In
addition, prescriber should be given the right to authorize other staff, such as nurses to use the
PDMP. This will save time for prescribers, hence enhancing PDMPs utilization. Proactive
reports is another important practice; sending unsolicited reports to prescribers will notify them
about high risk patients, and encourage them to coordinate care with other healthcare providers.
Other policies or practices that might synergize the impact of prescriber use mandates are
mentioned the NAMSDL report.31 In addition to these practices, states must adopt laws that
specifically provide immunity to prescribers and other intended users for accessing the system
and impose sanctions on those who fails to use it.
The current study should guide future research to examine the impact of other prescriber use
mandate policies on other opioid related-health outcomes. Findings of the current study are
promising; further research is required to support the effectiveness of the policy. Lastly, to curb
the prescription opioid abuse epidemic, PDMPs should not be the only area of focus; other plans
proposed by the federal government should be considered.30
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Section 7.2: Conclusion
The prescriber use mandate policy is effective in reducing prescription opioid poisoning ED
visits and their associated costs. However, the impact of the policy cannot be isolated from pain
clinic regulations and other regulations included in Kentucky HB1 legislation. PDMP use
mandates are one of several policies that can increase prescribers and pharmacists use of the
system, thereby support PDMPs effectiveness. Decision makers should consider ways to
maximize the implementation of prescriber use mandates, and adopt other policies or practices
that enhance the effectiveness of PDMPs.
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Appendix A

Single level CCS
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

Type of cancer
Cancer of head and neck
Cancer of esophagus
Cancer of stomach
Cancer of colon
Cancer of rectum and anus
Cancer of liver and intrahepatic bile duct
Cancer of pancreas
Cancer of other GI organs; peritoneum
Cancer of bronchus; lung
Cancer; other respiratory and intrathoracic
Cancer of bone and connective tissue
Melanomas of skin
Other non-epithelial cancer of skin
Cancer of breast
Cancer of uterus
Cancer of cervix
Cancer of ovary
Cancer of other female genital organs
Cancer of prostate
Cancer of testis
Cancer of other male genital organs
Cancer of bladder
Cancer of kidney and renal pelvis
Cancer of other urinary organs
Cancer of brain and nervous system
Cancer of thyroid
Hodgkin`s disease
Non-Hodgkin`s lymphoma
Leukemias
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40
41
42
43
44

Multiple myeloma
Cancer; other and unspecified primary
Secondary malignancies
Malignant neoplasm without specification of site
Neoplasms of unspecified nature or uncertain
behavior
Maintenance chemotherapy; radiotherapy

45

154

Appendix B

Total (four years) average cost of prescription opioid poisoning ED visits (in 2018 USD)

Kentucky:
Treat and release ED visits
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+
average cost in 2014) / 4 + physician fee cost.
= ($2,469.08 + $2,445.31 + $2,500.21 + $2,749.53)/ 4 + $170.58
= $2,711.6
ED visits that resulted in hospital admissions
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+
average cost in 2014) / 4 + physician fee cost.
= ($628.50 + $682.31 + $699.49 + $784.09) / 4 + $170.58
= $869.18
North Carolina:
Treat and release ED visits
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+
average cost in 2014) / 4 + physician fee cost.
= ($2,251.19 + $2,588.65 + 42,648.11 + $2,896.95)/ 4 + $ 170.44
= $12,766.67
ED visits that resulted in hospital admissions
Total (four years) average cost = (average cost in 2011 + average cost in 2012 + average cost in 2013+
average cost in 2014) / 4 + physician fee cost.
= ($765.26 + $832.34 + $850.04 + $918.35)/4 + $170.44= $1,011.94.
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